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Abstract  
To address the limitations of current commercially available tissue engineered skin 
substitutes, Clement et al has created a novel micro-patterned dermal-epidermal regeneration 
matrix (μDERM). This scaffold consists of a micro-patterned collagen gel coupled to a collagen 
sponge to replicate the dermal-epidermal junction of the skin. However, the ability of the scaffold 
to promote vascularization has not been assessed. In order to promote µDERM vascularization, 
the team added Fibroblast Growth Factor – 2 (FGF-2) and heparin to the collagen sponge. 
Additionally, the team produced an in vitro model to assess the efficacy of the enhanced system. 
To evaluate the effects of these factors on cellular outgrowth, the team designed a system that 
allowed for efficient analysis of the outgrowth of NIH/3T3 Fibroblast cells towards the collagen-
GAG sponge. Six different conditions were tested: 1) Non-heparinized with no FGF-2, 2) 
Heparinized with 100 ng/mL FGF-2, 3) Heparinized with 200 ng/mL FGF-2, 4) Heparinized with 
300 ng/mL FGF-2, 5) Non-heparinized with 300 ng/mL FGF-2, and 6) Heparinized with no FGF-
2. PDMS molds that allowed for uni-directional movement of the cells along rectangular channels 
were fabricated for each individual well of a 6-well plate. Image analysis was done over a period 
of twenty-four hours to obtain quantitative results. The fibroblast outgrowth rates were highest 
when exposed to 300 ng/mL of FGF-2 compared to a non-heparinized, non-growth factor 
stimulated scaffold. These results can most likely be attributed to the initial burst of growth factor. 
Overall, the addition of heparin alone did not show significant effect on fibroblast outgrowth 
rates, and thus it is suggested that a future study collects data over a longer period of time to 
understand the potential long-term angiogenic effect that heparin could have on the scaffold. 
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1.0 Introduction 
Modern day tissue engineering is driven by the crucial need for effective, long lasting 
chronic wound treatments. In the United States, over 6.5 million patients each year suffer from 
chronic wounds and need immediate medical attention (Sen et al., 2009). Additionally, over 
450,000 individuals are hospitalized each year for life-threatening burns (Burn incidence and 
treatment in the United States, 2012). Chronic wounds and chronic burns do not heal in the 
orderly way that most wounds do (Sen et al., 2009). Current treatment methods for chronic burns 
and wounds can be costly and ineffective. Wound inflammation and infection, patient 
discomfort, and repeat procedures are all adverse effects of clinical treatment methods (Sen et 
al., 2009). Thus, the crucial need for reconstructed tissue engineered skin substitutes with 
reduced side effects and improved efficacy is shown through these adverse issues.   
The current standards of care for large area full-thickness skin wounds include autografts, 
allografts and tissue engineered skin substitutes. The preferred treatment method for large area 
skin wounds is autografting. This process consists of transplanting large portions of a patient’s 
skin from one area of the body and relocating it to the wound site. However, autografts are 
limited in cases where patients possess large burns or skin traumas because there is a lack of 
healthy skin to be used as a donor site for transplantation. Allografting is the transplantation of 
same-species donor skin. Allografts are used for temporary wound coverage in patients with 
large wounds, but do not suffice for long term treatment because of problems with rejection and 
dermal growth (Kamel et al., 2013). Similarly to autografting, autologous cell culture involves 
taking a small biopsy of healthy tissue from the patient and allowing it to culture into 
transplantable sheets. However, autologous grafting requires long periods of time to produce 
sufficient amounts of skin (Kamel et al., 2013). Additionally, autologous grafting increases 
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susceptibility to infection with decreased efficacy through the presence of collagenase enzymes 
located within the wound (Kamel et al., 2013).  Now, synthetic skin substitutes are being 
explored as cellular, acellular, or composite products. Synthetic substitutes are stable, 
biodegradable three dimensional structures composed of immunocompatible materials (Halim et 
al., 2010). Examples of commonly used engineered skin applications are Apligraf, Integra, and 
Dermagraft. No single product, however, has been proven fully effective for all cases due to high 
costs and the need for additional surgeries (Kamel et al., 2013). Also, synthetic structures lack 
sufficient basement membranes and are not as architecturally stable (Halim et al., 2010). These 
skin grafting limitations prompt the need for improved, long-lasting, tissue engineered skin 
substitutes and corresponding application methods.  
The goal of this project is to enhance angiogenesis of a tissue engineered skin substitute 
through modification of a pre-existing scaffold called micro-patterned dermal-epidermal 
regeneration matrix (μDERM). Currently μDERM consists of two main layers, the top a micro-
patterned collagen gel and the bottom consisting of collagen sponge. The collagen gel is cast 
onto micro-patterned molds to create micro-niches onto the gel surface (Clement et al., 2013). 
However, the ability of the µDERM to promote vascularization has not yet been assessed. Thus, 
the team modified the µDERM to enhance angiogenesis and tissue ingrowth. Additionally, the 
team produced an in vitro model to assess the efficacy of the enhanced system.  
2.0 Literature Review 
2.1 Clinical Significance 
The ample prevalence of chronic wounds, severe burns, and additional preceding diseases 
creates a need for tissue engineered skin substitutes (Sen et al., 2009). In the United States alone, 
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over 6.5 million patients annually experience chronic wounds that need immediate medical 
treatment (Sen et al., 2009). These chronic wounds can stem from pre-existing diseases like 
ulcers, obesity, and diabetes (Sen et al., 2009). In addition, roughly 450,000 individuals in the 
United States are hospitalized as victims of severe burning (Burn incidence and treatment in the 
United States, 2012). Individuals suffering from severe burns need immediate medical treatment 
to assist in the skin regeneration process. Current treatment methods for severe burns and chronic 
wounds are ineffective due to high costs, time constraints, and the need for multiple surgeries 
(Atiyeh et al., 2005). Ineffective treatment methods can result in tissue infection, inflammation, 
or patient morbidity (Atiyeh et al., 2005). Tissue engineered skin substitutes and application 
methods with improved efficacy and longevity are necessary to efficaciously treat affected 
individuals.  
2.1.1 The Importance of Skin  
To understand the mechanisms of wound healing, the structure of healthy skin must first 
be examined. Skin is the largest organ in the body and acts as a crucial physiological defense 
mechanism by protecting the body from foreign microorganisms, environmental toxins, and 
ultraviolet radiation exposure (Venus et al., 2011). The three primary constructs of skin- the 
epidermal layer, dermal layer, and subcutaneous tissue- provide structural support through 
different components and functions (Mikesh et al., 2013).  
The epidermis is the outermost layer of skin and contains stratified cellular layers of 
keratinocytes, Langerhans cells, and melanocytes (Kanitakis, 2002). The epidermis consists of 
four major regions: basal cell layer, spinous cell layer, granular cell layer, and horny layer 
(Venus et al., 2011). Each layer aids in the differentiation and repair processes of epidermal cells 
(Kanitakis, 2002). In the basal layer, approximately 30% of epidermal cells will divide to 
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perform two specific functions (Powell, 2006). Epidermal cells will continue to divide in the 
basal layer while the remaining travel through the spinous, granular, and horny layers to 
differentiate into keratinocytes (Powell, 2006). Differentiated keratinocyte cells will release at 
the horny layer, beginning the skin shedding cycle. This cycle occurs every 28 days in healthy 
patients (Powell, 2006).   
The dermal layer of skin is comprised of elastic connective tissues (i.e. collagen and 
elastin fibers) and provides protection against physical injury or trauma to the epithelial layer 
(Kanitakis, 2002). Additionally, the dermal layer consists of collagen and elastin fibers which 
provide structural support, integrity, resilience, and elasticity to the skin (Venus et al., 2011). The 
three main cell types found in the dermal layer- fibroblasts, macrophages, and mast cells- play an 
important role in the wound healing cascade and tissue regeneration process (Kanitakis, 2002).  
The innermost and deepest layer of skin is subcutaneous tissue, or fatty tissue. 
Adipocytes are the fundamental cell type found in subcutaneous tissue. These cells are 
responsible for ensuring insulation, temperature regulation, protection from injury or trauma, and 
energy storage (Kanitakis, 2002).  
2.1.2 The Importance of Proper Wound Healing  
Cutaneous wound healing is comprised of three overlapping stages: inflammation, tissue-
formation, and tissue-remodeling. Factors affecting the rate of wound healing include location 
and depth of the wound and overall health of the patient. It is important for all stages of wound 
healing to be complete for maximum recovery.  
Inflammation, the first step in the wound healing process, begins when platelets form a 
blood clot and release a specific factor that attracts macrophages and fibroblasts. While 
neutrophils aid in the disposal of debris, macrophages help transition the phase of inflammation 
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into tissue formation with expression of colony-stimulating factor 1, tumor necrosis factor, 
platelet-derived growth factor (PDGF), transforming growth factor alpha and beta (TGF-alpha 
and TGF-beta), interleukin-1, and insulin like growth factor I. (Clark et al., 1999) 
Tissue formation begins one to two hours after inflammation. This allows lateral 
movement of epidermal cells from the wound margins, and later reattachment once the basement 
membrane is reestablished (Clark et al., 1999). Lateral movement of the epidermal cells creates a 
barrier between live tissue and the fibrin clot now present in the wound. Beneath the moving 
epithelial cells, new epidermal cells proliferate and basement membranes form from the deep 
tissue from the outer edge of the wound to the inner. Kucharska et al. have identified EGF, TGF-
alpha, and keratinocyte growth factor as potential growth factors that may cause this transition. 
(Kucharska et al., 2011) 
Neovascularization and the formation of granulation tissue are the next two steps in the 
tissue remodeling process. Granulation is the transitional process of the provisional extracellular 
matrix turning into the collagenous matrix, which occurs about four days after inflammation. 
Macrophages, blood vessels, and fibroblasts contribute significantly to this transition. 
Macrophages promote angiogenesis via growth factors, and blood vessels form the capillaries in 
the stroma that carry the nutrients needed for continued cell growth. Fibroblasts produce 
collagen, which forms the new extracellular matrix which allows cell ingrowth into the wound 
(Guo et al., 2010). The migration of fibroblast cells into the wound is rate limited. The tissue 
ingrowth and repair process can also be prohibited by integrin receptor binding. Integrin 
receptors bind fibronectin and fibrin to fibroblasts. If the necessary integrin receptors are not 
present, or fibronectin is slow to bind to fibroblasts, the fibroblasts will not produce collagen. 
Some growth factors that aid in fibroblast proliferation and expression of integrin receptors 
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include TGF- beta and PDGF. To summarize, factors that slow the formation of granulation 
tissue are integrin receptors and the level of cross-linking in the extracellular matrix. 
Plasminogen activator, collagenases, gelatinase A, and stromelysin are used to cleave a path for 
cell migration. (Clark et al., 1999) 
Neovascularization supports tissue granulation by facilitating angiogenesis. Angiogenesis 
is when endothelial cells are stimulated by growth factors and form new blood vessels at the site 
of injury. Endothelial cells release plasminogen activator and procollagenase. This release is 
stimulated by FGF-2. The plasminogen activator causes plasminogen to convert to plasmin and 
activates collagenase. The plasmin and collagenase digest the basement membrane (Clark et al., 
1999). This allows for the activated endothelial cells to move into the wound site and create new 
blood vessels. Once this process is complete, many cells and blood vessels are dissipated via 
apoptosis. Factors promoting blood vessel formation include fibroblast growth factor (FGF-2), 
TGF-beta, angiogenin, angiotropin, angiopoietin 1, thrombospondin, low oxygen tension, and 
elevated lactic acid. Macrophages and endothelial cells produce FGF-2 and vascular endothelial 
growth factor (VEGF); FGF-2 is used in the first three days of neovascularization and VEGF is 
needed in days four through seven. VEGF production can also be stimulated by hypoxia of the 
wound. Proteolytic enzymes can increase macrophages at the site of injury, also enhancing 
natural growth factors needed for angiogenesis. (Clark et al., 1999) 
The last step of tissue-remodeling occurs during the second week of healing with wound 
contraction and extracellular matrix reorganization. Wound contraction occurs when 
myofibroblasts, stimulated by TGF-beta one or TGF-beta two and PDGF, attach to the collagen 
matrix. The remodeling of collagen during this time is dependent on the rate of synthesis of 
fibrillar collagen, contraction of the wound, the rate of formation of larger collagen bundles, and 
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an increase in cross-links. After approximately three weeks the wound will have 20% tensile 
strength and after several months to a year the wound will gain 70% tensile strength (Clark et al., 
1999). Figure 1, adopted from Clark et al. demonstrates the components of vascularization as 
discussed above.  
 
Figure 1: Summarizes the discussed wound-healing response in terms of the granulation and 
vascularization stages of wound healing. (Clark et al., 1999) 
 
2.2 The Need for Skin Substitutes 
 There is a large clinical need for skin substitutes which provide healing for large, full-
thickness wounds. Wounds that are extremely deep and damage the dermal layer of the skin do 
not allow proper regeneration, as extensive damage has been done to essential regions of the 
dermis. Substitutes allow for immediate wound coverage and can stimulate the release of growth 
factors and cytokines to promote keratinocyte proliferation, fibroblast proliferation, and 
endothelial cell migration. The anatomical purpose of receiving tissue engineered skin is to 
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stimulate natural responses in the body while closely mimicking the anatomy of physiological 
skin with native mechanical and biological properties. Successful transplants of skin substitutes 
will result in no host toxicity or immune rejection (Kamel et al., 2013). For instance, chronic foot 
ulcers elicit multiple pathological factors like vascular insufficiency, altered cellular activity, and 
a dysfunctional extracellular matrix. These pathological factors impair proper healing and lead to 
an altered wound bed and failed response to conventional therapy alone. The goal of tissue 
engineered substitutes is to augment this healing process and trigger biological effects that allow 
for proper wound healing. Currently, many techniques and products have been developed in 
attempt to find a solution for successful treatment of full-thickness wounds.  
2.3 Current Skin Grafts 
 Skin grafts for treatment of wounds can be compiled into two prominent groups: 
biological and tissue engineered. Biologicals involve taking natural skin tissue and transplanting 
it onto the patient’s wound area. Tissue engineered skin grafts have a plethora of varieties and 
provide an alternative to the standard split-thickness grafts obtained in biological grafts. Tissue 
engineered grafts come in many forms, some solely cover the epidermal layer, some solely 
attempt to replace the dermal layer, and some are composites that attempt to regenerate the entire 
infrastructure of the dermal and epidermal layers (Kamel et al., 2013). It is important to examine 
multiple facets of biological and tissue engineered grafts so that their advantages and limitations 
can be fully understood.  
2.3.1 Biological Tissues  
Autografts are one of the current standards of care for wound healing of patients with 
serious tissue damage related to the skin. Autografting is the process in which a section of a 
patient’s healthy skin is surgically removed and transplanted onto the wound area. Since these 
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grafts are taken from the patient’s own healthy tissue, they provide the natural cells and 
mechanical structure to help stimulate tissue growth. These grafts integrate with the damaged 
tissue without causing an immune response in the patient (rejection) (Balasubramani et al., 
2001). Autografts also have been proven to provide reasonable cosmetic results due to the lack of 
scarring in the wound bed (Singer et al., 1999).  
Allografts, or “donor skin” from healthy patients or cadavers, were developed in the early 
1980s to help avoid the problem of treating large wound sites and creating second wound sites  
when performing autografts. Allografting technique includes seeding epidermal cells on a culture 
plate and allowing them to grow, which is beneficial because it makes preparation faster and 
easier. These skin substitutes are used to stimulate the host keratinocytes to proliferate through 
the release of cytokines to heal the wound. Due to this phenomenon, allografts are not 
appropriate for full-thickness wounds like autografts, but can be used for temporary wound 
coverage (Balasubramani et al., 2001).  
  Cultured composite autografts (CCA) are another form of natural grafting that can be 
implemented by surgeons. These grafts are composed of cultured keratinocytes and fibroblasts 
that are obtained through biopsies of the patient at multiple sites. Both cell types are cultured 
separately during the initial phases of growth. After nine days, the keratinocytes are cultured 
over the fibroblasts, causing the formation of a multilayered epidermal component and an 
extracellular dermal component through the secretion of proteins and glycoproteins. After the 
CCA cultures for 16 days, a histological examination will show stratified squamous epithelium 
overlying a dermal bed with a type IV collagen basement membrane. This provides the surgeon 
with a substantial neo-dermis to be grafted onto the patient (Caruso et al., 1999). Although this 
system mimics the infrastructure of the epidermal and dermal layers, it does not promote 
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vascularization (Caruso et al., 1999). Composite grafts can be considered a model system to 
engineered skin grafts.  
2.3.2 Engineered Tissues 
Although there is a moderate array of tissue engineered skin products on the market, each 
has particular advantages and disadvantages to its application. Products can be either cellular, 
acellular, or a composite of both, and can contain a dermal, epidermal, or combination of 
components. Cellular tissue engineered products use living cells such as fibroblasts or 
keratinocytes as the main component of a matrix or scaffold, while acellular products use a 
matrix or scaffold composed largely of materials like collagen or fibronectin. Dermal 
components in tissue engineered skin products are intended to prevent wound contraction and 
provide greater mechanical stability. Epidermal components could be responsible for wound 
coverage and closure, and may be responsible for cosmetic outcome. It is useful to focus on a 
select few tissue engineered skin products and compare their characteristics. There are currently 
three that appear to be most common for clinical use: Apligraf, Dermagraft, and Integra (Kamel 
et al., 2013).     
Engineered grafts can also be fabricated biologically by culturing cells from the patient or 
a donor site. Similar to autografts, autologous tissue engineered grafts utilize a patient’s own 
cells that can be grown into skin sheets to provide extensive wound coverage on victims with a 
large burn percentage on their body. For autologous tissue engineered grafts to be fabricated, a 
stamp-sized biopsy is taken from a patient’s healthy skin and is cultured to produce healthy 
epidermal sheets. Although effective, the limitations of engineered tissues will be discussed in 
section 2.4.3.  
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2.3.2.1 µDERM Description  
Clement et al have developed a composite skin substitute called the Micro-patterned 
Dermal-Epidermal Regeneration Matrix (µDERM). This tissue engineered product utilizes type I 
collagen, neonatal primary human foreskin fibroblasts (NHFs) and primary human foreskin 
keratinocytes (NHKs) to imitate the complex interface of the dermis and epidermis and serve as 
a full-thickness wound regeneration platform. It employs micro-niche topography to influence 
cellular behavior and subsequently enhance epidermal morphology and thickness. The following 
process is used to fabricate this matrix: 1) a silicon wafer is created with micro-niches 
resembling the dermal-epidermal junction (DEJ) and serves as a master pattern, 2) PDMS is cast 
on this pattern to create a negative mold onto which type I collagen is assembled, forming a 
collagen gel 3) a collagen-GAG sponge is laminated to the collagen gel, 4) the complete matrix 
is cross-linked for enhanced mechanical stability. The collagen-GAG sponge represents the 
dermal side while the micro-patterned gel represents the epidermal surface. Following the 
fabrication of µDERM, the dermal side is seeded with fibroblasts, and the epidermal side with 
keratinocytes. Clement et al notes that the micro-patterned tissue analog is implantable, and thus 
it has potential for significant in vivo success. (Clement et al., 2012) 
2.3.2.2 Apligraf® 
Apligraf® is a tissue engineered skin substitute currently on the market to treat diabetic 
foot ulcers and venous leg ulcers. Similarly to human skin, Apligraf® consists of living cells and 
structural proteins. The lower dermal layer combines bovine type 1 collagen and allogeneic 
human fibroblasts (dermal cells), which produce additional matrix proteins. The upper epidermal 
layer is formed by promoting allogeneic human keratinocytes (epidermal cells) first to multiply 
and then to differentiate to replicate the architecture of the human epidermis. Apligraf® is also 
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the only living, bi-layered cell based product FDA approved for use in these clinical settings. 
(Streit et al., 2000)   
2.3.2.3 Dermagraft® 
 Dermagraft® can be classified as a cellular, dermal tissue engineered skin product used 
to treat diabetic skin ulcers (Kamet et al., 2013). Dermagraft® is cryopreserved, three 
dimensional, and acts as a dermal substitute (Kamel et al., 2013). It is composed of human 
fibroblasts, an extracellular matrix, and a bioabsorbable polyglactin mesh scaffold. Dermagraft® 
helps to restore the compromised dermal bed to facilitate healing by providing a substrate over 
which the patient’s own epithelial cells can migrate to close the wound. (Halim et al., 2010) 
2.3.2.4 Integra® 
 Integra® is an acellular, semi-permanent collagen-silicone matrix used in over 10,000 
patients for treatment of chronic burns, diabetic ulcers, and auricular reconstruction (Hart et al., 
2012). It contains a dermal component composed of bovine collagen and shark cartilage-GAG 
that promotes tissue ingrowth of both fibroblasts and keratinocytes, while an epidermal 
component made of silicone is responsible for wound closure and prevention of fluid loss. The 
dermal component enhances ingrowth of fibroblasts. (Hart et al., 2012) 
2.4 Limitations of Current Skin Grafts 
2.4.1 Limitations of Biological Tissues 
As mentioned before, autografts and autologous cultured grafts provide coverage and 
immediate treatment of wounds to stimulate keratinocyte proliferation for wound healing. 
Although they provide an outer layer of skin that protects the body from infection, there are two 
major limitations to this standard of care (Balasubramani et al., 2001). The first, lesser important, 
major limitation to this type of procedure is the time it takes to culture a significant amount of 
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skin for coverage of large wounds. The second foremost limitation to this standard is the inability 
of these grafts to integrate with the patient’s wound to promote tissue in growth and 
vascularization. Similarly, allografts, which can be stored and produced in large quantities to 
avoid problems with autografts, have disadvantages as well. One limitation to allografts is that 
they only provide temporary wound coverage by merely stimulating host keratinocytes to 
proliferate (Kamel et al., 2013). This makes them unsuitable for treatment of full-thickness 
wounds because of their lack of ability to integrate with the dermal layer of skin. These skin 
grafts can also cause an immune response if the body rejects them as foreign (Kamel et al., 
2013). Neither grafting technique provides adequate angiogenesis as they do not sufficiently 
stimulate migration and differentiation of endothelial cells to trigger blood vessel growth and 
wound bed integration (Kamel et al., 2013). These major problems have led to research of other 
potential techniques to provide angiogenesis and new tissue ingrowth for full-thickness wound 
injuries.  
2.4.2 Limitations of Engineered Tissues 
 Currently, engineered skin substitutes come in a variety of forms. They are primarily 
categorized into three classes: (I) temporary impervious dressing materials, (II) single layer 
durable skin substitutes, and (III) composite skin substitutes (Halim et al., 2010). Dressing 
materials are single layer materials with the purpose of providing temporary wound closure, a 
barrier to bacteria, and a moist environment. Single layer substitutes serve as substitutes for 
either the dermal or epidermal layer alone, while composite substitutes aim to mimic the joint 
relationship of the dermis and epidermis (Halim et al., 2010). 
Like biological skin substitutes, tissue engineered skin products also have limitations. 
Kamel et al has recently published a review to comment on the current state of tissue engineered 
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products, including advantages and disadvantages for the majority – if not all – of the tissue 
engineered products commercially available; Apligraf®, Dermagraft®, and Integra® are 
included in this review (Kamel et al., 2013). Some limitations of Apligraf® include: required 
multiple applications, cells in the construct do not survive after 1-2 months in vivo, it poses a 
short shelf life, is difficult to handle, poses risk of disease transfer, and is manufactured at high 
costs. Limitations of Dermagraft® include: multiple applications are required, there is a chance 
of disease transfer or rejection, and it is costly. Integra®’s limitations primarily stem from its 
significant preparation time; three weeks are required for preparation prior to application, and 
thorough surgical preparation of the wound bed is necessary to guarantee successful graft take 
(Kamel et al., 2013). Most significantly, commercially available tissue engineered products do 
not yield adequate angiogenesis after implantation. Limitations to these products provide insight 
as to what must be considered when constructing an improved skin substitute.  
2.5 Innovations to Current Technology  
A major factor in skin engineering is integration of engineered skin with native 
surroundings. “Currently, the success of tissue engineering skin is very dependent on the skillful 
use of surgical techniques and preparation of the wound bed” (Mohamed et al., 2012). Increasing 
the success of graft take in synthetic tissues is complex. Current engineered skin does not 
sufficiently promote tissue ingrowth and vascularization. Inadequate tissue ingrowth causes graft 
failure because native tissue migration into the engineered skin scaffold is insufficient. Also, a 
lack of tissue vascularization causes graft failure because oxygen and nutrients will not properly 
transfer to the bottommost layer of the skin graft. It is logical to question the functions of 
increased tissue ingrowth and vascularization in graft take of engineered skin. 
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2.5.1 Endothelial Cells in Tissue Ingrowth and Vascularization 
As discussed in previous sections, endothelial cells migrate into the wound site after 
fibroblasts form a collagenous matrix in which endothelial cells may be guided in their 
migration. Once in the wound bed, endothelial cells form new blood vessels in the process of 
angiogenesis. Endothelial cell migration can be described in six stages: sensing, extension, 
attachment, contraction, release rate, and recycling (Burridge et al., 1996). Sensing occurs when 
filopodia (long tapering pseudopodium) extend in search of the VEGF gradient. Extension 
follows as protrusion of the leading edge of the endothelial cell ensues. In the attachment phase, 
protrusions attach to the focal adhesions of the extracellular matrix (ECM). A focal adhesion is a 
form of tight adhesion under the ECM that provides structure, which links the ECM to the actin 
cytoskeleton. Focal adhesions are also areas that allow for signal transduction, which controls 
growth (Burridge et al., 1996). Next, contraction occurs with stress fiber formation and induced 
cell contraction allowing for forward movement of the cell. This is followed by release of the 
endothelial cell via focal adhesion disassembly. Finally, adhesive and signaling components are 
recycled (Lamalice et al., 2007).  
Three mechanisms affect endothelial cell migration: chemotactic, haptotactic, and 
mechanotactic stimuli. Chemotaxis is endothelial cell migration toward chemoattractants like 
growth factors. Heptotaxis is endothelial cell migration toward immobilized ligands, which 
increases integrin binding to the ECM. Mechanotaxis is endothelial cell migration from 
mechanical forces, mainly shear stresses (Lamalice et al., 2007). Chemotactic stimuli, VEGF and 
FGF-beta, enhance and activate haptotactic stimuli by affecting integrins avb3, avb5, and a5b1 
(Byzova et. al, 2000). 
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Endothelial cell migration is vital to angiogenesis (Lamalice et al., 2007). Once 
endothelial cells migrate into the wound bed, they are stimulated by growth factors, reactive 
oxygen species (ROS), and other stimuli to form blood vessels at the site of injury.  
2.5.2 Current Factors for In Vitro Angiogenesis in Skin 
Growth factors which are crucial to angiogenesis in cutaneous wound healing include 
epidermal growth factor (EGF), FGF-2, TGF-beta, and PDGF. EGF is widely used as a mitogen 
for epithelial cells and accelerates wound repair via enhanced formation of granulation tissue and 
increased collagen content. Collagen can be coupled with FGF-2 and TGF-beta for promotion of 
full-thickness wound healing by increasing the rate of epithelialization, contraction, and blood 
vessel formation (Amankwah et al., 2007).  Additional growth factors include VEGF and 
platelet-derived growth factor-BB (PDGF-BB). When these factors are combined into a scaffold, 
VEGF is released faster and PDGF-BB is released slower. Together, VEGF and PDGF-BB 
support fibroblast growth, promote angiogenesis, increase re-epithelialization, and control 
granulation tissue formation. In the later stages of wound healing, the factors promote quicker 
collagen deposition and earlier remodeling of the injured site for faster healing (Xie et al., 2013). 
Anti-inflammatory macrophages (M2) promote angiogenesis. Studies have shown increased 
numbers of endothelial cells and tubular structures in the presence of M2 macrophages, which 
induce expression of FGF-2, insulin-like growth factor-1 (IGF1), chemokine (C–C motif) ligand-
2 (CCL2) and placental growth factor (PGF) (Jetten et al., 2014).  
2.5.3 Novel Factors for In Vitro Angiogenesis in Skin 
High levels of ROS are found in tumors and can have an effect on angiogenesis. ROS are 
regulated by endogenous antioxidant enzymes like superoxide dismutase (SOD) and thioredoxin. 
In endothelial cells, a major source of ROS is nincotinamide adenine dinucleotide phosphate 
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(NADPH) oxidase which is activated by VEGF, angiopoietin-1, hypoxia, and ischemia. ROS are 
involved in VEGF receptor-2 (VEGFR2), autophosphorylation, and redox signaling pathways 
that stimulate transcription/genes that promote angiogenesis. There is still more work being done 
on ROS in relation to angiogenesis (Ushio et al., 2008). 
In addition, research is being done on new complementary cell co-cultures to explore the 
effects of multi-cell stimulation of growth factors.  Two cells specifically being examined for co-
culture are mesenchymal stem cells (MSCs) and Muller cells. MSCs have been reviewed in 
cardiac tissue treatment because of their ability to promote angiogenesis and neurogenesis. In 
specific relation to skin, MSCs may be co-cultured with endothelial cells to increase wound 
healing properties for skin; specifically, MSCs from Wharton’s jelly promote microvasculature 
formation and cell migration on co-cultured endothelial cells (Hsieh et al., 2013). Muller Cells in 
retinal tissue when under conditions of hypoxia stabilize hypoxia-inducible factor-1 alpha (HIF-1 
alpha) and secrete angiogenic cytokines, promoting vascular permeability. Muller cells require 
HIF-1 alpha, but do not require VEGF. When applied to endothelial cells, the blocking of HIF-1 
alpha inhibited vascular permeability (Xin et al., 2013).  
Differing vascularization rates and efficiency can also be seen in factors that are 
chemically manipulated. An example of this is heparin, an anti-coagulant found in the liver. 
Heparin is chemically bound to polymer scaffolds and interacts with heparin-binding angiogenic 
growth factors including VEGF and FGF-2. Heparin is not directly a wound healing factor, but it 
is a chemical that attaches to the scaffold and directly interacts with the factors to promote factor 
regulation and release. By monitoring the rate at which these factors are distributed, the effects 
of the factors are enhanced over a longer period of time and this increases angiogenic potential. 
(Amankwah et al., 2007) 
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An additional novel option for up regulation of vascularization is microRNA, or 
noncoding RNA. Endothelial cell-specific microRNA-126 promotes angiogenesis when growth 
factors VEGF and FGF-2 are delivered to the wound bed. By increasing the microRNA-126 
presence, the effects of a given amount of growth factor may increase without increasing the 
quantitative amount of the factor. (Fish et al., 2009) 
2.5.4 In Vitro Controlled Release Mechanisms for Growth Factors 
Growth factors can significantly enhance angiogenesis of tissue engineered skin into the 
wound bed. However, in order to apply a growth factor or combination of growth factors, a 
controlled release mechanism is needed. Controlled release mechanisms allow for the growth 
factor to be released at a sustained rate that best mimics the stages of wound healing and 
facilitates the tissue regeneration process. Growth factors can be applied through bulk 
encapsulation, specific or non-specific surface adsorption, and biodegradable microsphere 
encapsulation. Studies have shown that the release of paracrine factors in a local and sustained 
manner may greatly enhance tissue remodeling and organogenesis. (Chung et al., 2007) 
2.5.4.1 Embedding Growth Factors within a Porous Scaffold 
One approach to sustained delivery of growth factors is to simply embed the factor during 
the fabrication process of a porous scaffold. The incorporation of angiogenic growth factors has 
been done by incorporating the factor into the polymeric solution prior to fabrication. This can be 
achieved by mixing the protein powder with polymer particles followed by cross-linking. This 
process has been seen to exhibit sustained release of  the growth factor VEGF, to promote 
cellular proliferation of endothelial cells in vitro and angiogenesis in vivo (Chung et al., 2007). In 
order for this method to be effective, the porous scaffold must undergo some degradation to 
allow for release of the embedded factor (Tabata et al., 1998). Modifying porous collagen-GAG 
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scaffolds cross-linking levels could potentially allow for an angiogenic factor to be directly 
incorporated into the collagen slurry and released at a controlled rate.  
2.5.4.2 Using Biodegradable Microspheres for Delivery 
Similar to embedding growth factors into the scaffold, biodegradable microspheres can 
be used to deliver growth factors at a controlled rate by combining them within a scaffold. One 
of the most common techniques used to achieve this is the use of poly(lactic-co-glycolic acid) 
(PLGA) microspheres to encapsulate the growth factor of choice. PLGA microspheres have good 
biodegradable properties as varying the ratio of PLA to PGA can result in a wide range of 
degradation rates. Similarly to embedding growth factors, these microspheres can be embedded 
within the scaffold during its fabrication process. These microspheres have been used in previous 
applications including entrapment within an alginate scaffold to deliver FGF-2 to induce 
proliferation of cardiofibroblasts in vitro and angiogenesis in vivo. However, some of the 
common issues with this method are the maintenance of physical integrity of the scaffold and 
bioactivity of the proteins (Chung et al., 2007). 
Another commonly used method for delivery of growth factors are gelatin microspheres. 
Gelatin microspheres are biodegradable and can be impregnated with growth factors such as 
FGF-2 for controlled release. These microspheres are fabricated through a process of 
gluteraldehyde cross-linking of gelatin aqueous solution. They can then be loaded by dropping a 
volume of aqueous solution of FGF-2 onto dried microspheres and allowing them to sit at room 
temperature and impregnate themselves. In a previous study, gelatin microspheres containing 
FGF-2 were implanted into the subcutaneous region of a mouse model that was induced with a 
diabetic ulcer (Kawai et al., 2005).  In vivo, angiogenesis in the mouse was much more 
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prominent in FGF-2 loaded microspheres as compared to FGF-2 applied at a single dose and a 
control containing no FGF-2 as seen in Figure 2 (Kawai et al., 2005).  
 
Figure 2: Shows the in vivo angiogenesis in a nude mouse model after 5 days of 
implantation. Image A shows the control of only gelatin microspheres alone, image B 
shows capillary formation in the presence of only FGF-2, and image C shows capillary 
formation in the presence of FGF-2 loaded gelatin microspheres. (Kawai et al., 2013) 
 
Angiogenesis was quantified by both fibroblast proliferation and capillary growth. At day 
5 of implantation, it was seen that the control group and single dosed FGF-2 group became less 
effective than in the first stages of healing. However, FGF-2 released at a controlled rate using 
gelatin microspheres continued to show fibroblast proliferation and capillary growth into day 10 
of healing. This study also proved that gelatin microspheres can be injected into the inner 
portions of porous collagen sponges for possible use in tissue engineered skin scaffolding 
(Kawai et al., 2005). One of the first steps of capillary and blood vessel formation in vivo is the 
migration of endothelial cells (Lamalice et.al, 2007). Although this study did not quantify 
endothelial cell migration, it can be hypothesized due to the extensive formation of capillaries in 
vivo that FGF-2 did have a large effect on the migration of endothelial cells.   
2.5.4.3 Immobilization of Scaffolds Using Heparin Engraftment 
 FGF-2 has been seen to have a large impact on fibroblast proliferation, 
neovascularization, osteogenesis, and nerve regeneration. Heparin is a highly sulfated 
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glycosaminoglycan that has the largest negatively charged density of any known biological 
molecule allowing it to bond to a variety of positively charged molecules.  Use of heparin on 
tissue regenerative scaffolds has been seen to be extremely effective as growth factors, including 
FGF-2, have a very high bonding affinity to it. This is very important as it protects the growth 
factor from protein denaturation and enzymatic degradation. It has been seen to be effective 
within PLGA microspheres as well collagen matrices (Ho et al., 2009). Heparin also has been 
seen to significantly enhance the controlled release of growth factors due to the presence of a 
reversible thermodynamic equilibrium between the immobilized heparin and the incorporated 
growth factor. Studies have combined immobilized heparin with collagen through a conjugation 
reaction between carboxyl groups on the heparin and amino groups on the collagen. Studies have 
shown that combing heparin with both VEGF and FGF-2 had a large increase in protein 
bioactivity to promote angiogenic activity (Chung et al., 2007). Heparin could be a very 
important factor in the advancement of scaffolds to enhance skin regeneration. 
2.6 Proposed Contibution to the Field 
The team hypothesized that mimicking parts of granulation and neovascularization in 
natural skin will allow for improved graft take of engineered skin. Improved graft take will 
include the ingrowth of endothelial cells into the scaffold. The increase in tissue ingrowth will 
create a stronger bond between the basement membrane and bottom of the dermal scaffold 
through increased endothelial cell migration and increased vascularization. An increase in blood 
vessel growth between the native tissue and scaffold will allow for increased circulation of 
nutrients and oxygen, which will make the tissue and cells connecting the scaffold to its native 
surroundings stronger. Additionally, a system that provides tunable regulation of factors 
affecting tissue ingrowth and vascularization will allow quantification of the relationship 
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bewteen graft take and native tissue response. These improvements to the field of skin grafts will 
aid patients by producing engineered skin with enhanced graft take components similar to that of 
native tissues. 
3.0 Project Strategy 
3.1 Design Process  
 Before objectives, functions, and constraints can be established, it was important to 
understand whom is fulfilling each role of the project. The three stakeholders include clients, 
users, and designers. The client played one of the major roles in the design process as they 
established the initial idea and statement defining the ultimate goals for the design. In this case, 
Professor George Pins was the client, as he was the driving force behind the eventual direction 
the project progressed.  The next important stakeholder of the project was the user. The user 
helped drive a different section of the project which was described as design usability and 
efficacy. If the design was not efficient or easy to use, the user would not want to invest in the 
design. It was important to establish Amanda Clement as the ultimate user of the device as she 
will be relying on the design and analytical process to perform further testing. Finally the 
designers were established as the Major Qualifying Project (MQP) group: Brittany DiCapua, 
Meaghan Dunn, Tyler Modelski, and Kristin Sundberg. It was ultimately the designer’s 
responsibility to translate the wants, needs and desires of all stakeholders into one device.  
3.2 Clarification of Design Goals 
 To obtain a better understanding of the initial client statement the team analyzed the 
initial client statement provided by Professor Pins.  
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Build upon the current µDERM scaffold to enhance vascularization and the 
rate of tissue ingrowth, and create a method to assess and validate the 
efficiency of the design.  
After further clarifying this client statement the team realized that this could be 
interpreted in many ways. After interviewing the client in multiple meetings, the team 
determined a list of objectives that would ultimately define the design of the project. Since the 
project had two goals, the first being enhancing vascularization and the second being validating 
the efficiency of the design, the team decided that two sets of objectives would best detail the 
client statement. 
Design Objectives for Enhancing Angiogenesis: 
 Efficient 
 Release Growth Factors at a Defined Rate 
 Easy to Use 
 Increases Tissue Ingrowth into Scaffold 
Design Objectives for an Assay to Assess Efficiency of the Design: 
 Efficient 
 Quantifiable 
 Effective 
 Easy to Use 
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One of the main concerns with the initial client statement was the particular system used 
to enhance the scaffold. Through developing the objectives above, the team determined that the 
most viable system would be the combination of a growth factor and controlled delivery method.  
After the initial objectives of the design were establish, other characteristics of the design 
were needed to solidify the boundaries and scope. Constraints are defined as characteristics of 
the design that need to be met under any circumstance or the device will fail. Constraints can be 
broken down into design constraints and project constraints. After researching and 
brainstorming, the team established the following lists of constraints for the project:  
Design Constraints: 
 Maintain Structural Stability 
 Collagen Sponge 
 Biocompatible 
 Cell Compatible 
 Ability to be Sterilized  
Project Constraints: 
 Time (28 weeks) 
 Budget ($524 refundable) 
 Material Access 
 Lab Equipment Availability 
After interviewing the client, constraints of the design included utilization of a collagen 
sponge with the same structural stability as µDERM which is biocompatible, cell compatible, 
and able to be sterilized. It was determined that maintaining the collagen sponge is a design 
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constraint as the user and client do not want to change the core design. In most medical devices, 
biocompatibility is a constraint because if the materials used are not compatible with the body, 
they are unsuitable for medical applications. The design must be biocompatible and cell 
compatible to allow for culture of endothelial cells and fibroblasts. The design must also be able 
to be sterilized using the same method of sterilization for the current µDERM (incubation in 
antibiotics). The current collagen-GAG sponge has not been quantified for scaffold stability; 
however, studies on collagen-GAG sponges that are fabricated with 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) cross-linking (same method as the current) have been 
performed (Boyce et al., 2006).  
Project constraints included time of completion, budget, material access, and lab 
equipment availability. The time constraint was very important in that there were only 28 weeks 
to complete the project. This prompted the need for a strict schedule throughout the year to keep 
the project and team on track for on time completion. The team also had a budget constraint of 
$524.00 to be used on the design. It was thus crucial to find materials that were affordable or free 
through utilization of materials from labs or other resources on campus. Other project constraints 
were determined to be material access and lab equipment availability. There was the possibility 
that a necessary material was not available. There was also the possibility that a piece of 
equipment was not able to be located on campus. Both design and project constraints were 
important when ranking alternative design ideas.  
3.2.1 Specifying Objectives 
After establishing the initial objectives of both the design and the assay, the objectives 
were organized into primary objectives and secondary objectives. Primary objectives were 
marked with roman numerals (I, II, III...) and multiple secondary objectives were marked with 
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letters (a, b, c…) beneath their corresponding primary objective. This was used to specify each 
layer of the design’s goals in an understandable manner.  
Goal: Enhance Angiogenesis 
I. Efficient 
 a) Cost effective (affordable for client) 
 b) Minimal addition of complexity to current scaffold design 
 c) Minimal manufacturing time of device 
 d) Reproduced accurately between batches 
II. Release factors at defined rate 
a) Release factors at constant rate 
b) Be able to precisely tailor the release rate 
c) Create scaffold with precise and reproducible release rate 
d) Create scaffold with accurate release rate 
IV. Easy to use 
 a) Minimal processing and handling time 
  i) Minimizes contamination 
 b) Easy to fabricate 
  i) Time to fabricate 
  ii) Equipment used to fabricate 
 c) Minimal complexity added to fabrication process 
 d) Maintain sterilization method 
V. Increase Tissue Ingrowth to Scaffold 
 a) Increase endothelial cell migration into sponge in vitro 
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 b) Initiate sprouting of endothelial cells for potential blood vessel formation in vivo 
 
Goal: Assay to Assess Efficiency of the Design 
I. Efficient 
a. High throughput 
b. Cost effective 
c. Minimize time for data collection 
d. Produces accurate results  
e. Produces precise/reproducible results 
II. Quantifiable 
a. Quantifies EC migration into sponge 
b. Quantifies rate of release of growth factor (or protein of similar MW) 
c. Accurate quantification 
d. Precise/reproducible quantification 
III. Effective 
a. Allows culture of ECs 
b. Allows for histological analysis 
c. Allows for fluorescence imaging 
d. Allows for staining of cells/proteins 
IV. Ease of Use 
a. Easily assembled/prepared 
b. Minimal time for assembly 
i. Reduce chance of contamination 
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c. Uses one variation of medium 
As detailed above, each objective was broken down into more specific objectives to 
better understand the details that the design must have. A more thorough, detailed list of the 
objectives and sub-objectives with corresponding objectives trees can be found Appendix A. 
Also, explanations for each sets of objectives has been provided and can be found in Appendix 
B.  
3.2.2 Quantitative Analysis of Objectives 
 The next step to the design process was to provide quantitative analysis of the seven 
primary design objectives. This analysis was used to determine the importance of each objective 
and to provide focus as to which objectives should be fulfilled first. To provide quantitative 
analysis, the team developed a pairwise comparison chart (PCC) to compare each of the primary 
objectives and sub-objectives for both the scaffold and assay. In the chart, each objective was 
compared against each other and given a score of 1, 0.5, or 0. The score corresponded to the 
objective that was in that row. A score of “1” indicated that the objective was more important 
than its comparison. A score of “0.5” indicated that the objective was equally as important as its 
comparison. A score of “0” indicated that the objective was not as important as its comparison. 
The PCC was filled out by the client, user, and design team to gather input from all views of the 
design. After the objectives and sub-objectives were ranked by each stakeholder, they were 
averaged and ranked based on importance. The charts below are a summary of Professor Pins 
(client), Amanda Clement (user), and the team (designers) rankings:  
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Goal: Enhance angiogenesis 
Table 1: Shows the pairwise comparison chart results from the client, user, and design team 
for the primary objectives of the goal to “enhance angiogenesis”. 
Primary Objectives Professor Pins Amanda Clement Team Average 
Efficient 0 0 1.0 0.33 
Release Factors at 
a Defined Rate 
3.5 2.0 2.0 2.5 
Easy to Use 1.0 1.0 0 0.67 
Increase Tissue 
Ingrowth in 
Scaffold in vitro 
3.0 4.0 3.5 3.5 
 
As seen from Table 1, it was determined that the two most important primary objectives 
for the scaffold to enhance angiogenesis was to 1) increase tissue ingrowth into the scaffold in 
vitro and 2) to release growth factors at a defined rate. The two lesser important objectives 
include efficiency and ease of use. After ranking the primary objectives the team ranked the sub- 
objectives. These rankings can be found in Table 2. 
Table 2: Shows the pairwise comparison chart results from the client, user, and design team 
for the secondary objectives of the objective “efficient”. 
 
Primary Objectives Professor Pins Amanda Clement Team Average 
Cost Effective 0 0 0 0 
Minimal Complexity 
of Current Design  
1.5 1.0 1.5 1.3 
Minimal 
Manufacturing 
1.5 2.0 1.5 1.7 
Reproduced 
Accurately Between 
Batches 
3.0 3.0 3.0 3.0 
 
It was determined that the most important sub-objective for efficiency is its 
reproducibility between fabrication of batches. This was important because the client and user 
would need a consistent model that could be tested- otherwise testing could not be considered 
significant because each fabricated design was not the same. It was also significant to note that 
cost effectiveness was ranked “0” for each stakeholder, which indicated that all were willing to 
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have a more expensive design if it produced the results needed. Table 3 shows the PCC results 
from the client, user, and team for the objective easy to use.  
Table 3: Shows the pairwise comparison chart results from the client, user, and design team 
for the secondary objectives of the objective “easy to use”.  
Easy to Use Professor Pins Amanda Clement Team Average 
Minimal Processing 
and Handling Time 
 
0.50 
 
1.0 
 
0.50 
 
0.67 
Easy to Fabricate 0.5 1 0.5 0.67 
Minimal Complexity 
Added to Fabrication 
Process 
1.5 2.0 2.0 1.8 
Maintain Sterilization 
Methods 
X X X X 
 
The objective, easy to use, was of main importance to the user (Amanda), as she will 
ultimately be the one manipulating the final design. According to the PCC, adding minimal 
complexity to the fabrication process was the most important sub-objective. If the fabrication 
process became too complex, there was a chance the user would not be able to fabricate it 
consistently, which would have a large effect on the ease of fabrication, fabrication time, and 
reproducibility. It should also be noted that maintaining the sterilization method of the scaffold 
was not ranked in the PCC, due to the fact that it was determined to be a constraint of the design 
instead of a sub-objective. Table 4 shows the PCC results from the client, user, and team for the 
objective release factors at a defined rate.  
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Table 4: Shows the pairwise comparison chart results from the client, user, and design team 
for the secondary objectives of the objective “release factors at defined rate”. 
Primary Objectives Professor Pins Amanda Clement Team Average 
Release Factors at a 
Constant Rate  
3.0 0 2.0 1.7 
Precisely Tailor 
Release rate 
0 1.0 0 0.33 
Precise and 
Reproducible 
Release Rate  
1.5 3.0 2.0 2.2 
Accurate Release 
rate 
1.5 2.0 2.0 1.8 
 
In order to best mimic the stages of wound healing, it was ideal for growth factors to be 
released at a defined rate. It was determined through the PCC for the objective, release factors at 
a defined rate, that the most important sub-objectives were having a precise, reproducible, and 
accurate release rate. These were most important because the design would ensure that the rate of 
release could easily be reproduced for the release mechanism of choice. The release method 
should also release growth factors at an accurate rate which mimics wound healing. Table 5 
shows the PCC results from the client, user, and team for the objective increase tissue ingrowth 
to the scaffold.  
Table 5: Shows the pairwise comparison chart results from the client, user, and design team 
for the secondary objectives “increase tissue ingrowth to scaffold”. 
Primary Objectives Professor 
Pins 
Amanda Clement Team Average 
Increase Endothelial 
Cell Migration into 
Sponge in vitro  
 
1.0 
 
1.0 
 
1.0 
 
1.0 
Initiate Sprouting of 
Cells for Blood Vessel 
Formation in vivo 
 
0 
 
0 
 
0 
 
0 
 
One of the main strategies to promote vascularization was to increase tissue ingrowth into 
the scaffold. There were two main aspects to this strategy which included increasing endothelial 
cell migration into the collagen sponge and initiating sprouting for potential blood vessel 
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formation. Through the PCC, it was unanimous that the most important sub-objective was to 
increase endothelial cell migration. This narrowed the goal, enhancing vascularization, 
significantly as it focused the scope of the objective and the design as a whole. 
Goal: Assay to Assess Efficiency of the Design 
 Since there were two main goals of the project, as discussed in section 3.2, it was 
important to assess them separately .This section differs from the previous section as it outlines 
the PCC for the outline rather than the scaffold. Table 6 summarizes the PCC results of the 
client, user, and design team.  
Table 6: Shows the pairwise comparison chart results from the client, user, and 
design team for the primary objectives of the goal to create an assay to assess efficiency 
of the design. 
Primary Objectives Professor 
Pins 
Amanda 
Clement 
Team Average 
Efficient 1.0 0 1.0 0.67 
Quantifiable 2.5 2.0 2.0 2.2 
Effective 2.5 3.0 3.0 2.8 
Ease of Use 0 1.0 0 0.33 
 
After performing the PCC for the primary objectives for the assay, it was determined that 
the most important objectives were to create an effective and quantifiable assay. Effectiveness 
was important as the assay must be able to mimic the system required to validate the design 
objectives. In addition, it must be quantifiable so that there was solid data to provide proof of 
concept of the design.   
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Table 7: Shows the pairwise comparison chart results from the client, user, and design team 
for the secondary objectives of the objective “efficient”. 
Primary Objectives Professor Pins Amanda Clement Team Average 
High Throughput 1.0 2.0 1.0 1.3 
Cost Effective 0 0 1.0 0.33 
Minimize Data 
Collection Time 
2.0 1.0 1.0 1.3 
Produce Accurate 
Results 
3.5 4.0 3.5 3.7 
Produce Precise/ 
Reproducible 
Results 
3.5 3.0 3.5 3.3 
 
The most important sub-objectives for the objective, efficient, were to produce accurate 
and reproducible results, as shown in Table 7. This indicated that the stakeholders believed the 
assay should allow for testing of the design to be accurate in comparison to the intended results 
of the scaffold design. It also indicated that the results should be reproducible between different 
trials of testing.  
Table 8: Shows the pairwise comparison chart results from the client, user, and design team 
for the secondary objectives of the objective “quantifiable”. 
Primary Objectives Professor Pins Amanda Clement Team Average 
Quantifies Cell 
Migration to Sponge 
2.0 2.0 2.0 2.0 
Quantifies Rate of 
Growth Factor 
Release 
0 0 0 0 
Accurate 
Quantification 
2.0 2.5 2.0 2.2 
Produce Precise/ 
Reproducible Results 
2.0 1.5 2.0 1.8 
 
The most important sub-objectives for the objective, quantifiable, were the ability of the 
assay to quantify endothelial cell migration into the sponge and be accurate, as seen in Table 8. 
This indicated that the assay would allow quantification of endothelial cell migration upwards 
into the sponge. Also, this method would be accurate and not subjective.  
  
44 
 
Table 9: Shows the pairwise comparison chart results from the client, user, and design team 
for the secondary objectives of the objective “effective”. 
Primary Objectives Professor Pins Amanda Clement Team Average 
Allows Cell Culture 3.0 3.0 3.0 3.0 
Allows for 
Histological Analysis 
0 0 0.50 0.17 
Allows for 
Fluorescence 
Imaging 
2.0 2.0 2.0 2.0 
Allows for Cell/ 
Protein Staining  
1.0 1.0 0.50 0.83 
 
The most important sub-objective for the objective, effective, was determined to be the 
allowance of endothelial cell culture, as seen in Table 9. This was very important, because if the 
assay did not allow for endothelial cell culture, there would be no way to assess the efficacy of 
the design. The assay also needed to allow for imaging so that quantification of endothelial cell 
migration could be obtained.  
Table 10: Shows the pairwise comparison chart results from the client, user, and design team 
for the secondary objectives of the objective “ease of use”. 
Primary Objectives Professor Pins Amanda Clement Team Average 
Easily Assembled 
and Prepared 
2.0 1.0 0.50 1.2 
Minimal Time for 
Assembly 
1.0 2.0 0.50 1.2 
Uses One Variation 
of Medium 
0 0 2.0 0.67 
 
For the primary objective, ease of use, there were two sub-objectives that were both 
ranked equally as important, as shown in Table 10. These sub-objectives were important in that 
the user would be able to easily assemble the assay through following a specific protocol. It 
would also require the minimum amount of assembly time which would help avoid potential 
problems such as contamination of endothelial cell cultures.  
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3.2.3 Revised Client Statement 
Through analysis of objectives, sub-objectives, and further research, a revised client 
statement was formed from the original client statement: “Build upon the current µDERM 
scaffold to enhance vascularization and the rate of tissue ingrowth, and create a method to assess 
and validate the efficiency of the design.” 
Modify the current µDERM scaffold by incorporating a growth factor and controlled 
release system into the porous collagen sponge. The factor should be released at a 
constant, tunable, precise and accurate rate and accelerate endothelial cell 
migration into the sponge. The design should also be easy to use, cost effective, 
efficient and add little complexity to current fabrication process. The design must 
also be validated using a cheap, high throughput assay. This assay should assess 
the rate of endothelial cell migration as well as rate of controlled release of the 
growth factor and should also allow for quantifiable results. The assay should also 
be easy to use and have reproducible, accurate, and precise results.  
The two main objectives discussed in the revised client statement include the design of a 
controlled release system of a growth factor that would enhance angiogenesis, and the design of 
an assay that would assess migration of endothelial cell into the collagen sponge. These two 
goals of the project were detailed significantly based upon the objectives and sub-objectives 
ranked in the PCCs and incorporated into the revised statement. 
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3.3 Design Approach 
3.3.1 Management Approach 
The team developed a management approach to help stay on track and meet specific 
requests. A Gantt Chart, found in Appendix C, was created as a timeline for specific deadlines 
and obligatory requirements. This chart allowed for scheduling of all assets of the project and 
timeline predictions. Throughout the duration of the project, each task was updated with a 
“percentage complete”, indicating which areas were falling behind track and should be focused 
on in more detail. The team continued to update the chart and track any advancements or draw-
backs and reconfigure accordingly. Additionally, the team held weekly meetings with the client 
and user to ensure successful progression. In these meetings, presentations were given and built 
upon from week to week. Client and user meetings also ensured that the project remained 
focused and on the correct path for all stakeholders. Once a final design was chosen, the final 
schedule for ordering materials, fabricating scaffold parts, assembling the assay, and ultimately 
testing the design in vitro were developed in detail.  
3.3.2 Design Approach 
3.3.2.1 The Approach 
 In order to ensure a successful project, a technical approach was made to plan the design 
process. The first step to the technical approach was to use the objectives, constraints, and 
functions that had been defined for the design to develop possible design ideas and sketches. 
From there, three design alternatives were chosen and ranked based on how well they fit the 
most important objectives of the project. This allowed final design determination in a 
quantitative manner, providing solid proof of why it was chosen. The final design was then 
drawn in computer aided design (CAD) to the specific dimensions. Once the final design was 
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solidified, materials needed for its fabrication and testing mechanism were ordered. At this point, 
specific protocols for fabrication of the design as well as preparation of the testing assay were 
obtained and a schedule was made for assembly. First, the design was fabricated and its design 
components verified. From there, the assay for testing endothelial cell outgrowth was assembled. 
Once assembled, testing was performed followed by a quantitative analysis of the data. This led 
to modifications of the design to improve its efficacy and the possibility of further testing before 
a final product was presented.  
3.3.2.2 Technical Limitations 
In any design project, there are possible limitations or problems that could arise 
throughout the technical approach. A potential obstacle was the project budget and whether or 
not enough money was allotted to incorporate all ideas into the design. Another possible 
limitation was failure to fabricate the design from the fabrication process of choice. Some of the 
potential problems that could have been out of the team’s hands were the cells adhering to the 
gel in vitro resulting in scarce cell migration. This could have happened if the cells were 
proliferating in their environment and attracted to the gel more so than the growth factors 
embedded into the scaffold. Also, with any cell culture experiment, the possibility of assay 
contamination could have been a major setback for the movement of the project. Meticulous 
labeling and cell culture techniques were essential in avoiding these limitations.  
3.3.3 Financial Approach 
 As outlined in the constraints for the project, the team was allotted $524.00 to be 
reimbursed by Worcester Polytechnic Institute (WPI) for the design. After preliminary research, 
the team found that commercial prices for growth factors, materials, cells, and medium were 
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very expensive. Although purchasing some of these materials, the team used outside resources 
and connections to obtain other necessary materials.   
4.0 Alternative Designs 
4.1 Needs Analysis 
In order to better identify the needs and wants of the system, the team performed a 
systemic needs analysis for both the scaffold and the assay. Systemic needs for the scaffold and 
assay are defined as metrics that must be maintained to ensure necessary objectives are met in 
order to warrant an effective design. Systemic wants for the scaffold and assay were desirable, 
preferred metrics that were not detrimental to the efficacy of the design. Systemic needs analysis 
charts for both the scaffold and assay are shown below. Table 11 represents the needs for the 
scaffold design, and Table 12 the wants for the scaffold design. Similarly, Table 13 represents 
the needs for the experimental assay and Table 14 the wants of the experimental assay.  
Table 11: Scaffold needs and corresponding definitions.  
Scaffold Needs Definition 
Increase migration Ability of the scaffold to enhance tissue ingrowth 
via endothelial cell migration to the collagen 
sponge in vitro 
Maintain porosity Ability of the designer to maintain scaffold 
stability in vitro by controlling the porosity of the 
collagen sponge  
Maintain degradation properties Ability of the designer to maintain scaffold 
stability in vitro through controlled degradation 
properties 
Flexibility Ability of the scaffold to maintain stability in 
vitro through minimal collagen sponge 
contraction 
Precise and reproducible release rate Ability of the scaffold to release growth factors in 
vitro at a defined rate that is consistent between 
batches 
Accurate release rate Ability of the scaffold to release growth factors in 
vitro at a defined rate that is consistent with valid 
scientific research 
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Accurate reproducibility Ability of the designer to produce the scaffold 
multiple times with consistent results between 
batches 
Minimal contraction Ability of the scaffold to maintain stability in 
vitro through controlled vertical flexibility 
 
 
Table 12: Scaffold wants and corresponding definitions. 
 
Scaffold Wants Definition 
Increase sprouting Ability of the scaffold to enhance tissue ingrowth 
via endothelial cell sprouting in vitro 
Tailored release rate Ability of the designer to alter the release rate of 
growth factors in vitro to desired specifications 
Minimal complexity Ability of the scaffold to be produced through a 
process with as few components as possible 
Ease of fabrication Ability of the designer to produce the scaffold 
with few to no complications 
Minimal processing Ability of the scaffold to be produced with as 
minimal processing requirements as possible 
Cost effective Ability of the scaffold results to outweigh its 
production cost 
 
 
Table 13: Assay needs and corresponding definitions. 
 
Assay Needs Definition 
Endothelial culture Ability of the assay to allow for simultaneous 
culture of the endothelial cells 
Accurate quantification Ability of the assay to numerically assess the 
results so that data can be easily interpreted and 
analyzed 
Quantify migration Ability of the assay to numerically asses the 
vertical movement of endothelial cells toward and 
into the collagen sponge 
Precise and reproducible quantification Ability of the assay to yield consistent data 
between trials 
Quantify growth factor release Ability of the assay to numerically assess the rate 
at which the growth factor is releasing 
Reasonably accurate results Ability of the assay to yield data that is reasonably 
consistent with the scientific literature  
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Table 14: Assay wants and corresponding definitions. 
 
Assay Wants Definition 
Imaging Ability of the assay to assess results through the 
use of cellular imaging  
Cellular staining Ability of the assay to assess results through the 
use of cellular staining 
High through-put Ability of the assay to analyze a variety of results 
in a time-efficient manner with consistent data 
Cost effective Ability of the assay results to outweigh the 
production costs 
Minimal time in data collection Ability of the assay to allow for assessment of 
results in the shortest amount of time possible 
Reproducible Ability of the designer to produce the assay 
multiple times with consistent results between 
trials 
Ease of assembly Ability of the designer to produce the assay with 
as few complications as possible 
Cellular medium Ability of the assay to only require one type of 
cellular medium for culture  
 
4.1.1. Systemic Needs 
4.1.1.1. Systemic Needs for Scaffold 
Systemic needs for the scaffold design were determined by consideration of the highest 
ranked objectives seen in the pairwise comparison charts. The team brainstormed and 
categorized the objectives as crucial metrics that warrant an effective design. The consequent 
placement of each systemic need was discussed with the client. It was determined that the 
scaffold must enhance tissue ingrowth via endothelial cell migration into the collagen sponge in 
vitro. The designer must be able to maintain scaffold stability in vitro by controlling the porosity 
of the collagen sponge and the degradation properties of the scaffold. The scaffold must maintain 
its stability in vitro through minimal collagen sponge contraction and controlled vertical 
flexibility. It must release growth factors in vitro at a defined rate that is consistent between 
batches and consistent with valid scientific research. The designer must be able to produce the 
scaffold multiple times with consistent results between batches. 
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4.1.1.2. Systemic Needs for Assay 
Systemic needs for the experimental assay were determined in the same manner as 
systemic needs for the scaffold. The team brainstormed and categorized the objectives as crucial 
metrics that warrant an effective design. The consequent placement of each systemic need was 
discussed with the client. It was determined that the experimental assay must allow for 
simultaneous culture of endothelial cells to ensure non-destructive data and accurate 
quantification. Vertical migration of endothelial cells in culture must be numerically defined and 
quantified to demonstrate the efficacy of the scaffold design in enhancing angiogenesis in vitro. 
The release of growth factor must also be numerically defined in the experimental assay to 
properly assess the effect of the factor on endothelial cell migration and further, angiogenesis. 
Lastly, data obtained in each experimental trial must be accurate and must not deviate from 
expected numeric found in literature.   
4.1.2 Systemic Wants 
4.1.2.1. Systemic Wants for Scaffold 
Systemic wants for the scaffold were determined in the same manner as systemic needs. 
Highly ranked objectives from the pairwise comparison charts were discussed by the team and 
client, and categorized accordingly. The team defined systemic wants as metrics that were 
important and not detrimental to the efficacy of the design. It was therefore determined that the 
scaffold should enhance tissue ingrowth via endothelial cell sprouting in vitro. The designer 
should be able to alter the release rate of growth factors in vitro to desired specifications. The 
scaffold should be produced through a process with as few components as possible and the 
designer should therefore be able to produce the scaffold with few to no complications. The 
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scaffold should be produced with as minimal processing requirements as possible, and ultimately 
the scaffold’s results should outweigh its production cost in order to ensure cost effectiveness. 
4.1.2.2. Systemic Wants for Assay 
 Systemic wants for the experimental assay were determined in the same manner as 
systemic needs. Highly ranked objectives from pairwise comparison charts were discussed by the 
team and client, and categorized accordingly. Systemic wants are important metrics which were 
not detrimental to the efficacy of the design. It was determined that the experimental assay 
should quantify endothelial cell migration through fluorescent cellular staining and imaging. 
Imaging endothelial cells will allow for accurate quantification of cellular movement through 
visual aid.  The assay should possess the ability to analyze a variety of results in a time efficient 
manner and be easily reproduced and assembled between trials. Lastly, the experimental assay 
should be a cost effective way to assess endothelial cell migration and further angiogenesis in 
vitro.  
4.2 Functions and Specifications 
Using the two highest ranked objectives from the PCCs, the team established specific 
functions for 1) the scaffold and 2) the experimental assay.  
4.2.1 Functions for the Scaffold Design 
The highest ranked objective for the scaffold design was to increase tissue ingrowth into 
the collagen sponge. To do so, the scaffold design must allow for an increase in endothelial cell 
migration. Endothelial cell viability must be maintained in order to ensure acquisition of 
quantifiable results and ultimately a successful system. Lastly, to promote adequate tissue 
ingrowth in vivo, the scaffold design must mimic the process of angiogenesis in vitro. The second 
highest ranked objective for the scaffold design was to release factors at a defined rate. It is 
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imperative that the chosen factor provides a controlled release. A controlled release rate will 
allow for a defined concentration of factor release. Table 15 shows each function for the two 
highest ranked objectives for the scaffold 
Table 15: Two highest ranked objectives and corresponding functions for the scaffold. 
Scaffold 
 
Increase Tissue Ingrowth into Collagen Sponge 
Increase endothelial cell migration 
Maintain endothelial cell viability  
Enhance angiogenesis  
Release Factors at a Defined Rate Provide controlled release  
 
4.2.2 Functions for the Assay Design 
The highest ranked objective for the experimental assay was the ability of the assay to be 
effective. To ensure an effective assay, the design must allow for endothelial cell culture. If the 
assay does not allow for continuous culture of endothelial cells, the cells may be destroyed. This 
will inhibit adequate analysis and consequentially interferes with evidence that proves desired 
objectives were satisfied. Additionally, the assay must allow for cellular marking. If the cells are 
not marked or labeled, cellular movement and morphology will be difficult to analyze and 
quantify, thus diminishing the effectiveness of the assay. The second highest ranked objective for 
the experimental assay was to produce results that are quantifiable; therefore, it must allow for 
accurate quantification of data. Additionally, the assay must allow for non-destructive data 
collection. A destructive assay may affect the project budget and be detrimental to the 
experimental procedure thus hindering desired results. Table 16 below shows each function for 
the two highest ranked objectives for the experimental assay.  
Table 16: Two highest ranked objectives and corresponding functions for the assay. 
Experimental Assay 
Effective Allow for endothelial cell culture 
Allow for cellular marking 
Quantifiable Allow for quantification of data 
Allow for non-destructive data collection  
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4.2.3 Specifications 
Through utilization of each function stated above, the team established numerical 
specifications for the scaffold design. Design specifications provide quantitative information 
about the necessary requirements for a device in regards to device assembly and usage. The team 
established each design specification through ample literature and client consent. The collagen 
sponge used for this design was 336 µm thick and two centimeters in diameter (Clement et al., 
2013). To provide mechanical structure to the scaffold system, the device must maintain a 
porosity of 400 µm2 and a stiffness of 35 mN/mm (Powell et al., 2006). If the scaffold is cross-
linked with 5 mM EDC, it is expected that approximately 40% of the scaffold will degrade after 
5 days; this is done with 60 mM EDC, there will be no predicted degradation (Powell et al., 
2006). In order to ensure the scaffold device promotes tissue ingrowth and mimics the 
angiogenesis stage of wound healing, it is expected that factors will be released at a controlled 
rate over a four day time span. This will ensure proper migration of endothelial cells in vitro 
which will translate to improved vascularization in vivo (Singer et al., 1999).  
4.2.4 Functions-Means Brainstorming  
Using the established design functions, the team conducted a brainstorming session to 
generate ideas for different means which could satisfy and fulfill each function for the scaffold 
design. Each team member was to research specific growth factors, conjugate methods or binders 
that could enhance angiogenesis and vascularization, and explain the pros and cons to each. Each 
design component was recorded on a white board and discussed as a team. Below, Figure 3 is a 
picture of the whiteboard where the team recorded potential design components for the scaffold. 
A second brainstorming session was held for the experimental assay. With consideration of the 
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design objectives, the team created numerous assay designs which would satisfy each function. 
Preliminary sketches for the assay designs are shown below as Figure 4. 
 
Figure 3: Picture of the white board used by the team to brainstorm specific growth factor 
components for the scaffold to be used to enhance tissue ingrowth and vascularization. After 
brainstorming, the team determined the top factors to improve vascularization include FGF-2, 
TGF-beta, MSC’s, VEGF, and hyaluronic acid. These factors were specifically chosen for their 
reliability in the field as well as for their alignment with the client statement.  
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Figure 4: Preliminary sketches which the team conducted to explore different components for the 
experimental assay which would test the efficacy of the newly modified and enhanced design. 
The sketches include two dimensional and three dimensional migration assays. 
 
Through the team brainstorming sessions, the team established means to achieve the 
stated functions for the scaffold design and assay. Given the time constraint for the project, the 
team and client established functions for only the two highest ranked objectives for the scaffold 
and assay. Due to time constraints and the high importance of these objectives in relation to the 
client statement, the team primarily focused on the top two objectives. Table 17 and Table 18 are 
representative of the established means from these corresponding functions for the scaffold and 
assay.  
Table 17:  Established means from the corresponding function for the two highest ranked 
objectives for the scaffold design 
Scaffold Objective: Increase Tissue Ingrowth into Sponge 
Function Established Means 
 
 
Increase endothelial cell migration 
RGD Peptide 
VEGF 
Micro-Topography 
FGF-2 
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Table 18: Established means from the corresponding function for the two highest ranked 
objectives for the experimental assay. 
Assay Objective: Effective 
Function Established Means 
 
 
Allow for endothelial cell culture 
Collagen 
Alginate 
PDMS 
Chitosan 
Agarose  
 
Allow for cellular marking 
GFP Marked Endothelial Cells 
Hoechst Staining 
Alexa-Flour488 Staining  
 
 
Allow for quantification of data  
Manual Counting 
MATLAB Programming 
ImageJ: Distance  
Cell Profiler  
ImageJ: Fluorescence  
 
 
 
Allow for non-destructive data collection  
Topographical Inward Migration  
Topographical Outward Migration 
Gel Inward Migration 
Gel Outward Migration 
Topographical Outward Boundary Migration 
Topographical Inward Boundary Migration 
Gel Inward Boundary Migration  
Gel Outward Boundary Migration  
Angiopoietin-1 
 
 
 
Maintain endothelial cell viability 
MSC’s + EC’s 
Hyaluronic Acid 
Heparin 
Mechanical Stretching 
5 mM EDC Crosslinking 
60 mM EDC Crosslinking 
 
 
 
Mimics angiogenesis 
Hypoxia 
Nitric Oxide 
FGF-2 
VEGF 
PDGF 
TGF-beta 
EGF 
 
Provide controlled release 
Gelatin microspheres 
PLGA Microspheres  
Binding Factor to Sponge  
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4.2.5 Design Matrices Analysis  
 In order to determine design alternatives, a design matrix analysis of the potential means 
brainstormed for each objective-driven function was used. This allowed for quantified rankings 
of each mean to express the method for choosing each alternative design. The design matrix took 
each mean under each function and “ranked” each mean a score of 1-4 (4 being the most suitable 
and 1 not suitable) against each objective. In order to rank each mean 1-4, scoring criteria was 
established and can be seen in Appendix D. Scoring criteria was based off what was seen to be 
considered successful in literature or off the educated opinion of the team about how many 
fabrication steps, fabrication time, etc. would be ideal. After a mean was ranked 1-4 against each 
objective that correlated to it, the resulting score was multiplied by a weight factor. Weight 
factors for each objective were determined based of the PCCs presented in section 3.2.2. For 
example, the highest ranked objective based on the PCC was “increase tissue ingrowth into the 
scaffold in vitro”. Thus, in this example, its weighted multiplier was “4” and the lowest ranked 
objective was “efficient” was weighted at a multiplier of “1”. The weighting system produced a 
weighted value for each objective that the mean was compared to. This number was then totaled 
and normalized using the following equation:  
Normalized Score = Mean’s Weighted Score / Maximum Weighted Total Score Possible 
This allowed for all means to be analyzed on a 100 point scale- 100 being the most 
suitable (all rankings of “4”) and 25 being the least suitable (all rankings of “1”). This design 
matrix was used for both the scaffold and assay and can be viewed in Appendix E. The results of 
ranking each mean against each other for each function can be seen in Tables 19 and 20.  
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Table 19: Design matrix results for the scaffold design. 100% indicated the most suitable design 
and 25% indicated the least suitable design. 
Increase Endothelial Cell Migration 
1st  FGF-2 88% 
2nd  VEGF 84% 
3rd  Micro-Topography  72% 
Maintain Cell Viability 
1st  5 mM EDC Cross-linked  76% 
2nd  Heparin  69% 
Mimic Angiogenesis 
1st  FGF-2 83% 
2nd  VEGF 78% 
3rd  PDGF 64 % 
Controlled Release Rate 
1st  Gelatin Microspheres 87% 
2nd  Bind factor to Sponge 73% 
3rd  PLGA Microspheres  63% 
 
Table 20: Design matrix results for the assay design. 100% indicated the most suitable design and 
25% indicated the least suitable design. 
Allow for Endothelial Cell Culture 
1st  Alginate 92% 
2nd  Collagen 87% 
3rd  Agarose  81% 
Allow for Non-Destructive Data Collection  
1st  Topographical Inward Migration 88 % 
2nd  Uni-Directional Single Strip  87% 
3rd  Topographical Outward Migration 86 % 
Allow for Quantification of data  
1st  MATLAB 89 % 
2nd  ImageJ  80 % 
2nd  Cell Profiler  80% 
2nd  ImageJ Fluorescence  80% 
Allow for Cellular Marking  
1st  GFP Marked Endothelial Cells 93% 
2nd  Alexa-Flouro488 Stain 89% 
3rd  Hoechst Stain  89%  
 
As seen from Tables 19 and 20, the number one factor to both enhance endothelial cell 
migration and angiogenesis was FGF-2. Both FGF-2 and VEGF were found in literature to be 
significantly more effective in enhancing endothelial cell migration compared to other factors; 
however, VEGF was much more expensive and a small portion of FGF-2 was available for the 
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team. Ideally, to maintain endothelial cell viability it was determined that 5 mM EDC cross-
linking of a collagen-GAG sponge was ideal (Powell et al., 2006). From Table 19, it was 
determined that to prevent denaturation of FGF-2, heparin could be a good binding agent to 
incorporate into the scaffold (Ho et al., 2009). Controlled release rates of the factor was 
determined to be very suitable in gelatin microspheres as they showed tailorable release kinetics 
in literature and were readily available and free to manufacture (Kawai et al., 2005).  
In determining the gel to be used for endothelial cell culture, alginate, collagen, and 
agarose gels all scored relatively high and were all available for free in the lab. Very similar 
results were seen for the allowance of non-destructive data collection. Many designs had been 
brainstormed as previously stated and further feasibility testing was performed on the highest 
scoring designs. For quantification of data, it was determined that the team ideally would use a 
MATLAB program to quantify migration due to the fact it is automated and accurate compared 
to manual data collection. The three means that fell in second place could all be used and their 
results compared to determine the most accurate and efficient method during the final assay. For 
cellular marking, the team ranked the top three means, but similarly to the above methods, will 
be evaluated during feasibility testing. The ranked results of both the scaffold and assay design 
matrices were factors which led to the formation of three design alternatives that are outlined in 
section 4.3.  
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4.3 Design Alternatives  
4.3.1 Design Alternative 1: FGF-2 Impregnated Gelatin Microspheres Analyzed by a 
Topographical Inward Endothelial Cell Migration Assay 
 
 
Figure 5: Computer drawing of design alternative one. FGF-2 will impregnate dry gelatin 
microspheres which are injected into the collagen sponge. 
 
After analyzing the design matrices for the scaffold, design alternatives were made by 
combining the top scoring means for separate functional requirements. The number one design 
was determined to be the incorporation of FGF-2 impregnated gelatin microspheres within the 
collagen-GAG sponge. Figure 5 is a schematic of design alternative one. FGF-2 has been proven 
to enhance angiogenesis through fibroblast proliferation and in particular endothelial cell 
migration (Kawai et al., 2005). Gelatin microspheres would be used as a controlled release 
mechanism and could be tailored to the desired release rate by controlling microsphere diameter. 
Gelatin microspheres could retain FGF-2 through adsorption of the protein as the resultant of the 
electrostatic interactions of the positively charged FGF-2 and negatively charged gelatin (Tabata 
et al., 1998). Ideally, these could be injected into the pores of the collagen-GAG sponge. Table 
21 shows a summary of the pros and cons of using FGF-2 impregnated microspheres.  
 
  
62 
 
Table 21: Pros and cons list for the FGF-2 impregnated gelatin microspheres incorporated into the 
collagen-GAG sponge 
Fibroblast Growth Factor-2 + Gelatin Microspheres 
Pros:  Cons: 
Stimulates EC Migration Cannot be used in vivo in free form due to short half-life 
Increases synthesis of collagenase Need balance of isoforms (2,7,10) for proper 
vascularization 
Can be loaded in microspheres for effective 
delivery 
FGF-2 is somewhat expensive 
Can be combined because of suitable  isoelectric 
points 
Can't cross-link after protein is present to avoid 
denaturation 
Range of biodegradability into non-toxic 
byproducts 
  
Injectable   
Gelatin microspheres inexpensive fabrication 
process 
  
 
The first design alternative for the assay included endothelial cells plated on an alginate 
gel with topographical inward endothelial cell migration. Figure 6 below shows the conceptual 
idea behind topographical inward endothelial cell migration.  
 
Figure 6: Computer drawing of the topographical inward migration assay. The green represents 
seeded endothelial cells on an alginate gel and the yellow represents the scaffold and factor 
secured to the alginate gel. Migration of the cells inwards from all directions towards the growth 
factor/collagen sponge conjugate will be measured.  
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As shown above, fluorescently labeled endothelial cells could be plated on the outer 
edges of an alginate gel with the angiogenic factor and sponge secured to the middle of the gel. 
The gel and sponge assembly could be placed in a six well plate and be completely engulfed in 
medium. Endothelial cell migration could be analyzed by measuring the gap closure between the 
cells and scaffold on multiple points on the gel and migration could be quantified by measuring 
the distance particular cells moved at multiple preceding time points after seeding. The pros and 
cons of this assay design are outlined in Table 22.  
Table 22: Pros and cons list for the topographical inward migration assay on an alginate gel. 
Topographical Inward Migration on an Alginate Gel 
Pros:  Cons: 
Simple and cheap fabrication Migration may be hard to quantify precisely 
Alginate supports EC viability EC have ability to migrate diagonally 
Non-destructive and allows for many data points Release gradient of FGF-2 due to micro-fluidics 
Gap closure imaging is clearer than imaging in scaffold   
 
4.3.2 Design Alternative 2: VEGF Impregnated PLGA Microspheres Analyzed by a 
Unidirectional Single Strip Endothelial Cell Migration Assay 
 
 
 
Figure 7: Computer drawing of design alternative two. VEGF loaded PLGA microspheres were 
embedded into the collagen-GAG sponge. 
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The second design alternative incorporated VEGF into PLGA microspheres within the 
collagen-GAG sponge. The apparatus was cross-linked using 5 mM of EDC. Figure 7 is a 
drawing of the proposed apparatus. VEGF is a well-known growth factor which has been proven 
to enhance angiogenesis and increase blood vessel formation in vivo (des Rieux et al., 2011). 
PLGA microspheres could be used as a mechanism for controlled release.  It has been 
demonstrated by Liu et al. that PLGA microspheres produce porous structures with high drug 
loading and encapsulation capabilities (Liu et al., 2010). This could allow for a controlled, 
slowed, and sustained release of the growth factor.  VEGF can be incorporated into PLGA 
microspheres through conjugation methods and protein adsorption. Table 23 is a summary of the 
pros and cons for using PLGA microspheres to deliver VEGF in the collagen-GAG sponge.  
Table 23: Pros and cons list for utilization of VEGF impregnated PLGA microspheres incorporated 
into the collagen-GAG sponge. 
Vascular Endothelial Growth Factor + PLGA Microspheres 
Pros:  Cons: 
VEGF induces neovascularization  PLGA potential for being toxic (synthetic) 
PLGA has a highly tailorable release rate  Overexpression of VEGF can promote disease formation 
VEGF can be effectively loaded into PLGA 
microspheres 
VEGF is expensive 
VEGF induces proliferation and migration of 
endothelial cells  
VEGF has a short biological half-life 
 
The second design alternative for the assay incorporated endothelial cells plated on the 
collagen-GAG sponge with examination of unidirectional migration. Figure 8 demonstrates the 
conceptual idea of the assay. A collagen gel could be added to a cell plate, and a strip of the 
collagen scaffold could be layered on top of the gel. Endothelial cells, stained with 
AlexaFluoro488 red to enhance cellular visibility, could be plated on the top of the scaffold strip. 
The migration of endothelial cells downward to the bottom of the scaffold strip could be 
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examined and quantified using an imaging processing program, ImageJ. The pros and cons of 
using the unidirectional single strip migration assay on the collagen gel are outlined below in 
Table 24. 
 
Figure 8: Computer drawing of the unidirectional single strip migration assay. The green 
represents the endothelial cells. The yellow represents the collagen-GAG scaffold with the 
incorporation of VEGF impregnated PLGA microspheres. Migration of the cells down the 
scaffold will be measured.  
 
Table 24: Pros and cons of using a unidirectional single strip migration assay on collagen gel. 
Unidirectional Single Strip Migration on Collagen Gel  
Pros:  Cons: 
Migration analysis is cheap and easy to perform User variability in migration measurements 
Collagen will support endothelial cell viability Endothelial cells may migrate diagonally 
Non-destructive and allows for many data points Migration may be hard to quantify precisely  
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4.3.3 Design Alternative 3: Micro-topography Collagen-GAG Sponge with Heparin Bound to 
FGF-2 Analyzed by a Topographical Outward Endothelial Cell Migration Assay 
 
 
Figure 9: Computer drawing of design alternative three. The heparin-bound micro-patterned 
collagen sponge will be combined with FGF-2.  
 
The third design alternative was the incorporation of FGF-2 into the collagen-GAG 
sponge through a heparin-bound micro-patterned surface. Heparin is a highly negatively-charged 
molecule known to specifically bind to growth factors and regulate their activity; FGF-2 displays 
a particularly positive surface charge that is complimentary to this anionic characteristic (Taylor, 
2007). Micro-patterned surfaces have been shown to improve cell attachment and migration into 
scaffolds, and thus ultimately improve tissue formation (Papenburg et al., 2007). Heparin could 
be incorporated into the collagen sponge in two ways: during material synthesis or through 
postmodification of the prepared scaffold. To procede with the former, heparin could be added to 
the collagen solution prior to fabrication and stabilization. To procede with the latter, heparin 
could be dissolved in a buffer into which the crosslinked scaffold could be added. This would be 
followed by rinses to remove unbound heparin, and finally freeze-drying (Knaack et al., 2013). 
The collagen sponge could be either cast onto a pattern with the incorporation of heparin 
(method one) or prior to submersion in the heparin buffer. The addition of FGF-2 to the scaffold 
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could be the final step necessary to complete design alternative three. Figure 9 depicts a drawing 
of the appartus, and Table 25 below displays the pros and cons of this option. 
Table 25: Pros and cons list for heparin-bound micro-patterned collagen sponge with addition of FGF-2. 
Heparin-bound Micro-patterned Sponge + Fibroblast Growth Factor-2  
Pros:  Cons: 
Stimulates growth of fibroblasts and EC 
Migration 
Cannot be used in vivo in free form due to short half-life 
Increases synthesis of collagenase Need balance of isoforms (2,7,10) for proper 
vascularization 
Heparin has affinity for FGF2 FGF-2 is somewhat expensive 
Heparin binding to FGF2 increases half life Doesn’t extend FGF2 release rate 
Extremely low isoelectric point for protein 
binding 
Possibility of mechanical failure 
  
Microtopography increases surface area 
 
Fabrication challenges (ability to change sponge 
topography) 
 
Microtopography shown to attract EC migration  
 
The third design alternative for the assay included endothelial cells plated on an agarose 
gel with topographical outward endoethlial cell migration. Figure 10 shows the conceptual idea 
behind topographical outward endothelial cell migration. 
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Figure 10: Computer drawing of the topographical outward migration assay. The green 
represents seeded endothelial cells on an agarose gel and the yellow represents the scaffold and 
factor secured to the gel. This representation does not depict the surrounding culture plate. Cell 
migration will be examined outward in all directions towards the collagen sponge FGF-2 
heparin conjugate boarder. 
As shown, the collagen-GAG scaffold (with microtopography, heparin, and FGF2) could 
surround a bolus of fluorescently stained endothelial cells. A uniform size square could be cut 
from the center of the scaffold with a razor blade to allow for injection of the cells. The center 
cut-out could not span the width of the agarose gel on the bottom of the plate so that cells could 
still be in contact with it. The gel and sponge assembly could be placed in a six-well plate and 
completely submerged in medium to sustain cell viability. Migration could be observed and 
analyzed by examining the gap closure between the cells and scaffold at multiple points on the 
gel. It could be quantified by measuring the distance that particular cells moved at various time 
points after seeding. The pros and cons of this assay are shown in Table 26  
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Table 26: Pros and cons list for the topographical outward migration assay on an alginate gel. 
Topographical Outward Migration on an Agarose Gel 
Pros:  Cons: 
Simple and cheap fabrication Migration may be hard to quantify precisely 
Agarose supports EC viability  EC have ability to migrate diagonally 
Non-destructive and allows for many data points Release gradient of FGF-2 may be affected by 
micro-fluidics 
Gap closure imaging is clearer than imaging in scaffold   
5.0 Feasibility Study/Experiments 
In some cases, additional research is sufficient to quantify one mean over the other, but 
when the top three means are ranked closely and there is not ample research to differentiate 
them, experiments are completed to further determine the components for the final design.  
5.1 Cell Culture  
5.1.1 Material for Cell Culture 
5.1.1.1 Collagen versus Agarose and Alginate 
Alginate, agarose, and collagen gels were examined in the laboratory and their fabrication 
and imaging abilities were assessed. Fabrication methods for collagen, agarose, and alginate gels 
can be seen in Appendix F. Collagen was clear and weak in mechanical stability. Alginate and 
agarose were both thick and translucent. Alginate, like collagen, had poor mechanical stability, 
whereas agarose was stronger and not as easily broken. Due to the mechanical integrity of 
agarose, it was able to be cut into thin slices. These small marks caused light diffraction and 
contributed to high background light in microscope images, making it harder to fabricate and 
creating a rough surface that was poor for imaging. A second fabrication limitation of alginate 
was that it was not possible to make a flat gel. NIH/3T3 fibroblasts were seeded onto each gel 
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type and their ability to be imaged was assessed. The images can be seen in Appendix G. The 
collagen gel was found to yield the most optimal images.  
5.1.1.3 Outgrowth Assay  
The team ran an outgrowth assay to determine if NIH 3T3 cells migrated on polystyrene. 
Cells were plated on a polystyrene dish and allowed to come to ~70% confluence. A scratch was 
made using a plastic pipette tip. Movement from the edges of the scratch towards the middle was 
monitored, with pictures taken at 0, 12, and 24 hours. Figure 11 details the results of the 
outgrowth assay. 
 
Figure 11: Outgrowth assay results of NIH-3T3 fibroblast cells. Images are taken at time points 
0 hours, 12 hours, and 24 hours. As seen from the photo, NIH-3T3 cells do migrate inward on 
polystyrene substrate. The vertical white lines mark cell movement from the edge of the scratch 
towards the middle. The horizontal dashed lines shows how the distance in the middle gets 
smaller over time as the cells migrate into the middle. This concluded that NIH 3T3 cells will 
migrate on polystyrene.  
 
5.1.2 Cell Viability 
5.1.2.1 Initial Cell Seeding Concentration  
The goal of this experiment was to determine the ideal seeding density of fibroblasts for 
the assay. NIH 3T3 cells at a concentration of 100,000 cells/200 µL of medium were used in the 
mock assay, and 200 µL was placed in the well. This cell concentration was not high enough to 
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form a confluent layer of cells after 24 hours. The team would like to reduce the cell seeding 
time to 4 hours and increase the confluence to at least 80% or if possible, 100%. Figure 12 
details the experiment used to determine the initial seeding concentration of cells, where the 
same area was used and the amount of medium used for the mock assay was maintained. In the 
left picture of Figure 12, 200,000 NIH 3T3 are seeded and to the right 500,000 NIH 3T3 cells are 
seeded. The cells were incubated at 37 degrees Celsius and 5% CO2 for four hours and the 
medium recipe for NIH 3T3 fibroblasts can be found in Appendix F. 
Figure 12: Two seeding concentrations of NIH 3T3 cells after four hours used to compare and 
determine the ideal seeding concentration. The ideal concentration to seed NIH 3T3 fibroblast 
cells is at 500,000 cells. This will allow 100% confluence of cells which is desirable for this 
experiment.  
 
Analysis of the pictures in Figure 12 showed that for NIH 3T3 fibroblasts, the ideal initial 
seeding concentration to allow for 100% confluence after four hours was 500,000 cells. Note that 
if the validation experiment was to be completed with any other cell type, the above experiment 
would also have to be performed a second time to determine initial cell seeding concentration of 
the new cell type in relation to the parameters of the assay.  
5.1.2.2 Sterilization of Components 
Each component of the design that was intended to come into contact with cells was 
sterilized effectively. Some of the methods utilized to sterilize materials include autoclaving, 
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ethylene oxide (ETO), and the use of antibiotics.  Autoclaving is a process that utilizes a high 
heat and moisture environment to kill bacteria. ETO is a chemical process that also kills bacteria, 
and is utilized in situations which autoclaving cannot perform. However, ETO poses a risk of 
leaving residuals. Both of these sterilization methods can induce changes in the protein chemistry 
and physical properties of collagen, and potentially affect absorption rate, mechanical integrity, 
and performance. Sterilization via autoclaving, however, is a safe method for PDMS, and thus 
the PDMS molds were sterilized in this way. Because autoclaving would denature collagen and 
ETO may leave residuals, the collagen gels were sterilization using antibiotics. Collagen gels 
were harvested and placed into six well plates, and an antibiotic solution was then added to each. 
The plates were then incubated for eight hours and subsequently rinsed and seeded with cells.  
5.2 FGF-2 Immobilization Technique 
5.2.1 Gelatin Microspheres 
The team originally utilized gelatin microspheres as a controlled release mechanism for 
delivering FGF-2. The fabrication process used to fabricate the gelatin microspheres can be 
found in Appendix F. Gelatin microsphere fabrication, though successful, had limitations. One of 
the main limitations to the fabrication process was collecting the microspheres into the beaker 
after formation. Next, the olive oil was removed by adding acetone and centrifuging the 
microspheres down. Microspheres were then re-suspended in acetone. At this point, the acetone 
and microsphere mixture was centrifuged again and the supernatant solution (acetone) was 
aspirated off the top. This left microspheres in a pellet form at the bottom of the centrifuge tube 
that needed to be transferred to a beaker for drying. However, when they were transferred to the 
beaker, many of the microspheres remained stuck to the bottom or on the sides of the centrifuge 
tubes. During the fabrication process six centrifuge tubes were filled with oil and gelatin 
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microspheres. This should have yielded a significant amount of particles; however, due to the 
limitations above approximately 75% of the microspheres were unable to be transferred for 
drying. Figure 13 below shows the gelatin microspheres that were formed. Only a small portion 
of the microspheres were imaged, but this proved the feasibility of their fabrication was 
insufficient.  
 
Figure 13: Gelatin microspheres shown with bright field imaging at 10X. Microspheres 
were fabricated via a water in oil emulsion technique.  
 
5.2.2 Microspheres to Heparin Binding Rationale  
As shown from the limitations in section 5.2.1, gelatin microspheres as a controlled 
release mechanism were deemed inadequate for the design. As seen from the design matrices in 
Appendix E, heparin binding to FGF-2 recorded the second highest score. Since the cost of 
heparin was relatively cheap and the protocol for fabricating heparinized FGF-2 sponges 
realistically feasible within the time constraint, it was chosen as the second design alternative.  
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5.3 Data Collection Technique 
5.3.1 Inverted Microscope Feasibility  
The goal of the inverted microscope feasibility experiment was to determine the ability to 
image fibroblasts in the collagen gel and collagen-GAG sponge components of µDERM. In 
Figure 14, cells can be clearly seen in the bright field images of the collagen gel, but cannot be 
seen in the collagen-GAG sponge. The large black areas seen on the collagen sponge indicate the 
porous structure of the material. There are many layers to the collagen-GAG sponge, making 
imaging particularly blurry due to a poor ability to focus the microscope between layers.  
300,000 NIH/3T3 
cells/100 µL plated on 
materials: 
 
Inverted Microscope (10X) 
 
 
Collagen gel 
 
 
 
 
 
 
 
Collagen-GAG sponge 
secured on top of gel 
 
 
Figure 14: Brightfield images after 24 hours of NIH/3T3 cell incubation on collagen gel and 
collagen-GAG scaffold on collagen gel. This figure shows that it is not possible to image cells on 
the collagen/GAG sponge unless additional dye markers are utilized. 
 
In conclusion, the second imaging idea was used. This imaging idea included the imaging 
of an un-seeded section of gel between the seeded cell population and the collagen-GAG sponge 
to measure endothelial cell migration. 
A limitations of this experiment was the lack of green fluorescence protein (GFP) marked 
cells or fluorescently stained cells, which could have aided in the visualization of cells in the 
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collagen-GAG scaffold. Another limitation was the usage of an inverted microscope for imaging, 
which images through all the layers of the gel and scaffold instead of imaging from the top 
down. Since the cells were plated topographically, the potential to see clear images of cells 
decreased with the increase in translucent layers. 
5.3.2 Non-Destructive Data Collection 
The three non-destructive assays tested were topographical outward, topographical 
inward, and unidirectional single strip migration assays. Figure 15 displays the experimental 
design of the topographical outward, inward, and unidirectional single strip migration assays. In 
Figure 15, the row of images titled ‘before assay set-up’ show the lack of ease of assay set-up in 
the topographical outward migration. This was because it was challenging to cut the inner square 
cutout without tearing the scaffold or making uneven edges and corners. It took the least amount 
of time to cut the unidirectional single strip scaffold. In terms of material conservation, the 
unidirectional single strip scaffold utilized the smallest area. This decreased costs of running an 
assay and allowed for more assays to be run at the same time due to the decrease in assay size. 
At time zero, assay mechanical integrity was good, but by hour 24 the topographical outward 
migration assay showed signs of poor mechanical structure because one of the sides of the assay 
fell off the collagen gel.  
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Figure 15: Pictures of topographical outward, topographical inward, and unidirectional single 
strip migration assays at stages of set up, zero, and 24 hours. These experiments were conducted 
to help determine the mechanical properties of the scaffold when subject to the conditions of the 
assay.  
 
In conclusion, the best non-destructive assay is the unidirectional single strip migration 
assay as it has good ease of assay set-up, good long term mechanical integrity, and uses the least 
amount of material increasing the ability for high-throughput assays. The team was able to 
further modify the unidirectional single strip assay as detailed in section 6.1.5 to further increase 
the high throughput ability of the final design. 
5.3.3 Imaging on Collagen Coated PDMS Well 
The purpose of this imaging experiment was to gauge the image quality and cell viability 
in a 10 mm or 5 mm wide and 3 mm deep well environment with a collagen gel coating. The 
control was the PDMS well without collagen. Once the PDMS molds were fabricated and 
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sterilized using an autoclave machine, the base of the wells were coated with collagen gel. The 
collagen was added to the wells using a syringe. Depending on the size of the well, different 
amounts of collagen were added. The goal was to coat the bottom of the well with a thin layer of 
evenly spread gel. Once the gelation process is complete, the gels were soaked in antibiotics for 
8 hours, then washed three times with Dulbecco’s Modified Eagle Medium (DMEM). The cells 
were then plated at 5 x 106 NIH/3T3 cells/1mL and incubated for three hours at 37 degrees 
Celsius and 5% CO2 to allow for cells to adhere. After three hours of incubation, additional 
medium was added covering the entire material, and incubated for 24 hours at 37 degrees Celsius 
and 5% CO2. The cells were post-stained with 20 µg of 1 mg/mL Hoechst in 1 mL of medium.  
These wells were imaged using fluorescence microscopy and analyzed quantitatively to 
determine if imaging was possible on wells of this size. Figure 16 shows the images collected 
from both the sides and middles of the wells. 
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0.5 x 106 
NIH/3T3 
cells/µL 
plated on 
materials: 
DAPI Imaging of Side of Well DAPI Imaging of Middle of Well 
Well 1- 
10 mm 
width and 
3 mm 
depth, 
with  
collagen 
gel 
     
 
Well 2- 
10 mm 
width and 
3 mm 
depth, 
PDMS 
 
 
Well 3- 
5 mm 
width and 
3 mm 
depth, 
PDMS 
  
Well 4- 
5 mm 
width and 
3 mm 
depth, 
with 
collagen 
gel 
 
 
 
Figure 16: DAPI images after 24 hours of NIH/3T3 cell incubation on collagen gel and PDMS. 
Column two represents images taken on the side of the well at different well dimensions. 
Similarly, column three represents images taken in the middle of the well at different well 
dimensions.  
The concern that diffraction would increase background light was minimal in all images. 
The images showed cell viability in both PDMS and collagen gel coated PDMS, but in different 
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locations in the well. The PDMS had viable cells congregated at the edges of the wells and 
significantly fewer cells in the middle. The cells of collagen gel coated PDMS gravitated towards 
the middle of the wells. In conclusion, cell viability was better on the sides and middle of the 
collagen gel than on the PDMS, but both the PDMS and collagen showed good image quality.  
5.3.4 Final Preliminary Migration Quantification Strategy 
The team discussed the migration quantification strategy for the final assay. Initially, it 
was decided that scratches were to be placed at defined distances on the bottom of the 
polystyrene dish using a metal blade and ruler. These scratches would be used as initial markers 
for cell migration when imaging. Details on the design process for quantification of migration 
and the final quantification design are described in section 6.1.6, the data collection procedure.  
5.4 Assay Fabrication 
5.4.1 Preliminary Design 
5.4.1.1 Description  
The preliminary design chosen was a PDMS mold with miniature wells coated with 
collagen gel and plated with cells at either end. The scaffold with implanted FGF-2 gelatin 
microspheres was placed in the center of the well. This preliminary design concept can be found 
in Appendix H. The design would allow for high throughput and non-destructive data collection 
of endothelial cell migration towards the collagen-GAG scaffold imbedded with FGF-2 gelatin 
microspheres.   
5.4.1.2 Computer Aided Design 
To fabricate the preliminary design as explained in section 5.4.1.1, CAD drawings were 
produced using SolidWorks to create a mold that could be used to make a pathway model out of 
PDMS. This section outlines the progression of CAD drawings and their limitations which 
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eventually led to the final design that was rapid prototyped. Figure 17 is a schematic of the 
concept behind the pathway design assay.  
 
Figure 17: Computer drawing of fundamental concept behind pathway design assay to quantify 
endothelial cell migration. Cells were seeded at the edges of each pathway with scaffold 
containing angiogenic growth factor in the middle of the pathway. Cellular migration could be 
imaged in the space between cells and scaffold.  
 
The team determined that this assay design was best suited if it could fit into the well of a 
six well plate. This would allow for multiple models to be plated at once to optimize the number 
of data points that could be quantified. Six well plates were measured to have the following 
dimensions: 17.4 mm depth, top diameter of 35.4 mm, and bottom diameter of 34.8 mm. These 
dimensions set the parameters for the dimensions selected for the computer aided design models. 
The first model created in SolidWorks can be seen in Appendix I. 
The design was a mold with dimensions 34 mm wide x 34 mm long x 15 mm depth. This 
mold created a PDMS model with the dimensions of 30 mm wide x 30 mm long x 10 mm depth. 
This would allow the PDMS model to fit into a standard six well plate. This model consists of 
five migration pathways that are 1 mm wide x 28 mm long x 1 mm depth.  A collagen coating 
would also be implemented on the surface of the PDMS to allow for endothelial cell attachment. 
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These pathways are the area in which cells would be seeded and the scaffold would be added. 
These channels would also hold the medium to be supplied for the cells.  
This design was then evaluated by the team and limitations of the design were analyzed. 
The team realized that this design was not feasible as rapid prototyping or machining (aluminum 
parts) could not be achieved with 1 mm cuts. This led the team to investigate new mold models 
that would not violate any of the constraints of machining or rapid prototyping.  
The second model that was designed using CAD incorporated a different plan of attack to 
allow for larger migration pathways that did not violate rapid prototyping or machining 
constraints. The intent of this model was also to produce molds of PDMS that could be placed 
into a six well plate. The second model created in SolidWorks can be seen in Appendix J.   
The second model created was an improvement compared to the first design. This model 
had the potential to create six PDMS molds with a diameter of 30 mm to allow placement in a 
six well plate. This model also allowed the team to analyze the results of each mold to determine 
the ideal pathway, width, and depth for seeding cells and analyzing migration. The first design 
produced three molds with a total of six pathways of varying depths and a 9 mm width. The 
second design produced three molds with a total of nine pathways of varying depths and a 4.5 
mm width. These parts were sent to the rapid prototyping machine at WPI where limitations of 
the design arose. These parts could be fabricated; however, there was a large cost constraint. The 
two models in Appendix J were estimated to be $120 which was too expensive for this portion of 
the project. It was determined that the reason for the large cost estimate was the amount of 
excess material that was being incorporated into the design. This led the team to reevaluate the 
design to reduce material and create a third model using CAD.  
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 The third model of the design incorporated similar concepts as the second CAD design; 
however, it incorporated much less material by cutting out the excess. The third model created in 
SolidWorks can be seen in Figure 18.  
 
  
Figure 18: Third computer aided design models of pathway design. The top two images 
represent the negative control to make PDMS design of varying depths (3mm, 5mm, and 7 mm) 
and a pathway width of 5mm. The bottom two images represent the negative control to make 
PDMS design of varying depths (3mm, 5mm, and 7 mm) and a pathway width of 7mm. 
 
This design incorporated all the advantages of the second CAD design while also 
reducing material costs. The design allowed for the team to determine the ideal depth and width 
that the migration pathway should have and was analyzed for imaging feasibility.  
  
83 
 
5.4.1.3 Mold Fabrication Technique 
The final CAD drawing of the mold for the final design from section 5.4.1.2 was sent to 
the rapid prototyping lab and the machine shop for fabrication. The team felt that two versions of 
the mold would be beneficial in that each provided varying migration pathway dimensions. 
Rapid prototyping was faster and made smaller parts than machining could have produced, but 
rapid prototyping was expensive and caused rigid pathways from fabrication. These rigid 
pathways could hinder cellular migration and increase diffraction leading to poor image quality. 
Machining had a fabrication process that allowed for a smoother finish, minimizing diffraction 
and not hindering cellular migration as much as rapid prototyping. Machining was also free, but 
could not be completed in the desired time.  
Due to time constraints, the only mold received and validated through testing was the 
rapid prototype mold. PDMS was made using the protocol in Appendix F. Figure 19 shows 
images of the PDMS once out of the mold and details some unexpected problems with PDMS 
casting in rapid prototyped plastic. 
 
Figure 19: Images of proper PDMS molds at 3 mm depth. The middle row shows 5mm deep 
molds and the top row shows 7 mm deep molds that were both too deep to remove properly. 
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The team was unsure as to the best depth and width of the mold, so the rapid prototyped 
molds were constructed at 5 mm and 10 mm in width and 3 mm, 5 mm, and 7 mm in depth. The 
molds with the lowest depth were able to be removed, but only after heating to 60 degrees 
Celsius and then cooling in a freezer for three minutes to loosen the PDMS from the mold. 
Molds containing larger depth dimensions were not able to be removed fully from the molds 
without breaking.  
5.4.2 Preliminary Design Changes 
5.4.2.1 Converting Assay from Bi-Directional to Uni-Directional 
As discussed in section 4.3.1, the team originally believed that a topographical inward 
migration assay from two directions would be the most viable design for maintaining the project 
goals. However, through validation testing, the team realized a unidirectional migration assay 
was best fit. In the new design, a long narrow well will contain the scaffold and growth factor 
conjugate on one end and the cells on the other. Cell migration toward the scaffold will be 
measured in one direction only and any potential concentration gradients of FGF-2 will be 
negligible. Also, the well will be narrow enough to disallow diagonal cell migration.  
5.4.2.2 Changes in PDMS Mold Dimensions and Fabrication 
The previously discussed PDMS mold was too small to allow for PDMS removal without 
breaking the PDMS. To fix this problem, the team used a Corning® 3295 sterile 60 mm x 15 mm 
round cell culture dish, with CellBIND® treated polystyrene and made six wells inside this one 
large round dish.  
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Figure 20: A) Five glass microscope slides fastened together to make imprints in PDMS to form 
wells, B) Post fabrication of slide imprinted PDMS. This shows the final design of well imprints 
in PDMS along with the PDMS barriers, fabricated in the same fashion as the well imprints.  
Three steps encompassed the PDMS well fabrication process. The first step, shown in 
Figure 20 part A, was making the glass slides that will hold the form of the wells as the PDMS is 
poured around them. The glass slides were made of five glass microscope slides from Fisher 
Scientific (cat#12-544-7) taped together to make a firm, smooth base and sides. Smooth sides 
were important for the base of the slides so that minimal PDMS gets under the base during 
fabrication. In addition, smooth slides will form smooth sides of the wells, which will increase 
image quality when collecting microscope data.  The PDMS fabrication procedure can be found 
in Appendix F. The third step shown in part B of Figure 20 indicates post fabrication steps to 
prepare the wells where the PDMS was removed from the dish and the inner edges of the wells 
were scraped to make sure no PDMS appeared at the base of the well. Part B of Figure 20 also 
shows the PDMS barriers, which were used to separate the cells from the scaffold during the first 
hours of the assay. The barriers were fabricated in the same fashion as the PDMS wells and 
followed the same post-fabrication procedure.  
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5.4.3 Feasibility Study of Changed Preliminary Design 
5.4.3.1 Mock Assay 
After changing the PDMS mold dimensions and fabrication technique, the team verified 
that the new PDMS wells and barriers would work in the assay by running a mock assay. It was 
called a mock assay because untreated scaffolds were used and the purpose was for verification 
of design compatibility with the assay not validation of the final design. Figure 21 details the set-
up of the mock assay, specifically part A. 
Figure 21: A) Plate layout. Each well was seeded with 50,000 or 100,000 cells at one end. Two 
or three collagen/GAG sponges were cut and placed at the opposite end of the well. Barriers 
were set in place at the cell ridge, and the well was flushed with medium. B) Schematic of wells 
fit to the previously discussed set up in part a.  
 
Part B of Figure 21 represents the plate layout showing that in the mock assay only two 
wells were used. The first well had 500,000 NIH-3T3 cells plated on the left side of the barrier 
and two scaffolds on the right side. The second well had 100,000 NIH-3T3 cells plated on the 
left side of the barrier and three scaffolds on the right side. The distance between the left wall 
and the edge of the barrier was 8 mm for each well to ensure a uniform area for cellular 
adherence to the polystyrene dish. The scaffolds were tightly pressed to the left wall of the well 
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to keep them from moving across the well during the assay. The cells were allowed 24 hours to 
adhere before the barrier was removed.  
Some concerns regarding the mock assay include PDMS adherence to the polystyrene 
dish, initial concentration of cells to plate, effectiveness of the barrier in preventing cellular 
movement, the effect of barrier removal on cellular viability, and adherence of the scaffold to the 
back wall of the well.  
For the mock assay set-up, the outer edges of the PDMS containing the six wells were cut 
so that the edges of the PDMS would not touch the polystyrene dish, as seen in part A of Figure 
22. Cutting the edges decreased resistance on the PDMS from the sides of the polystyrene well, 
which increased the ability of the PDMS to stick to the polystyrene dish. It was important that 
the PDMS was completely sealed to the polystyrene well to ensure no medium movement 
between wells. Additionally, the PDMS was sprayed with ethanol and allowed to air dry to 
ensure proper sterilization and allow for better adhesion to polystyrene. Part B of Figure 22 
shows the PDMS barriers and part C shows how the PDMS barriers were placed in the wells.  
Figure 22: A) Cutting outer edges of PDMS to decrease exterior stresses from the six well plate 
on the PDMS. This was done to create a vacuum seal of PDMS on the bottom of the polystyrene 
dish. B) PDMS barrier used to separate the cells from the sponge when the cells are adhering to 
the polystyrene dish, C) PDMS wells placed in dish and barriers placed in wells. 
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Figure 23: A) This is an example of adding the scaffold to the wells as the initial assay set up, B) 
This details where the cells, medium, and sponge are located in the well in relation to the PDMS 
barrier. 
 
Once the PDMS wells and barriers were in place, the cells and the scaffold were added, 
as seen in Figure 23. Using forceps the scaffold was wedged at the end of the well on the right 
side and 200 µL of medium was added. Cells were plated to the left side of the barrier in 200 µL 
of medium. The assay was incubated at 37 degrees Celsius and 5% CO2 and was only taken out 
of the incubator to take images at the chosen time points.  
Data collected from the mock assay is shown in Figure 24. The first column shows the 
interface between the cells and PDMS barrier. The images were collected to see if the cells 
crossed the PDMS barrier. This was important to know because it would affect the accuracy of 
the experiment if the cells moved beyond the barrier prior to the designated start time. The 
second column shows the interface between the scaffold and the back right wall of the PDMS 
well. This data was collected to determine if the scaffold remained attached to the PDMS well 
wall or if the scaffold detached from the wall and deteriorated across the well. This was 
important because if the scaffold deteriorated it would come in contact with the cells and 
negatively impact the accuracy of the experiment. Two images were taken for time point 24, in 
which the first picture is from pre-barrier-removal and the latter is from post-barrier removal.  
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Figure 24: Data collected from an outgrowth assay where the NIH 3T3 Fibroblasts are plated at 
50,000cells in the designated area between the left PDMS well wall and the PDMS barrier. The 
scaffold is placed against the right PDMS well wall. The first column is data collected from the 
cell-PDMS barrier interface and the second column is data collected from the scaffold-PDMS 
right wall interface at different time points (hours) 0,3,18, 24. The second 24 hour time point 
shows data after PDMS barrier removal. The dashed yellow line indicates the approximate cell-
PDMS barrier interface and the horizontal yellow lines indicate scaffold detachment from the 
right PDMS wall.  
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As seen in column two of Figure 24, the cell-PDMS barrier interface, highlighted by the 
yellow dashed line, showed no cellular movement across the PDMS barrier. The data showed the 
PDMS barriers will stop cell movement for up to 24 hours. For the final assay procedure, the 
team only needed the PDMS barriers to stop cell movement for 4 hours, so this method was 
adequate. In the second 24 hour time point the PDMS barrier was removed. Again, in the second 
column of Figure 24, the yellow dashed line indicated the prior cell-PDMS barrier interface and 
presence of the scaffold. This showed that the scaffold had deteriorated from its initial position at 
the right well wall to encompass a majority of well. Figure 25 details the extent of scaffold 
deterioration. The third column in Figure 24 showed that not only is the scaffold deteriorating, it 
also moved away from the right wall of the PDMS well. The horizontal yellow line indicated the 
sections of the scaffold that are completely unattached to the PDMS wall and the distance they 
had moved from the wall.  
 
 
Figure 25: Overview of experiment at 24 hour time point after PDMS barrier removal. At time 
point 0 the scaffold is pinned closely to the back right wall of the PDMS well and only takes up 
one frame. Now at 24 hours it can be seen (above) that the scaffold has deteriorated into 5 
frames, which is most of the well. This shows encroachment of the scaffold into the cell region. 
The long term mechanical stability of the scaffold is lacking. The scaffold must be secured to the 
right hand wall of the well for experimental success in order for the cells to be undisturbed by 
scaffold degradation. 
 
When looking at Figure 25, it can be seen that the scaffold had moved over four frames 
and was encroaching upon the cell seeded section of the PDMS well. If the scaffold deteriorated 
across the well, there would be no concentration gradient which would defeat the purpose of the 
experiment. It was noted that while the PDMS barrier was effective, the scaffold placement 
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against the back wall the PDMS well was not. The team proceeded to brainstorm design changes 
to the assay that would allow for the securing of the scaffold to the PDMS wall. 
5.4.3.2 Verification of PDMS Barrier Leakage 
The mock assay determined that the cells would not cross the PDMS barrier, but it did 
not determine if the fluid would cross the PDMS barrier.  
 
Figure 26: Dye test, imaged after 24 hours, to determine microfluidic movement between the left 
and right sides. The wells on the left are controls, containing medium only. The wells located on 
the right are variable wells filled with medium, the PDMS barrier, and Trypan blue stain to 
determine whether or not leakage was present across the PDMS barrier.  
 
In Figure 26, the two wells on the left are control wells containing only medium. The 
wells on the right contain Trypan blue dye on one side and medium on the other side of the 
barrier. At 0 and 24 hours the wells were imaged, and the images are presented in Figure 27.  
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Figure 27: Dye test results indicating no presence of microfluidic movement across the PDMS 
barrier as data from the controls mimic data of the variable wells. The control is a well with 
medium and no dye. The control was used to show a comparative control so conclusions could 
be drawn on other conditions regarding medium leakage across the PDMS barrier of the well.  
 
Figure 27 showed that the side that did not contain Trypan blue matched with the control 
at both time points. This indicated that even after 24 hours there was no dye movement into the 
other side of the well, therefore there was no leakage between the left and right sides of the 
barrier. 
5.4.3.3 PDMS Adhesion to Polystyrene 
The team researched sterile ways to adhere PDMS to polystyrene. One method was to use 
A-100 medical silicone adhesive or vacuum grease, which can be found in a local hardware 
store. Vacuum grease dries clear and when properly sterilized produced no cytotoxic effects. The 
team chose vacuum grease as an adherent method because it was already available in the 
laboratory. The grease was placed into a syringe and the syringe was autoclaved. Then, a small 
amount of grease was syringed on the bottom of the PDMS. A thin razor edge was used to spread 
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the grease over the entire bottom of the well. Any excess grease that fell into the wells was 
removed using the corner of the razor. Next, the PDMS was placed on the polystyrene and light 
pressure was applied. The entire plate was placed under ultra violet (UV) light for 20 minutes to 
complete the sterilization process.  
5.4.3.4 Containment of Scaffold 
To contain the scaffold against the back right wall of the well, three mechanisms were 
devised: a high, medium, and low scaffold security gate made of medical grade stainless steel 
wire mesh. The mesh was small enough to contain the scaffold, but large enough to allow for 
fluidic movement across the well so the release of growth factors by the scaffold was unaffected. 
Figure 28 is a schematic of the three different types of scaffold security. 
 
 
Figure 28: Scaffold securing mechanisms at high security, medium, and low. A stainless steel, 
mesh barrier was placed to secure the scaffold to the wall; ensuring no movement of the scaffold 
throughout the assay.  
 
The purpose of looking at three different mechanisms was to determine what level of 
scaffold confinement was needed. The high security barrier gate wrapped entirely around the 
area where the scaffold was located and requried the most time and resources to produce. The 
medium security gate wrapped around the top of the scaffold, but the botom part just touched the 
bottom of the well. Both the high and medium gates were secured by the top part of the gate 
attaching to the back wall of the PDMS well. The low scaffold security gate touched the bottom 
of the well, but not the top of the well and anchored into the sides of the PDMS well.  
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Gates were fabricated from a stainless steel mesh sheet. The length of the gates varied 
and were not considered a factor in the migration assay as long as they were big enough to 
contain the scaffold and to be secured in the PDMS well. All the gates were placed in the wells 
first, leaving 3 mm of space between the gate and back of the well wall where the scaffold was 
then added. Once the scaffold was placed in the well, the gates that connected to the back wall 
were bent over the scaffold using forceps and connected to the PDMS. Medium (200 uL) was 
added to each side of the barrier to mimic a typical assay set-up and the barrier was then 
removed after several hours. Images of the wells were taken at zero hours after barrier removal 
and 24 hours after barrier removal. The data is presented Appendix K. 
The data showed that all three versions of the gate were successful in containing the 
scaffold. For both zero and 24 time points the scaffold was contained on the left side by the gate. 
At no point did the scaffold cross the gate into the other side of the well. For the final assay, the 
low security gate was used because it utilized the least amount of materials.  
5.4.4 Final Design 
5.4.4.1 Final Fabrication of PDMS 
A holder for the glass slides was created and sent to be rapid prototyped. The concept is 
detailed in Figure 29. 
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Figure 29: Schematic of rapid prototyped holder for glass slides. The top piece to the rapid 
prototype is 2.0 cm thick, and the legs are 4.5 cm. The distance between each of the slots 
horizontally in the rapid prototype piece is 3.5 cm and vertically 1.4 cm. The slot allows a glass 
slide of 0.5 cm in width to pass through.  
 
The holder was placed on top of an open six well plate to allow for glass slide placement 
in individual wells. The glass slides were placed through the slots on the holder and rested on the 
bottom of the plate. Next, PDMS was poured under the holder and into each well of the plate.  
5.4.4.2 Final CAD Design and Description 
The final design included individual PDMS wells with cells on one end and scaffold on 
the other end. There was a gate confining the scaffold to keep it in place. In addition, a 
removable PDMS barrier was used to keep the cells in place and prevent medium leakage prior 
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to the start of the assay. There were scratches on the bottom of the polystyrene for migration 
quantification. The final design concept is shown below in Figure 30. Figure 31 is a blown up 
and labeled schematic of all the parts involved in making the final design seen in Figure 30. 
 
 
 
Figure 30: CAD of final design. This details the placement of the cells in relation to the PDMS 
barrier, mesh stainless steel gate, and scaffold. Each well is 3.48 cm in diameter and the well 
channels are 0.5 cm in width and 2.5 cm in length.   
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Figure 31: Schematic of parts comprising the final design. All of the components including the 
glass slide holder, scaffold, mesh stainless steel gate, PDMS barrier, wells, and polystyrene 
scratches.  
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6.0 Validation  
6.1 Validation Procedure  
The final revised design was determined in chapter five. The team took the final revised 
design and applied it to the experiment set-up. Thus validating the revised final design in the 
context of the experiment, as seen in the below sections of the experimental procedure.  
6.1.1 Assay Procedure  
The first step was to get the rapid prototyped glass slide holder, as seen in Figure 32. 
 
 
Figure 32: Picture of the rapid prototyped glass slide holder. 
 
The rapid prototyped part was placed on top of the six well plate from CELLTREAT 
(product #229106) and the glass slides were placed through the slots on the glass slide holder. 
The PDMS was made and poured into the wells on the plate. Figure 33 shows the fabrication of 
PDMS wells. 
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Figure 33: Schematic of final PDMS well fabrication procedure. The glass sides and slide holder 
were inserted into the six well plate. PDMS was then added to each of the six wells and it was 
placed in the vaccuum chamber for one hour to remove all air bubbles. The arrows indicate the 
order of the fabrication process.  
 
After PDMS well fabrication and five minutes in the freezer, the rapid prototyped slide 
holder was removed and the glass slides were removed from the PDMS. This allowed for easier 
removal of PDMS from the wells of the plate. First, the glass slides were removed by gently 
moving them back and forth. The PDMS then detatched from the glass and the slide could be 
pulled out of the well. The PDMS was then removed using a metal spoon and forceps. The edges 
of the PDMS were then sterilized and vaccum grease was added. The PDMS molds were then 
and placed in a new six well plate. Figure 34 details the post-fabrication process descibed above. 
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Figure 34: Schematic of the post-fabrication process for PDMS wells.  
Once the PDMS wells were secured in a new six well plate, the plate was flipped over 
and scratches were made on the bottom of each well. These scratches would help the team line 
up the printed grid with the appropriate areas on the well.  
The six well plate was then placed upward and the barriers were added 8 mm from the 
left end of the top of the well wall, and gates were added 3 mm form the right end of the bottom 
of the well wall. Section 5.4.3.1 details barrier and gate fabrication and techniques for placement 
in the assay. The lid to the six well plate was then left open under the hood, as the plate was 
placed under UV light for 20 minutes to sterilize the assay surface.  
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Figure 35: Addition of cells, barriers, gates, and scaffold to the assay. One millimeter grid paper 
was fastened to the bottom of the six well plate to create a grid system to aid in image 
consistency.  
 
             In a sterile environment, the cells were then added at a concentration of 500,000 NIH 
3T3 cells/200 µL medium with 200 µL being added to the left side of the well. One scaffold was 
added to each well between the gate and the right wall.  
            The plates were labeled with permanent marker to indicate different concentrations of 
heparin and FGF-2 added to the scaffold, as seen in Figure 35. Section 6.1.5 explains the 
experimental set-up in detail including the type of experimental conditions and how many data 
collection repetitions of each were performed. After four hours of cell incubation in a 37 degree 
Celsius and 5% CO2 incubator, the barriers were removed.   
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6.1.2 Scaffold Preparation  
6.1.2.1 Heparin Immobilization of Collagen-GAG Sponges 
Simultaneously while prepping the assay, the modified collagen-GAG sponges were 
fabricated. Collagen-GAG sponges were obtained as scrap material and cut into appropriate size 
using a 9 mm biopsy punch. In order to perform calculations as to how much heparin and FGF-2 
were needed for each biopsy, the sponges were weighed and an average weight was determined. 
The average weight of the 9 mm scaffolds was 1.59 mg and this value was used for all 
calculations. Table 27 shows the weights of each of the collagen-GAG sponges that were cut 
using the 9 mm punch biopsy.  
Table 27: This table shows the data for the weights of each of the collagen-GAG 
sponges that were cut using a 9 mm biopsy punch.  
 
Weight (mg) 9mm 
 Biopsy Punch 
1 1.6 
2 1.3 
3 1.3 
4 1.5 
5 1.8 
6 1.4 
7 1.5 
8 1.9 
9 1.9 
10 1.5 
11 1.8 
12 1.6 
AVG 1.6 
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In order to run the experiment six different conditions were given to the scaffolds. These 
conditions included collagen-GAG sponges that were: 
1) Non-heparinized with no FGF-2  
2) Heparinized with FGF-2 (100 ng/mL) 
3) Heparinized with FGF-2 (200 ng/mL) 
4) Heparinized with FGF-2 (300 ng/mL) 
5) Non-heparinized with FGF-2 (300 ng/mL) 
6) Heparinized with no FGF-2 
As seen in the conditions above, four included sponges that needed to be heparinized. 
Two experiments were to be run per condition using two scaffolds per experiment indicating that 
sixteen heparinized sponges were needed to be made.  
Sixteen collagen-GAG sponge biopsies were incubated in 2-ethanesulfonic acid (MES) 
buffer solution for thirty minutes in a standard cell culture dish. The MES buffer solution had a 
concentration of 0.5 M and a pH of 8.0. While incubating each scaffold, a heparin solution was 
prepared.  This solution consisted of heparin sodium salt, EDC, and N-hydroxysulfoccinimide 
(NHS) at specific molar ratios. The EDC and NHS were used to activate the carboxylic acid 
groups on the heparin chain to allow for binding to the scaffolds. The protocol for this procedure, 
as seen in Appendix L, was adapted from a protocol used by Wissink et al.  
The following calculations were performed to determine the amount of MES buffer, 
heparin salt, EDC, and NHS to add to the solution. Since there were eight sponges to be 
heparinized, the total weight of collagen that was incubating in MES buffer was 25.4 mg (16 
sponges).  
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Next, the amount of MES buffer needed to be calculated. As seen in the protocol, 188.3 
mL of MES buffer solution is used to heparinize 1 g of collagen. Using this ratio, the amount of 
MES buffer needed to prepare the solution was calculated using the equation 188.3 mL MES 
buffer * 0.0254 g collagen which yielded a 4.78 mL volume of MES buffer solution.  
Heparin sodium salt was added to the solution first. It can be seen in the protocol that 
heparin sodium salt is added at 2% w/v to the MES buffer. The following calculation determined 
the amount of heparin added: 4.78 mL* 0.02 = 0.0957 g = 95.7 mg heparin sodium salt. From 
this the amounts of EDC and NHS were calculated using molar ratios as shown in the protocol. 
The molecular weights for heparin, EDC and NHS used were as follows: Heparin sodium salt 
(4,000 g/mol), EDC (155.24 g/mol), and NHS (115.09 g/mol). The molar amount of heparin 
sodium salt was determined using its molar ratio by dividing its weight by its molecular weight; 
0.0957 g / 4,000 g/mol = 2.39 * 10-5 mol heparin. Since the molar ratio of EDC to heparin used 
to make the solution was 0.5, the amount of EDC was half the amount of the molar amount of 
heparin indicating that 1.20 * 10-5 mol EDC should be used. Multiplying this by its molecular 
weight yielded a weight of 1.86 mg of EDC to be used for the heparin solution. NHS and EDC 
were then to be added to the heparin solution at a ratio of 0.6 moles EDC: 1 mole NHS. Using 
this ratio the amount of moles of NHS was determined to be 1.99 * 10-5 mol NHS. Multiplying 
this by its molecular weight yielded a weight of 2.29 mg of NHS to be used for the heparin 
solution. 
Due to the inability to measure small amounts of EDC and NHS (~1 mg) with the scale 
provided, the team realized this procedure needed to be slightly scaled up. In order to make the 
heparin solution the following amounts of solution components were used (slightly larger than 
the calculations); however, the amount of heparin was kept the same in order to maintain the 
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correct amount for the sixteen sponges. Table 28 displays the amount of each solution 
component which was added to the heparin solution.  
Table 28: The table below records the actual amount of each solution component 
added to the heparin solution. These amounts are larger than the calculated 
due to the inability to measure very small amounts using the scale of access. 
Component Amount Added 
MES Buffer 5 mL 
Heparin Sodium Salt 96.4 mg 
EDC 7.4 mg 
NHS 13.6 mg 
 
This heparin solution was left to sit for ten minutes allowing activation of the heparin to 
occur. Once the solution was ready, the sixteen collagen sponges were transported from the 
original MES buffer solution to the heparin activated solution using forceps.  
The collagen-GAG sponges were allowed to incubate at room temperature in a 24 well 
plate (16 wells used) containing 400 µL of heparin activated solution per well for approximately 
two hours to allow for heparin binding. Once incubation was complete, the sponges were rinsed 
in 5 mL of DPBS (-) and then stored in 5 mL DPBS (-) overnight. The eight extra sponges (not 
containing heparin) were also stored in DPBS (-) overnight in order to prepare for FGF-2 binding 
and full assay set up.  
6.1.2.2 FGF-2 Binding to Collagen-GAG Sponges 
Following heparinizing and washing of the scaffolds, they were prepared for FGF-2 
binding. As seen by the conditions listed in the previous section, the following scaffolds needed 
to undergo FGF-2 binding:  
2) Heparinized with FGF-2 (100 ng/mL) 
3) Heparinized with FGF-2 (200 ng/mL) 
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4) Heparinized with FGF-2 (300 ng/mL) 
5) Non-heparinized with FGF-2 (300 ng/mL) 
This provides six different heparinized sponges at different concentrations of FGF-2 and 
a non-heparinized FGF-2 sponge. Three separate vials of FGF-2 were used for this experiment. 
Each vial contained 0.25 µL FGF-2 solution at a concentration of 100 µg / mL. This was a larger 
concentration than needed for the experiments and each FGF-2 solution was diluted as follows 
using phosphate buffered saline (PBS) containing 1 mg/mL bovine serum albumin (BSA). It was 
determined that all the FGF-2 would be used from each vial and diluted using the appropriate 
calculated value of PBS solution to provide the correct concentration. First the amount of FGF-2 
in the vials (in nanograms) needed to be determined. First, the equivalent amount of FGF-2 in 
nanograms was determined from its concentration: 100,000 ng / 1,000 µL = FGF-2 concentration 
in vial (100 µg / mL). This ratio could then be used to determine the amount in nanograms of 
FGF-2 in each 25 µL vial of solution: 100,000 ng / 1,000 µL = x / 25 µL (amount of solution in 
vial) where x = 2,500 ng FGF-2 per vial.  
Three concentrations of FGF-2 solution were desired for this experiment; 300 ng FGF-2 / 
mL PBS, 200 ng FGF-2 / mL PBS, and 100 ng FGF-2 / mL PBS. Since it was determined that 
there was 2,500 ng in each vial the amount of PBS to add was determined using the following 
calculations: 2,500 ng FGF-2 / Volume PBS = 300 ng/mL. This provided the amount of PBS 
needed to prepare a 300 ng/mL concentration of FGF-2 solution. The amount of PBS added to 
each vial was as follows: 8.33 mL PBS to obtain 300 ng/mL FGF-2 solution, 12.4 mL PBS to 
obtain 200 ng/mL FGF-2 solution, and 25 mL PBS to obtain 300 ng/mL FGF-2 solution 
Each vials contents were micro-pipetted (25 µL) and added to the corresponding volume 
of PBS to obtain the three desired concentrations. Next, 400 µL of the FGF-2 solution was added 
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to a 24-well plate for each of the four conditions (16 wells). Figure 36 is a diagram representing 
the layout of the FGF-2 binding assay. Wells represented by “1” are designated to 400 µL FGF-2 
solution at 300 ng/mL, well “2” was designated to 400 µL FGF-2 solution at 200 ng/mL, and 
well “3” was designated to 400 µL FGF-2 solution at 100 ng/mL. 
 
Figure 36: The diagram above shows the set up for the FGF-2 binding assay. 
The wells labelled “1” were designated for 400 µL FGF-2 solution at 300 ng/mL. 
Wells labelled “2” were designated for 400 µL FGF-2 solution at 200 ng/mL and 
wells labelled “3” were designated for 400 µL FGF-2 solution at 100 ng/mL. 
 
The heparinized sponges were then moved from heparin solution into the FGF-2 solution 
wells, leaving four sponges behind as heparinized sponges with no FGF-2. The sponges were 
incubated for 90 minutes at room temperature. All of the sponges for all conditions were then 
rinsed in PBS, sterilized, and transferred to a new 24-well plate and stored in an antibiotic 
cocktail to be sterilized. The 24-well plate was then placed in the incubator overnight. The next 
day, after the sponges incubated in antibiotics for approximately 19 hours, the assay set up was 
prepared. The sponges were then rinsed three times for 20 minutes in medium to ensure no 
antibiotics would be present on the sponges. The sterile sponges were then moved into the 
pathways using sterile forceps.  
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6.1.3 Cell Preparation  
NIH 3T3 fibroblast cells (Ambady Lab) were cultured in T75 flasks and passaged once a 
week. The medium recipe can be found in Appendix F. No special preparation of NIH 3T3 cells 
was needed for this assay. NIH 3T3 cells were incubated at 37 degrees Celsius in 5% CO2.  
All the above experimentation has been completed with fibroblasts while waiting for 
endothelial cells to reach desirable confluence. The assay validation will also be completed with 
endothelial cells. 
Human pulmonary artery endothelial cells (HPAECs) were received from the Pins Lab in 
a frozen cryovial containing 1x106 cells. Endothelial cell growth medium was purchased from 
LONZA Clonetics (cat # 3024A). The medium included a vial of bovine brain extract (BBE, cat# 
cc-4092), which was added to the medium. After mixing the two components, medium only 
lasted for 30 days and was kept in a dark refrigerator or wrapped in foil. The vial of cells was 
thawed and plated at 375,000 cells/75cm2 (per T75 flask). HPAEC’s were incubated ay 37 
degrees Celsius in 5% CO2.  
6.1.4 Power Analysis and ANOVA 
6.1.4.1 One-way ANOVA Testing for Sample Size  
In order to determine the experimental design, statistical analysis needed to be performed 
to indicate the number of samples needed for each condition why. Since there were more than 
two conditions being tested and only one type of data being analyzed, a one way analysis of 
variance test (ANOVA) for sample size could be performed using the software application 
SigmaStat 12.5. The following six conditions were tested.  
1) Non-heparinized with no FGF-2  
2) Heparinized with FGF-2 (100 ng/mL) 
  
109 
 
3) Heparinized with FGF-2 (200 ng/mL) 
4) Heparinized with FGF-2 (300 ng/mL) 
5) Non-heparinized with FGF-2 (300 ng/mL) 
6) Heparinized with no FGF-2 
SigmaStat 12.5 allows prediction of the number of samples needed to obtain significant 
statistical data for a number of conditions and a confidence level. The following information was 
needed for the software to perform the calculation: minimum detectable difference between 
means, expected standard deviation, number of groups, desired power, and an alpha value. The 
minimum detectable difference and expected standard deviations were values that were 
estimated through literature. The following values were entered into the program and the 
predicted number of samples shown.  
Minimum Detectable Difference Between Means: 7 µm/hr 
Expected Standard Deviation: 5 µm/hr 
Number of Groups: 6 
Desired Power: 0.95 
Alpha: 0.05 
The calculated number of samples was determined to be twenty one. Twenty one samples 
would be ideal; however, due to time and budget constraints as many samples will be generated 
as possible even if lower than the calculated value.  
6.1.5 Experimental Set-Up 
As discussed, six conditions (non-heparinized with no FGF-2, heparinized with FGF-2 at 
100 ng/mL, heparinized with FGF-2 at 200 ng/mL, heparinized with FGf-2 at 300 ng/mL, non-
heparinized with FGF-2 at 300 ng/mL, and heparinized with no FGF-2) were tested on two six 
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well culture plates. Figure 37 is a diagram of the plate set up of different conditions at different 
concentrations.   
Figure 37: Schematic of the six well plate set up for the assay design. Six conditions were tested 
and each condition was tested twice for accuracy. In the schematics of plate one (left) and plate 
two (right) the rectangular zone inside the polystyrene well is the medium filled column. The 
media is represented as the pink in each well. The scaffold was seeded on the upper-half of the 
well, as seen by the white coloring in the pink medium. The barriers were set in place and the 
cells were seeded on the lower-most half of the well. Plate one represents to trials of the 
conditions heparinized FGF-2 at positive 300 ng/mL, negative 300 ng/mL, and positive 20 
ng/mL. Plate two, respectively, represents the two trials of the conditions heparinized FGF-2 at 
200 ng/mL, heparinized with no FGF-2, and non-heparinized FGF-2.  
 
The team decided to create a “notch” system for quantifying cell migration. Using a small 
blade, cuts were made on the bottom of the culture plate 0.5 centimeters apart through each well. 
Each cut, or notch, would help create a distinguished zone of imaging to track cell migration. For 
example, if cells migrated from notch 0 to notch 0.4 in a specific time period, the zone of 
imaging in the following time period would begin at notch 0.4. At the end of the experiment, the 
total notch distance which the cells migrated would be converted to a measurement.  
The team shortly discovered the notch system would not accurately quantify cell 
migration because the notch distances were too large. Cells would not travel through more than 
one notch, and the exact placement of cells between notches could not be properly measured. 
Thus, one square millimeter graph paper was photocopied onto clear transparent sheets. The 
transparent grid sheets were fastened on the bottom of the six well plates in alignment with the 
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pre-scratched notches under each well. The grid pattern was used as a coordinate system. A 
thorough description on the usage of the coordinate system may be found in the following 
section 6.1.6.  
 
6.1.6 Data Collection Procedure  
The team has established a unique and precise procedure to gather data. A study by Rose 
examined the effect of specific growth factors on equine oral and limb fibroblast cells. Through 
an in vitro bi-directional scratch assay, cell proliferation and migration of fibroblast cells was 
studied when in conjunction with PDGF and FGF-2 (Rose, 2012). Rose imaged the gap zone of 
the scratch at time points 0 hours, 5 hours, 10 hours, 24 hours, and 36 hours using Ziess 
microscopy and Axiovert 40 CFL (Rose, 2012). The team conducted a uni-directional cell 
migration assay with a data collection strategy based off the protocol by Rose. However, rather 
than collecting data every five and twelve hours respectively, the team collected data every four 
hours. At each time point, two images of each well were taken. This was done to ensure accuracy 
in the images as well as provide a comparative tool between images. Collecting data every four 
hours allowed for an ease in scheduling; evenly breaking up the 24 hour day and ensuring every 
team member had an equal responsibility in the process. Thus, the team collected data beginning 
at time point zero hours and continued data collection every four hours until time point 100 hours 
(four days total). The experimental assay was initially performed with NIH 3T3 mouse fibroblast 
cells to practice collecting data and ensure experimental success. The final assay utilized 
endothelial cells to support the main objective of creating an in vitro assay promoting 
vascularization and tissue ingrowth of the µDERM tissue engineered skin substitute.   
Prior to the start of this protocol, the team created a document to track specific activity 
throughout data collection. First, the barriers set in place inside each well were removed and 
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marked to distinguish the initial starting point for cell migration. To begin collecting data, the 
Zeiss microscope was set to a magnification of 20X. Using the grid pattern on the bottom of the 
well plate, the specific area of interest – the well- was located. This was done through an analysis 
of color; the well appeared pink under 20X magnification because of the medium presence while 
the PDMS appeared a yellow-brown. Figure 38 demonstrates the well under 20X magnification 
and the location of the cell edge. Once the area of the well was positioned, the coordinates of the 
barrier removal line were found and recorded at time point zero hours. The coordinates were 
determined using a simple counting procedure. Grid lines were counted horizontally and 
vertically to isolate a single square of focus. For example, if the barrier removal line was at 
coordinates horizontal 6-7 and vertical 3-4, a single square would be isolated between horizontal 
lines 6 and 7, and vertical lines 3 and 4. The isolated square would mark the starting location of 
fibroblast cells before migration.  
 
Figure 38: An illustration of how the well was located under 20X magnification. The medium in 
the well appeared pink, while the solid PDMS was a grey-brown color. Once the area of the well 
was located, the zone of imaging was determined. The team examined the cell edge found in the 
well. This was the rightmost edge of cells, or the starting point of the cells. Once this edge was 
found, the team chose a particular square along the ridge to begin measuring. The chosen 
square displayed the cell edge. Then, the team used a simple counting procedure to create a 
coordinate system. If the starting position had coordinates horizontal 6-7 and vertical 3-4, the 
square of interest for imaging would be found by counting lines 6 and 7 from left to right, and 
vertical lines 3 and 4 downward. The zone of imaging is the square formed from the four 
coordinate lines and was used to locate the imaging zone to ensure each team member was 
imaging the same “spot” on the cell edge for consistency.  
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After isolating the square of interest, the Zeiss microscope was set to a magnification of 
10X to display a more magnified image of the cells in that particular zone. Using the software 
AxioVision, an image was taken to document cell position. An image was taken of each well at 
each time period and saved in folders following a very specific format. At the start of each time 
point, the responsible team member would refer to the tracking document to recognize the 
imaging coordinates found in the prior time period. From this, the team member would use the 
coordinates and examine the area. If the cells seemed to migrate out of the previous coordinates, 
the new found coordinates were recorded to determine the new imaging zone to be examined by 
the next responsible team member.   
 At the final time period, time point 100 hours, a total of 26 photos were taken per well 
and 52 photos taken per condition. The team used the photos in conjunction with ImageJ to 
quantify cell migration. Each image obtained in one well was aligned vertically to show the 
horizontal migration of the cells after each time period.  It was noted that each team member 
possessed different imaging techniques. Some team members imaged directly between the 
necessary coordinates, while other team members imaged slightly to the left of the necessary 
coordinates to show the concentration gradient of the cells as they migrated horizontally. In both 
situations, the grid coordinate lines were used as reference points. Using ImageJ, a horizontal 
measurement line was drawn from the leftmost horizontal grid line to the visible resting point of 
the cells in each photograph. These lines were then converted into measurements. The migration 
of cells could then be seen by noting the difference in length between two consecutive time 
points. This measurement will be taken into account with the 100 hour time allocation and a rate 
will be calculated. Additionally, the grid coordinate system was a second technique used to 
quantify cell migration. The difference in horizontal grid coordinates was measured by 
  
114 
 
converting each square into a length. If the fibroblast cells only traveled through one and a half 
grid lines, for example, the migrated distance is the length of one square, 1 millimeter, multiplied 
by the distance of 1.5 squares. Figure 39 is a schematic illustrating the quantification strategy 
described using ImageJ.  
 
Figure 39: After isolating the imaging zone along the cell edge, as discussed in Figure 42, the 
team zoomed to 10X magnification. Figure 43 depicts the image of the cell edge in the isolated 
coordinates in 10X magnification. Two images were taken, and in ImageJ, three lines were 
drawn from the leftmost grid coordinate to the outermost cell.  
 
7.0 Discussion 
7.1 Discussion of Project Changes 
Due to time and monetary constraints, fibroblasts instead of endothelial cells are used for 
the project design validation testing. The use of fibroblasts instead of endothelial cells does not 
change the variables measured in the validation testing or affect the potential for tissue ingrowth 
and subsequent angiogenesis. This is because fibroblasts are actually one of the primary cells 
needed at the commencement of angiogenesis where fibroblasts allow for endothelial cell 
movement into the matrix by producing collagen, which forms the post- granulation tissue 
extracellular matrix (Jetten et al., 2014). The migration of fibroblasts into the wound is a rate 
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limiting step, in that, if fibroblasts are not present, collagen is not produced, endothelial cells will 
not migrate into the wound, and no angiogenesis will occur. An outgrowth assay to assess 
fibroblast or endothelial cell migration towards a collagen/GAG sponge with heparin bound 
FGF-2, will aid in determining if angiogenesis is possible in this application.  
7.2 Discussion of Obtained Results  
After utilizing the data collection strategy outlined in section 6.1.6, image and data 
analysis needed to be performed in order to represent and quantify findings from the assay. As 
discussed previously, images for each condition were taken every four hours for twenty hours 
after cells were adherent. Image analysis was accomplished utilizing the open source program 
ImageJ which allows the user to set image scales and perform accurate and reproducible 
measurements for each image taken. Figure 40 shows the image progression from zero hours to 
twenty hours for the control, heparin positive FGF-2 negative, heparin positive FGF-2 positive, 
and heparin negative FGF-2 positive (300 ng/mL). This figure aims to show the outgrowth of 
NIH/3T3 fibroblasts toward the collagen-GAG sponge under these various conditions. These 
conditions were shown in particular because it was seen from the analysis that 300 ng/mL of 
FGF-2 was most prominent in signaling fibroblast outgrowth.  
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Figure 40: This figure shows the NIH/3T3 fibroblast outgrowth for four of the six conditions 
tested. The line in each image represents the relative position of the start location for the cells 
(T0). The left most images represent the control (heparin negative and FGF-2 negative), the left 
inner images represent heparin positive FGF-2 negative sponges, the right inner images 
represent heparin positive FGF-2 300 ng/mL sponges, and the right most images represent 
heparin negative FGF-2 300 ng/mL sponges. 
 
Although only four sets of images are represented above, image analysis was performed 
on all six conditions for two separate trials. Although not represented in Figure 40, these images 
can be found in Appendix M. Measurements were made by measuring from the reference point 
(black line on left of images) to the three furthest points the cells migrated to. These 
measurements were made using ImageJ and the data were saved to CSV files for each image. 
Figure 41 shows an example of how the measurements were made. 
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Figure 41: This figure shows how measurements were made for each image and the format in 
which these measurements were saved. The yellow lines in the image represent the distance that 
was measured from the reference.  
 
Being consistent with image analysis techniques was essential for automating the data 
analysis process. Since the measurements being made for each image were saved to a CSV file 
with the same format, a program could be used to perform data analysis. The team utilized a 
program written in Python that read in the 60 CSV files provided from the image analysis and 
performed calculations to provide the outgrowth rates for each condition. The program also 
allowed the team to graph and determine whether there was linear correlation in each of the trials 
performed. Figure 42 represents the distance travelled from the reference for the control, heparin 
positive FGF-2 (300 ng/mL), and heparin negative FGF-2 (300 ng/mL).   
T16 
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Figure 42: This figure shows the graphs of the distance the fibroblasts were located from the 
reference versus time. This allows for linear correlation assessment to determine if the graphs 
are linear as outgrowth rates have shown to be so.  
 
It was important to graph the data so that R2 values for each condition could be 
calculated. Since the desired value for each condition is an outgrowth rate, the R2 value should 
be somewhere between 0.9-1.0 indicating that the data is linear. Although not shown in Figure 
42, linear correlation values were calculated for each condition. Fibroblast outgrowth rates of 
each condition were then calculated. This rate was calculated by subtracting the start position 
(distance from reference at T0) from the final position (distance from reference at T20). The 
fibroblast outgrowth rates for each condition are summarized in Figure 43.  
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Figure 43: This figure summarizes the fibroblast outgrowth rates for each of the six conditions 
tested. The graph also includes an error bar showing the standard deviation of each data set. 
The outgrowth rates are an average of the two trials (n=2) performed for each condition.  
 
In order to better represent this data, Table 29 below summarizes the outgrowth rates, 
linear correlation values, and standard deviation for each of the six conditions.  
Table 29: This figure summarizes the fibroblast outgrowth rates for each 
of the six conditions tested. The table also includes standard deviation and 
linear correlation values for each condition.  
  Rate (um/hr) Stnd Deviation Linear Correlation 
Control  15.6 0.21 0.95 
H(+)FGF2(-)  13.6 3.73 0.95 
H(+)FGF2(100)  13.5 2.14 0.93 
H(+)FGF2(200)  13.5 1.32 0.89 
H(+)FGF2(300)  17.8 0.68 0.91 
H(-)FGF2(300)  22.9 0.41 0.93 
 
It can be seen from Table 29 that heparin negative FGF-2 positive (300 ng/mL) had the 
largest outgrowth rate. This was followed by heparin positive FGF-2 positive (300 ng/mL), 
0.0
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indicating that FGF-2 at a concentration of 300 ng/mL had an increasing effect on fibroblast 
outgrowth rates when compared to the control.  
7.3 Impact Analysis 
This project analyzed the potential of a modified collagen scaffold to enhance 
vascularization, and it is therefore not confirmed that this design will be marketed or mass-
produced in any way. The design incorporates the use of heparin and Fibroblast Growth Factor – 
2 to promote the migration of endothelial cells toward the scaffold, and in turn indicate that the 
treatment would in fact stimulate the growth of blood vessels into the scaffold if tested in vivo. 
The following is the team’s analysis of the societal impact of the design 
7.3.1 Environmental Impact 
This project has a negligible environmental impact. The project did not work with any 
materials that would affect the environment in production, use, or distribution. The primary 
components, Fibroblast Growth Factor-2, heparin sodium salt, and collagen type I, are not 
proven to have any hazardous effects that would raise concern for the environment.  
7.3.2 Economics  
Economics in the medical industry deals with the efficiency, effectiveness, value, and 
behavior in the production and consumption of drugs, devices and treatment. The study of 
economics is crucial to determining that the overall benefits of a product will outweigh the costs, 
and that the producer is maximizing the benefits of the product within the available resources. To 
understand the entire scope of the economic impact of a product, the producer must consider the 
micro-economic evaluation of the product at the treatment level, the demand and regulation for 
the product, market equilibrium, and cost-benefit analysis – to name a few (Cheltenham, 1997). 
By FDA standards, this project worked with a cell – scaffold product, falling under the 
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“combination product” class of regulation: “a product composed of any combination of a drug 
and a device, a drug and a biological product or a drug, device, and biological product.” The 
modification that the team made to the scaffold is a step towards developing it into a market-
ready product that would have the ability to treat patients with wounds incapable of healing 
naturally, and thus have a need for tissue engineered skin. While this project solely focused on 
the concept of promoting angiogenesis into the scaffold, if the complete product is eventually 
approved and reaches the point where it can be used effectively as treatment for patients, it has 
the ability to change the treatment and care for severe burn victims, among others. Overall, in a 
broader scope, the product would ultimately benefit patients, surgeons, and hospitals. It would 
save patients personal time and money, would save hospitals money, and would save surgeons 
invaluable time. Although growth factors and testing are expensive, long-term analysis would 
prove these benefits to validate any costs. 
7.3.3 Societal Influence   
The work that this project did alone could significantly impact the final scaffold product, 
increasing its likelihood of being approved and taken to market. It therefore has the ability to 
largely influence society, in the realm of tissue engineering research, and in the healthcare 
industry as a whole. If the scaffold has the ability to adequately promote vascularization into the 
treated wound bed of the patient, it could be used to facilitate the restoration of skin in a range of 
injuries, and therefore definitively impact the types of treatment that society would have access 
to. Within the clinical space of tissue engineering, the findings of this project could impact 
research across all areas of concentration – the need for adequate vascularization is not unique to 
skin alone; all organs and tissues in the body need proper vascularization in order to optimize 
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regeneration. If further testing could support that the methods in this project significantly 
promote angiogenesis, further application for similar research could be explored.  
7.3.4 Political Ramifications  
The team does not expect any political ramifications to result from the work on this product.  
7.3.5 Ethical Concerns  
Due to the inherent nature of cellular and tissue engineering, there are ethical concerns; 
however, in regards to this project, they are minimal. Experimentation utilized human Pulmonary 
artery endothelial cells (HPAECs) and bovine type I collagen. An ethical concern may be the 
sourcing of these materials, as they are human and animal, respectively. However, the HPAECs 
will not be a component of the final product, and therefore the ethical concern is negligible.  
7.3.6 Health and Safety Issue   
Like stated previously, health and safety concerns are also inherent of any cellular and 
tissue engineering, medical research, and medical device production. This project worked on a 
product that is to ultimately be used as treatment for human patients. All materials are proven 
biocompatible, and able to be fully sterilized. The only component of this project that may pose 
an increased health and safety issue is the use of HPAECs, as they are a human cell source. The 
work with the HPAECs must be done with proper precaution and protection to ensure complete 
safety of the user. 
7.3.7 Manufacturability  
The fabrication of the assay was kept to a relatively simple process. A protocol could be 
developed to enable outside researchers to easily develop the system independently. 
Additionally, a CAD drawing was made of the final design, and this could allow for mass-
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production of the hardware component, making it marketable and distributable. The team cannot 
comment on the manufacturability of the µDERM scaffold as a whole; the project solely dealt 
with one component of it and did not observe nor practice fabrication of the entire product.   
7.3.8 Sustainability  
Sustainability is based on the principle that the well-being of mankind is directly 
dependent on the environment, and as such the natural resources available to us must be 
maintained and protected to ensure lasting human health. None of the components of this project 
utilize natural resources that are in danger of over-consumption.    
8.0 Conclusions and Recommendations 
8.1 Conclusion 
The project assessed vascularization of a collagen-GAG sponge modified with FGF-2 using an 
efficient assay developed to evaluate the effectiveness of the modification. The design incorporated 
the use of heparin and FGF-2 to promote the migration of fibroblast cells toward the scaffold, and 
in turn indicate that the treatment would potentially stimulate the growth of blood vessels into the 
scaffold if tested in vivo. The fibroblast outgrowth rates were highest when exposed to 300 ng/mL 
of FGF-2 compared to a non-heparinized, non-growth factor stimulated scaffold. These results can 
most likely be attributed to the initial burst of growth factor. Overall, the addition of heparin alone 
did not show significant effect on fibroblast outgrowth rates, and thus it is suggested that a future 
study collects data over a longer period of time to understand the potential long-term angiogenic 
effect that heparin could have on the scaffold. However, the results do suggest that the addition of 
FGF-2 to the µDERM would successfully enhance the scaffold’s angiogenic ability, and thus overall 
increase its performance as an engineered skin substitute. 
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8.2 Future Recommendations  
Future recommendations include design changes for the fabrication process in which the 
initial top mold that hold the glass slides has been modified for ease of use. As seen in Figure 44, 
the top part is brought closer to the six well plate and holes are spaced directly down into the 
wells to increase ease of use.  
 
a)  
b)  
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c)  
Figure 44: The new design process with a customized top part for ease of use when creating 
PDMS wells. a) Shows the addition of the top part and glass slides to the 6-well plate b) shows 
the addition of media through the upper channels using a pipette c) shows the removal of 
pipettes  
 
The use of specific holes to add PDMS will also add to the precision and even coating of 
the PDMS in the well. Additionally, the decrease in materials needed to create the top part and 
slides will decrease costs.  
Future recommendations for experimental changes include lowering the initial cell 
seeding density and waiting twenty-four hours before barrier removal. Waiting twenty-four hours 
will allow for cells to come to confluence without, but no enough time for cells to over-grow. 
This will decrease the amount of outlier cells that, when the barrier is removed, float ahead and 
adhere just in front of the actual starting point. These outliers skew data and decrease image 
quality. Making the above changes will create more accurate experiments and increase the 
quality of the data.  
Additional steps include incorporation of endothelial cells into the assay, in which the 
endothelial cells will be measured travelling toward the collagen-GAG sponge and the sponge. 
The team would also like to look at the sponge via histological analysis at the end of the assay so 
as to determine the amount of migration and viability of endothelial in the scaffold. The team 
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predicts that they will see endothelial cell migration into the scaffold and initial micro-sprouting 
due to angiogenesis.  
The team would then like to confirm vascularization through incorporation of the 
modified collagen-GAG sponge into µDERM and evaluation of overall performance of the entire 
system and in vivo animal testing. The team would like to place µDERM at a wounds site on the 
skin of the rat and measure the graft take and tissue in-growth over a period of 14 days. Each day 
after day four, a different rat would have µDERM removed and the team would perform 
histological analysis on the scaffold to determine if vascularization is occurring. The expected 
outcome is that initially there will be no vascularization, but that after four days, once the 
endothelial cells have migrated from the wound bed into µDERM, angiogenesis will begin to 
take place. It is believed by the team that angiogenesis will begin to occur around days 4-6 due to 
background research on when granulation and neovascularization stages intersect (Dipietro et al., 
2010). The team also chose a 14 day experiment because after angiogenesis occurs, there is still a 
need for tissue-remodeling wound contraction and extracellular matrix reorganization which 
occurs during the second week of wound healing (Clark et. al, 1999). Similar research has been 
done on the topic of in vivo testing of dermal matrix in the rat model where Richter et al has done 
research on both cadaveric and porcine dermal matrices (Richter et al., 2007).  For this 
experiment a 1 mm thick piece of AlloDerm, ENDURAGen, and meshed ENDURAGen where 
placed on rates and then harvested at 4 and 8 weeks. The grafts were analyzed using histological 
quantification and immunocytochemistry. It was found that AlloDerm showed better tissue 
ingrowth and micro vascularization density than the other two grafts (Richter et al., 2007). While 
Richter et al has an 8 week experiment, the team has cut the experimental time by 6 weeks 
because of the addition of the growth factor, FGF-2, to the collagen-GAG sponge, which is 
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predicted to allow for faster tissue in-growth into the dermal portion of µDERM and 
coincidently, an increased rate of angiogenesis.  
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Appendix A: Objective Trees 
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Appendix B: Explanation of Objectives 
Enhancing Angiogenesis:  
I. Maintain scaffold stability 
The process by which the collagen sponge is fabricated by the team should yield the same 
stability as the current collagen sponge. Scaffold stability in this case refers to the measurement 
of degradation, flexibility and porosity. Degradation is defined as the rate at which the collagen 
sponge breaks down over a period of time. Flexibility can be sought as the scaffold should not be 
stiff. The current scaffold is very flexible (can be bent in half without tearing) and any addition 
to the design should maintain that property. The current scaffold also has a very specific porosity 
that through literature has been proven to be idea; therefore, porosity should be maintained as 
close as possible to the porosity of the original sponge.  Also, when the sponge is enhanced with 
growth factors it should not contract and maintain its stability as it currently stands 
II. Efficient 
The scaffold should also be efficient in the sense that it is cost effective, adds minimal 
complexity to the current design, has a minimal manufacturing time, and can be reproduced 
accurately by anyone in the lab. The scaffold must be cost effective in that it is affordable for the 
client. It also should be efficient in that the final design is not so complex that it takes away from 
the current sponge and should also be able to be manufactured as efficiently as it is currently. 
The scaffold should also be able to be fabricated accurately by performing its fabrication 
process. 
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III. Release factors at defined rate 
Factors that can be added to the scaffold to enhance angiogenesis should be released at a defined 
rate. Defined rate include release at a constant rate, a precisely tailored rate, a precise and 
reproducible rate and an accurate rate. The rate should be constant in that it releases a factor over 
a period of time in a consistent manner. The release rate should also be able to be tailored 
(changed) depending on the time period in which the factor needs to be released to effectively 
enhance angiogenesis. The release rate should also be precisely reproducible being that it is the 
same for each time the growth factor is incorporated. The release rate should also be accurate to 
the time period of growth factor release in natural wound healing.  
IV. Easy to use 
The scaffold should be easy to use in that there is minimal processing and handling time, an easy 
fabrication process, minimal complexity added to fabrication process, and maintains the 
sterilization method of the current design. Minimal processing and handling time is important in 
that it minimizes the chances of contamination during the process as well as minimizes the 
chances of the user making a mistake during fabrication. The fabrication process should also be 
easy for the user to fabricate in that the user shouldn’t need to execute the process at odd hours 
of the day or for extremely lengthy perio of time. The user should also be able to use equipment 
available to her/him and not rely too much on manual labor. There should also be minimal 
complexity added to the current fabrication process. Also, it would be ideal to use the same 
sterilization technique used for the current scaffold.  
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V) Increase Tissue Ingrowth to Scaffold 
For proper vascularization to occur there must be interaction between the epidermal and dermal 
layers of the scaffold. A key aspect to obtaining this phenomenon is the migration of endothelial 
cells into the collagen sponge (dermal layer). The design must allow for endothelial cells to 
migrate into the sponge. If migration occurs, blood vessel formation (vascularization) can be 
achieved through the initiation of “sprouting” of endothelial cells which could potentially be 
assessed in vivo.  
Assay to Assess Efficiency of Design:  
I. Efficient 
The assay must be efficient in the sense that it is high throughput. High throughput means that it 
collects the maximum amount of different data in one analysis. It must also be cost effective 
because there is a chance that the assay will have to be produced multiple times. The assay must 
also minimize the time for data collection to make it easier for the user as well as reduce the time 
in which contamination can occur. The assay must also produce accurate results that are also 
precise and reproducible.  
II. Quantifiable 
The assay must also be quantifiable because if it is not there is no way to compare the designs 
efficacy to the actual stages of wound healing. The assay must be able to quantify the rate of 
endothelial cell migration into the sponge and quantify the rate of controlled release of the 
growth factor. This quantification should produce results that are accurate to the expected rates 
as well as be precise and reproducible between trials.  
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III. Effective 
The assay must be effective in that it performs all the necessary functions that would be ideal to 
examine the efficacy of our design. It must allow for culture of EC’s as we are trying to quantify 
their migration rates. In order to view this migration, it is important that the assay allows for 
histological analysis/imaging of the sponge.  The assay must also allow for staining of EC’s so 
that their migration can be tracked in vitro.  
IV. Ease of Use 
The assay must be easy to use for the user. It should be able to be easily assembled/prepared 
using a protocol written by the design team. The assay should allow for its assembly to be time 
efficient which will make it easier on the user as well as reduce chance of contamination. It 
should also be easy to use in that only one variation of medium is used and that it is readily 
available. 
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Appendix C: Team Management Gantt Chart  
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Appendix D: Scoring Criteria 
Scoring Criteria Scaffold Design 
Increase Tissue Ingrowth:  
a. Increase EC ingrowth 
-4 points: 200% increase in ingrowth compared to control 
-3 points: 125% increase in ingrowth compared to control 
-2 points: 75% increase in ingrowth compared to control 
-1 point: 25% increase in ingrowth compared to control 
b. Increase sprouting 
-4 points: 200% in capillary formation in vivo compared to control 
-3 points: 125% in capillary formation in vivo compared to control 
-2 points: 75% in capillary formation in vivo compared to control 
-1 point: 25% in capillary formation in vivo compared to control 
Release Factors at a Controlled Rate 
a. Precisely and reproducible rate 
-4 points: All trials within 5% of each other 
-3 points: All trials within 10% of each other 
-2 points: All trials within 15% of each other 
-1 point: All trials within > 20% of each other 
b. Accurate rate 
-4 points: All trials within 5% of intended release 
-3 points: All trials within 10% of intended release 
-2 points: All trials within 15% of intended release 
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-1 point: All trials within > 20% of intended release 
c. Constant rate 
-4 points: Rate is constant at all time points 
-3 points: Rate is constant at 75% of time points 
-2 points: Rate is constant at 50% of time points 
-1 point: Rate is constant at 25% of time points 
d. Precisely tunable rate 
-4 points: Tailored to unlimited number of rates 
-3 points: Tailored to multiple rates  
-2 points: Tailored to 1 rate 
-1 point: Release rate can’t be tailored 
Easy to Use: 
a. Minimal complexity added to fabrication process (current 9 steps) 
-4 points: < 5 steps added 
-3 points: 6-10 steps added 
-2 points: 11-15 steps added 
-1 point:  > 16 steps added 
b. Minimal processing and handling  
-4 points: 1 person to handle 
-3 points: 2 people to handle 
-2 points: 3 people to handle 
-1 point: 4+ people to handle 
c. Easy to fabricate (components = materials and/or equipment) 
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-4 points: < 5 components    
-3 points: 6-10 components 
-2 points: 11-15 components  
-1 point: > 16 components  
Efficient: 
a. Reproduction is accurate 
-4 points: All trials within 5% of control 
-3 points: All trials within 10% of control 
-2 points: All trials within 15% of control 
-1 point: All trials within > 20% of control 
b. Minimal manufacturing time 
-4 points: < 3 hours 
-3 points: 3-6 hours 
-2 points: 6-9 hours 
-1 point: > 9 hours 
c. Minimal complexity added to design (factor = component to achieve tissue ingrowth) 
-4 points: 1 “factor” 
-3 points: 2 “factors” 
-2 points: 3 “factors” 
-1 point:  > 4 “factors” 
d. Cost effective 
-4 points: Free-$75 
-3 points: $76-$150 
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-2 points: $151-$225 
-1 point: > $226  
Scoring Criteria Assay Design 
Effective:  
a. Allow culture of EC’s 
-4 points: 100% adhesion of ECs (cells are spread out and fully attached) 
-3 points: 75% adhesion of ECs (cells are semi balled up) 
-2 points: 50% adhesion of ECs (not all ECs present, ones that are look unhealthy) 
-1 point: 25% adhesion of ECs (almost no ECs present) 
b. Allow for fluorescence imaging 
-4 points: <100% clear image 
-3 points: 75% clear image 
-2 points: 50% clear image 
-1 point: >25% clear image 
c. Allow for staining of cells 
-4 points: 100% of cells are able to be stained 
-3 points: 75% of cells are able to be stained 
-2 points: 50% of cells are able to be stained 
-1 point: 25% of cells are able to be stained 
d. Allow for histological analysis 
-4 points: allows for assay to be sliced without mechanical degradation 
-3 points: allows for assay to be sliced with minimal degradation 
-2 points: allows for assay to be sliced, but there is degradation 
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-1 point: assay is unable to be sliced due to degradation 
Quantifiable 
a. Accurate quantification 
-4 points: 100% accurate from control 
-3 points: 75% accurate from control 
-2 points: 50% accurate from control 
-1 point: 25% accurate from control 
b. Quantifies EC ingrowth 
-4 points: able to quantify amount of EC’s in scaffold 
-3 points: able to get a rate of EC ingrowth 
-2 points: able to get a rate of EC migration 
-1 point: able to see movement, but unable to quantify it.  
c. Precise/Reproducible quantification 
-4 points: 100% reproducible 
-3 points: 75% reproducible 
-2 points: 50% reproducible 
-1 point: 25% reproducible 
d. Quantify release rate 
-4 points: able to quantify release rate in scaffold 
-3 points: able to quantify release rate outside of scaffold 
-2 points: maybe able to get a number 
-1 point: not able to quantify release rate 
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Efficient 
a. Produce accurate results 
-4 points: 100% accurate to control 
-3 points: 75% accurate to control 
-2 points: 50% accurate to control 
-1 point: 25% accurate to control 
b. Produce reproducible results 
-4 points: 100% reproducible 
-3 points: 75% reproducible 
-2 points: 50% reproducible 
-1 point: 25% reproducible 
c. Minimize data collection time 
-4 points: < 24 hours 
-3 points: 24-48 hours 
-2 points: 48-72 hours 
-1 point: > 72 hours 
d. High throughput 
-4 points: multi-use (3+ times), non-destructive 
-3 points: non-destructive, two-use 
-2 points: non-destructive, one-use 
-1 point: destructive 
e. Cost effective 
-4 points: < $25 
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-3 points: $25-50 
-2 points: $50-75 
-1 point: > $75 
 
Ease to Use: 
a. Easily assembled/prepared 
-4 points: <5 parts 
-3 points: 6-7 parts 
-2 points: 7-9 parts 
-1 point: 10+ parts 
b. Minimal time for assembly 
-4 points: < 3 hours 
-3 points: 3-6 hours 
-2 points: 6-9 hours 
-1 point: > 9 hours 
c. Use 1 variation of medium 
-4 points: 1 variation 
-3 points: 2 variations 
-2 points: 3 variations 
-1 point: > 4 variations 
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Appendix E: Design Matrices  
Design Matrices for Scaffold Design 
Increase Endothelial Cell Migration         
            
MAX WEIGHTED SCORE = 
100  
RGD 
peptide 
Weighte
d 
Normaliz
ed VEGF 
Weight
ed 
Normaliz
ed 
micro- 
Topography 
Weight
ed 
Normaliz
ed 
 
Objectives: 
Weig
ht           
I. Increase Tissue 
Ingrowth            
a. Increase EC migration 4 3 12 0.12 4 16 0.16 1 4 0.04  
b. Increase EC sprouting 4 1 4 0.04 4 16 0.16 1 4 0.04  
            
II. Easy to Use            
a. Minimal complexity 
added 3 4 12 0.12 4 12 0.12 4 12 0.12  
b. Minimal processing  3 4 12 0.12 4 12 0.12 4 12 0.12  
c. Ease of fabrication 3 3 9 0.09 4 12 0.12 4 12 0.12  
            
III. Efficient            
a. Reproduction is 
accurate 2 4 8 0.08 3 6 0.06 2 4 0.04  
b. Minimal 
manufacturing time 2 1 2 0.02 2 4 0.04 4 8 0.08  
c. Minimal complexity to 
design 2 3 6 0.06 3 6 0.06 4 8 0.08  
d. Cost Effective 2 3 6 0.06 1 2 0.02 4 8 0.08  
TOTAL  26 71 0.71  86 0.86 28 72 0.72  
Constraints:            
Collagen-GAG Sponge  No   No   No    
Cell Compatible  No   No   No    
Biocompatible  No   No   No    
Sterilizable  No   No   No    
Maintain Mechnical 
Structure  No   No   No    
Budget ($524)  No   Yes   No    
Time (28 weeks)  No   No   No    
Material Availability  No   No   No    
Lab Equipment 
Availability  No   No   No    
            
 FGF-2  Weighted 
Normaliz
ed  
mRNA-
126 
Weight
ed 
Normaliz
ed 
Angiopoieti
n-1 
Weight
ed 
Normaliz
ed  
Objectives:    Weight         
I. Increase Tissue 
Ingrowth             
a. Increase EC migration 4 16 0.16 4   0 0 4 16 0.16  
b. Increase EC sprouting 4 16 0.16 4   0 0 4 16 0.16  
             
II. Easy to Use             
a. Minimal complexity 
added 4 12 0.12 3   0 0 3 9 0.09  
b. Minimal processing  4 12 0.12 3   0 0 4 12 0.12  
c. Ease of fabrication 4 12 0.12 3   0 0 4 12 0.12  
             
III. Efficient             
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a. Reproduction is 
accurate 4 8 0.08 2   0 0 3 6 0.06  
b. Minimal 
manufacturing time 1 2 0.02 2   0 0 3 6 0.06  
c. Minimal complexity to 
design 3 6 0.06 2   0 0 3 6 0.06  
d. Cost Effective 2 4 0.04 2   0 0 1 2 0.02  
TOTAL 30 88 0.88    0 0 29 85 0.85  
Constraints:            
Collagen-GAG Sponge No    No   No    
Cell Compatible No    No   No    
Biocompatible No    No   No    
Sterilizable No    No   No    
Maintain Mechnical 
Structure No    No   No    
Budget ($524) No    Yes   No    
Time (28 weeks) No    No   No    
Material Availability No    No   No    
Lab Equipment 
Availability     No   No    
 
Maintain Endothelial Cell Viability         
            
MAX WEIGHTED SCORE = 
100  
MSC's + 
EC's 
Weight
ed 
Normaliz
ed 
Hepari
n 
Weight
ed 
Normaliz
ed 
Mechanic
al 
Stretchin
g 
Weight
ed 
Normaliz
ed 
 
Objectives: 
Weig
ht             
I. Increase Tissue Ingrowth              
a. Increase EC migration 4   0 0 2 8 0.08   0 0  
b. Increase EC sprouting 4   0 0 2 8 0.08   0 0  
              
II. Easy to Use              
a. Minimal complexity 
added 3   0 0 3 9 0.09   0 0  
b. Minimal processing  3   0 0 3 9 0.09   0 0  
c. Ease of fabrication 3   0 0 3 9 0.09   0 0  
              
III. Efficient              
a. Reproduction is 
accurate 2   0 0 4 8 0.08   0 0  
b. Minimal manufacturing 
time 2   0 0 3 6 0.06   0 0  
c. Minimal complexity to 
design 2   0 0 3 6 0.06   0 0  
d. Cost Effective 2   0 0 3 6 0.06   0 0  
Total   0 0 26 69 0.69  0 0  
Constraints:            
Collagen-GAG Sponge  No   No   No    
Cell Compatible  No   No   No    
Biocompatible  No   No   No    
Sterilizable  No   No   No    
Maintain Mechnical 
Structure  No   No   Yes    
Budget ($524)  Yes   No   No    
Time (28 weeks)  Yes   No   Yes    
Material Availability  No   No   No    
Lab Equipment Availability  No   No   No    
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Hyaluroni
c 
Acid 
Weight
ed 
Normaliz
ed 
5mM 
EDC 
crossli
nk 
Weight
ed 
Normaliz
ed 
60mM 
EDC 
crosslink 
Weight
ed 
Normaliz
ed 
 
Objectives: 
Weig
ht             
I. Increase Tissue Ingrowth              
a. Increase EC migration 4   0 0 2 8 0.08   0 0  
b. Increase EC sprouting 4   0 0 1 4 0.04   0 0  
              
II. Easy to Use              
a. Minimal complexity 
added 3   0 0 4 12 0.12   0 0  
b. Minimal processing  3   0 0 4 12 0.12   0 0  
c. Ease of fabrication 3   0 0 4 12 0.12   0 0  
              
III. Efficient              
a. Reproduction is 
accurate 2   0 0 4 8 0.08   0 0  
b. Minimal manufacturing 
time 2   0 0 4 8 0.08   0 0  
c. Minimal complexity to 
design 2   0 0 2 4 0.04   0 0  
d. Cost Effective 2   0 0 4 8 0.08   0 0  
Total   0 0 29 76 0.76  0 0  
Constraints:            
Collagen-GAG Sponge  Yes   No   No    
Cell Compatible  No   No   Yes    
Biocompatible  No   No   No    
Sterilizable  No   No   No    
Maintain Mechnical 
Structure  Yes   No   No    
Budget ($524)  No   No   No    
Time (28 weeks)  No   No   No    
Material Availability  No   No   No    
Lab Equipment Availability  No   No   No    
 
Mimics 
Angiogenesis              
              
MAX WEIGHTED SCORE = 
120  
Hypo
xia 
Weigh
ted 
Normali
zed 
Nitric 
Oxide 
Weigh
ted 
Normali
zed 
FG
F-2 
Weigh
ted 
Normali
zed 
VE
GF 
Weigh
ted 
Normali
zed 
Objectives: 
Wei
ght               
I. Increase Tissue 
Ingrowth                
a. Increase EC migration 4   0 0   0 0 4 16 
0.1333
333 4 16 
0.1333
333 
b. Increase EC sprouting 4   0 0   0 0 4 16 
0.1333
333 4 16 
0.1333
333 
                
II. Release Factors at 
Defined rate                
a. Precise and 
reproducible rate 3   0 0   0 0 3 9 0.075 3 9 0.075 
b. accurate rate 3   0 0   0 0 3 9 0.075 3 9 0.075 
c. Constant rate 3   0 0   0 0 3 9 0.075 2 6 0.05 
d. Precicely tunable rate 3   0 0   0 0 2 6 0.05 2 6 0.05 
                
III. Easy to Use    0 0   0 0       
a. Minimal complexity 
added 2   0 0   0 0 4 8 
0.0666
667 4 8 
0.0666
667 
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b. Minimal processing  2   0 0   0 0 4 8 
0.0666
667 4 8 
0.0666
667 
c. Ease of fabrication 2   0 0   0 0 4 8 
0.0666
667 4 8 
0.0666
667 
                
IV. Efficient                
a. Reproduction is 
accurate 1   0 0   0 0 4 4 
0.0333
333 3 3 0.025 
b. Minimal 
manufacturing time 1   0 0   0 0 1 1 
0.0083
333 1 1 
0.0083
333 
c. Minimal complexity to 
design 1   0 0   0 0 3 3 0.025 3 3 0.025 
d. Cost Effective 1   0 0   0 0 2 2 
0.0166
667 1 1 
0.0083
333 
Total        41 99 0.825  94 
0.7833
3 
Constraints:              
Collagen-GAG Sponge  No   No   No   No   
Cell Compatible  No   Yes   No   No   
Biocompatible  No   No   No   No   
Sterilizable  No   No   No   No   
Maintain Mechnical 
Structure  No   No   No   No   
Budget ($524)  No   No   No   No   
Time (28 weeks)  No   No   No   No   
Material Availability  No   No   No   No   
Lab Equipment 
Availability  Yes   No   No   No   
              
  
 
PDGF 
 
Weigh
ted 
 
Normali
zed 
 
TGF-
beta 
 
Weigh
ted 
 
Normali
zed 
 
EG
F 
 
Weigh
ted 
 
Normali
zed    
Objectives: 
Wei
ght             
I. Increase Tissue 
Ingrowth              
a. Increase EC migration 4 1 4 
0.0333
333 1 4 
0.0333
333 1 4 
0.0333
333    
b. Increase EC sprouting 4 3 12 0.1 2 8 
0.0666
667 2 8 
0.0666
667    
              
II. Release Factors at 
Defined rate              
a. Precise and 
reproducible rate 3 3 9 0.075 3 9 0.075 3 9 0.075    
b. accurate rate 3 3 9 0.075 3 9 0.075 3 9 0.075    
c. Constant rate 3 2 6 0.05 3 9 0.075 3 9 0.075    
d. Precicely tunable rate 3 2 6 0.05 2 6 0.05 2 6 0.05    
              
III. Easy to Use              
a. Minimal complexity 
added 2 3 6 0.05 2 4 
0.0333
333 3 6 0.05    
b. Minimal processing  2 4 8 
0.0666
667 4 8 
0.0666
667 4 8 
0.0666
667    
c. Ease of fabrication 2 4 8 
0.0666
667 3 6 0.05 3 6 0.05    
              
IV. Efficient              
a. Reproduction is 
accurate 1 3 3 0.025 3 3 0.025 3 3 0.025    
b. Minimal 
manufacturing time 1 1 1 
0.0083
333 2 2 
0.0166
667 3 3 0.025    
c. Minimal complexity to 
design 1 3 3 0.025 2 2 
0.0166
667 4 4 
0.0333
333    
d. Cost Effective 1 2 2 
0.0166
667 1 1 
0.0083
333 1 1 
0.0083
333    
Total   77 
0.6416
7  71 
0.5916
7  76 
0.6333
3    
Constraints:  
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Collagen-GAG Sponge  No   No   No      
Cell Compatible  No   No   No      
Biocompatible  No   No   No      
Sterilizable  No   No   No      
Maintain Mechnical 
Structure  No   No   No      
Budget ($524)  No   No   No      
Time (28 weeks)  No   No   No      
Material Availability  No   No   No      
Lab Equipment 
Availability  No   No   No      
 
Controlled Release Rate          
            
MAX WEIGHTED SCORE = 
132  
Gelatin 
Microsphe
res 
Weight
ed 
Normaliz
ed 
PLGA 
Microsphe
res 
Weight
ed 
Normaliz
ed 
Bind 
Facto
r to 
Spong
e 
Weight
ed 
Normaliz
ed 
 
Objectives: 
Weig
ht           
I. Release Factors at 
Defined rate            
a. Precise and reproducible 
rate 4 3 12 
0.090909
1 4 16 
0.121212
1 3 12 
0.090909
1  
b. accurate rate 4 4 16 
0.121212
1 2 8 
0.060606
1 2 8 
0.060606
1  
c. Constant rate 4 4 16 
0.121212
1 1 4 0.030303 3 12 
0.090909
1  
d. Precicely tunable rate 4 4 16 
0.121212
1 4 16 
0.121212
1 1 4 0.030303  
            
II. Easy to Use            
a. Minimal complexity 
added 3 2 6 
0.045454
5 2 6 
0.045454
5 4 12 
0.090909
1  
b. Minimal processing  3 4 12 
0.090909
1 4 12 
0.090909
1 4 12 
0.090909
1  
c. Ease of fabrication 3 3 9 
0.068181
8 3 9 
0.068181
8 4 12 
0.090909
1  
            
III. Efficient            
a. Reproduction is accurate 2 3 6 
0.045454
5 4 8 
0.060606
1 3 6 
0.045454
5  
b. Minimal manufacturing 
time 2 4 8 
0.060606
1  0 0 3 6 
0.045454
5  
c. Minimal complexity to 
design 2 3 6 
0.045454
5  0 0 4 8 
0.060606
1  
d. Cost Effective 2 4 8 
0.060606
1 2 4 0.030303 2 4 0.030303  
Total  38 115 0.87121 26 83 0.62879 33 96 0.72727  
Constraints:            
Collagen-GAG Sponge  No   No   No    
Cell Compatible  No   No   No    
Biocompatible  No   No   No    
Sterilizable  No   No   No    
Maintain Mechnical 
Structure  No   No   No    
Budget ($524)  No   No   No    
Time (28 weeks)  No   No   No    
Material Availability  No   No   No    
Lab Equipment Availability  No   No   No    
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Design Matrices for Assay Design: 
Allow for EC 
Culture           
            
MAX WEIGHTED SCORE = 84 
 
Collage
n 
Weighte
d 
Normalize
d 
Alginat
e 
Weighte
d 
Normalize
d 
PDM
S 
Weighte
d 
Normalize
d 
Objectives: 
Weigh
t          
I. Effective           
a. Allow culture of EC's 4 4 16 
0.1904761
9 4 16 
0.1904761
9 1 4 
0.0476190
5 
b. Allow for fluorescence 
imaging 4 3 12 
0.1428571
4 4 16 
0.1904761
9 3 12 
0.1428571
4 
c. Allow for staining of cells 4 4 16 
0.1904761
9 4 16 
0.1904761
9 4 16 
0.1904761
9 
d. Allow for histological analysis 4 3 12 
0.1428571
4 3 12 
0.1428571
4 4 16 
0.1904761
9 
           
III. Efficient           
a. Cost effective 3 4 8 0.0952381 3 6 
0.0714285
7 4 8 0.0952381 
           
IV. Ease of Use           
a. Easily assembled/prepared 2 4 4 
0.0476190
5 4 4 
0.0476190
5 4 4 
0.0476190
5 
b. Minimal time for assembly 2 1 1 
0.0119047
6 3 3 
0.0357142
9 1 1 
0.0119047
6 
c. Use 1 variation of media 2 4 4 
0.0476190
5 4 4 
0.0476190
5 4 4 
0.0476190
5 
Totals  27 73 0.869048 29 77 0.916667 25 65 0.77381 
Constraints:           
Maintains scaffold structure  No   No   No   
Scaffold Imaging  No   No   No   
Budget ($524)  No   No   No   
Time (28 weeks)  No   No   No   
Material Availability  No   No   No   
Lab Equipment Availability  No   No   No   
            
MAX WEIGHTED SCORE = 84 
 
Chitosa
n 
Weighte
d 
Normalize
d 
Agaros
e 
Weighte
d 
Normalize
d    
Objectives:           
I. Effective           
a. Allow culture of EC's 4 3 12 
0.1428571
4 2 8 0.0952381    
b. Allow for fluorescence 
imaging 4 2 8 0.0952381 3 12 
0.1428571
4    
c. Allow for staining of cells 4 4 16 
0.1904761
9 4 16 
0.1904761
9    
d. Allow for histological analysis 4 2 8 0.0952381 3 12 
0.1428571
4    
           
III. Efficient           
a. Cost effective 3 3 6 
0.0714285
7 4 8 0.0952381    
           
IV. Ease of Use           
a. Easily assembled/prepared 2 3 3 
0.0357142
9 4 4 
0.0476190
5    
b. Minimal time for assembly 2 2 2 
0.0238095
2 4 4 
0.0476190
5    
c. Use 1 variation of media 2 4 4 
0.0476190
5 4 4 
0.0476190
5    
Totals  23 59 0.702381 28 68 0.809524    
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Constraints:           
Maintains scaffold structure  No   No      
Scaffold Imaging  No   No      
Budget ($524)  No   No      
Time (28 weeks)  No   No      
Material Availability  No   No      
Lab Equipment Availability  No   No      
 
Allow for non-destructive data 
collection           
               
MAX WEIGHTED 
SCORE = 136 
 
topographical 
inward migration 
Wei
ghte
d 
Norm
alized 
topogr
aphical 
outwar
d 
migrati
on 
Wei
ghte
d 
Norm
alized 
gel 
inward 
migrat
ion 
Wei
ghte
d 
Norm
alized 
gel 
out
war
d 
migr
atio
n 
Wei
ghte
d 
Norm
alized 
Objectives: 
We
igh
t             
I. Effective              
a. Allow culture of 
EC's 4 4 16 
0.117
6470
6 4 16 
0.117
6470
6 4 16 
0.117
6470
6 4 16 
0.117
6470
6 
b. Allow for 
fluorescence imaging 4 4 16 
0.117
6470
6 4 16 
0.117
6470
6 3 12 
0.088
2352
9 3 12 
0.088
2352
9 
c. Allow for staining 
of cells 4 4 16 
0.117
6470
6 4 16 
0.117
6470
6 3 12 
0.088
2352
9 3 12 
0.088
2352
9 
d. Allow for 
histological analysis 4 2 8 
0.058
8235
3 2 8 
0.058
8235
3 3 12 
0.088
2352
9 3 12 
0.088
2352
9 
              
II. Quantifiable              
a. Accurate 
quantification 3 3 9 
0.066
1764
7 3 9 
0.066
1764
7 2 6 
0.044
1176
5 2 6 
0.044
1176
5 
b. Quantifies EC 
ingrowth 3 4 12 
0.088
2352
9 3 9 
0.066
1764
7 4 12 
0.088
2352
9 3 9 
0.066
1764
7 
c. 
Precise/Reproducible 
Quantification 3 3 9 
0.066
1764
7 3 9 
0.066
1764
7 2 6 
0.044
1176
5 2 6 
0.044
1176
5 
              
III. Efficient              
a. minimize data 
collection time 2 4 8 
0.058
8235
3 4 8 
0.058
8235
3 3 6 
0.044
1176
5 3 6 
0.044
1176
5 
b. High throughput 2 4 8 
0.058
8235
3 4 8 
0.058
8235
3 3 6 
0.044
1176
5 3 6 
0.044
1176
5 
c. Cost effective 2 3 6 
0.044
1176
5 3 6 
0.044
1176
5 3 6 
0.044
1176
5 3 6 
0.044
1176
5 
              
IV. Ease of Use              
a. Easily 
assembled/prepared 1 4 4 
0.029
4117
6 4 4 
0.029
4117
6 3 3 
0.022
0588
2 3 3 
0.022
0588
2 
b. Minimal time for 
assembly 1 4 4 
0.029
4117
6 4 4 
0.029
4117
6 4 4 
0.029
4117
6 4 4 
0.029
4117
6 
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c. Use 1 variation of 
media 1 4 4 
0.029
4117
6 4 4 
0.029
4117
6 4 4 
0.029
4117
6 4 4 
0.029
4117
6 
Totals  47 120 
0.882
353 46 117 
0.860
294 41 105 
0.772
059 40 102 0.75 
Constraints:              
Maintains scaffold 
structure  No   No   No   No   
Scaffold Imaging  No   No   No   No   
Budget ($524)  No   No   No   No   
Time (28 weeks)  No   No   No   No   
Material Availability  No   No   No   No   
Lab Equipment 
Availability  No   No   No   No   
               
   
topographical 
outward boundary 
migration 
Wei
ghte
d 
Norm
alized 
gel 
inward 
bound
ary 
migrati
on 
Wei
ghte
d 
Norm
alized 
gel 
outwa
rd 
bound
ary 
migrat
ion 
Wei
ghte
d 
Norm
alized    
Objectives: 
We
igh
t             
I. Effective              
a. Allow culture of 
EC's 4 4 16 
0.117
6470
6 4 16 
0.117
6470
6 4 16 
0.117
6470
6    
b. Allow for 
fluorescence imaging 4 4 16 
0.117
6470
6 3 12 
0.088
2352
9 3 12 
0.088
2352
9    
c. Allow for staining 
of cells 4 4 16 
0.117
6470
6 3 12 
0.088
2352
9 3 12 
0.088
2352
9    
d. Allow for 
histological analysis 4 2 8 
0.058
8235
3 3 12 
0.088
2352
9 3 12 
0.088
2352
9    
              
II. Quantifiable              
a. Accurate 
quantification 3 4 12 
0.088
2352
9 2 6 
0.044
1176
5 2 6 
0.044
1176
5    
b. Quantifies EC 
ingrowth 3 2 6 
0.044
1176
5 2 6 
0.044
1176
5 2 6 
0.044
1176
5    
c. 
Precise/Reproducible 
Quantification 3 2 6 
0.044
1176
5 2 6 
0.044
1176
5 2 6 
0.044
1176
5    
              
III. Efficient              
a. minimize data 
collection time 2 3 6 
0.044
1176
5 2 4 
0.029
4117
6 2 4 
0.029
4117
6    
b. High throughput 2 4 8 
0.058
8235
3 3 6 
0.044
1176
5 3 6 
0.044
1176
5    
c. Cost effective 2 3 6 
0.044
1176
5 3 6 
0.044
1176
5 3 6 
0.044
1176
5    
              
IV. Ease of Use              
a. Easily 
assembled/prepared 1 4 4 
0.029
4117
6 3 3 
0.022
0588
2 3 3 
0.022
0588
2    
b. Minimal time for 
assembly 1 4 4 
0.029
4117
6 4 4 
0.029
4117
6 4 4 
0.029
4117
6    
c. Use 1 variation of 
media 1 4 4 
0.029
4117
6 4 4 
0.029
4117
6 4 4 
0.029
4117
6    
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Totals  44 112 
0.823
529 38 97 
0.713
235 38 97 
0.713
235    
Constraints:              
Maintains scaffold 
structure  No   No   No      
Scaffold Imaging  No   No   No      
Budget ($524)  No   No   No      
Time (28 weeks)  No   No   No      
Material Availability  No   No   No      
Lab Equipment 
Availability  No   No   No      
               
   
Unidirectional 
single strip 
migration 
Wei
ghte
d 
Norm
alized 
Patter
ned 
Gel  
for 
Unidri
ection
al 
migrati
on 
Wei
ghte
d 
Norm
alized 
topogr
aphica
l 
inward 
bound
ary 
migrat
ion 
Wei
ghte
d 
Norm
alized    
Objectives: 
We
igh
t             
I. Effective              
a. Allow culture of 
EC's 4 4 16 
0.117
6470
6 4 16 
0.117
6470
6 4 16 
0.117
6470
6    
b. Allow for 
fluorescence imaging 4 4 16 
0.117
6470
6 4 16 
0.117
6470
6 4 16 
0.117
6470
6    
c. Allow for staining 
of cells 4 4 16 
0.117
6470
6 4 16 
0.117
6470
6 4 16 
0.117
6470
6    
d. Allow for 
histological analysis 4 1 4 
0.029
4117
6 2 8 
0.058
8235
3 2 8 
0.058
8235
3    
              
II. Quantifiable              
a. Accurate 
quantification 3 4 12 
0.088
2352
9 4 12 
0.088
2352
9 4 12 
0.088
2352
9    
b. Quantifies EC 
ingrowth 3 4 12 
0.088
2352
9 3 9 
0.066
1764
7 2 6 
0.044
1176
5    
c. 
Precise/Reproducible 
Quantification 3 3 9 
0.066
1764
7 3 9 
0.066
1764
7 2 6 
0.044
1176
5    
              
III. Efficient              
a. minimize data 
collection time 2 4 8 
0.058
8235
3 4 8 
0.058
8235
3 3 6 
0.044
1176
5    
b. High throughput 2 4 8 
0.058
8235
3 4 8 
0.058
8235
3 4 8 
0.058
8235
3    
c. Cost effective 2 3 6 
0.044
1176
5 2 4 
0.029
4117
6 3 6 
0.044
1176
5    
              
IV. Ease of Use              
a. Easily 
assembled/prepared 1 3 3 
0.022
0588
2 3 3 
0.022
0588
2 4 4 
0.029
4117
6    
b. Minimal time for 
assembly 1 4 4 
0.029
4117
6 3 3 
0.022
0588
2 4 4 
0.029
4117
6    
c. Use 1 variation of 
media 1 4 4 
0.029
4117
6 4 4 
0.029
4117
6 4 4 
0.029
4117
6    
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Totals  46 118 
0.867
647 44 116 
0.852
941 44 112 
0.823
529    
Constraints:              
Maintains scaffold 
structure  No   No   No      
Scaffold Imaging  No   No   No      
Budget ($524)  No   No   No      
Time (28 weeks)  No   No   No      
Material Availability  No   No   No      
Lab Equipment 
Availability  No   No   No      
 
 
 
 
Allow for Quantification of Data         
            
MAX WEIGHTED SCORE = 
140  Manual Counting 
Weigh
ted 
Normali
zed 
MATLAB 
Program 
Weigh
ted 
Normali
zed 
Image
J  
meas
ure 
distan
ce 
Weigh
ted 
Normali
zed 
Objectives: Weight          
I. Quantifiable           
a. Accurate quantification 4 2 8 
0.05714
286 4 16 
0.11428
571 3 12 
0.08571
429 
b. Quantifies EC ingrowth 4 3 12 
0.08571
429 3 12 
0.08571
429 4 16 
0.11428
571 
c. Precise/Reproducible 
Quantification 4 2 8 
0.05714
286 4 16 
0.11428
571 3 12 
0.08571
429 
d. Quantify release rate 4 1 4 
0.02857
143 3 12 
0.08571
429 2 8 
0.05714
286 
            
II. Efficient           
a. Produce accurate results 3 2 6 
0.04285
714 4 12 
0.08571
429 3 9 
0.06428
571 
b. Produce reproducible 
results 3 2 6 
0.04285
714 4 12 
0.08571
429 3 9 
0.06428
571 
c. minimize data collection 
time 3 1 3 
0.02142
857 4 12 
0.08571
429 3 9 
0.06428
571 
d. High throughput 3 1 3 
0.02142
857 4 12 
0.08571
429 3 9 
0.06428
571 
e. Cost effective 3 4 12 
0.08571
429 4 12 
0.08571
429 4 12 
0.08571
429 
            
III. Easy to Use           
a. Easily 
assembled/prepared 2 3 6 
0.04285
714 2 4 
0.02857
143 4 8 
0.05714
286 
b. Minimal time for assembly 2 3 6 
0.04285
714 2 4 
0.02857
143 4 8 
0.05714
286 
   24 74 
0.52857
1 38 124 
0.88571
4 36 112 0.8 
Constraints:           
Maintains scaffold structure  No   No   No   
Scaffold Imaging  No   No   No   
Budget ($524)  No   No   No   
Time (28 weeks)  No   No   No   
Material Availability  No   No   No   
Lab Equipment Availability  No   No   No   
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   Cell Profiler 
Weigh
ted 
Normali
zed 
ImageJ  
Quantify 
Fluorese
nce 
Weigh
ted 
Normali
zed    
Objectives: Weight          
I. Quantifiable           
a. Accurate quantification 4 3 12 
0.08571
429 3 12 
0.08571
429    
b. Quantifies EC ingrowth 4 4 16 
0.11428
571 3 12 
0.08571
429    
c. Precise/Reproducible 
Quantification 4 3 12 
0.08571
429 3 12 
0.08571
429    
d. Quantify release rate 4 3 12 
0.08571
429 3 12 
0.08571
429    
            
II. Efficient           
a. Produce accurate results 3 3 9 
0.06428
571 3 9 
0.06428
571    
b. Produce reproducible 
results 3 3 9 
0.06428
571 3 9 
0.06428
571    
c. minimize data collection 
time 3 3 9 
0.06428
571 3 9 
0.06428
571    
d. High throughput 3 3 9 
0.06428
571 3 9 
0.06428
571    
e. Cost effective 3 4 12 
0.08571
429 4 12 
0.08571
429    
            
III. Easy to Use           
a. Easily 
assembled/prepared 2 3 6 
0.04285
714 4 8 
0.05714
286    
b. Minimal time for assembly 2 3 6 
0.04285
714 4 8 
0.05714
286    
   35 112 0.8 36 112 0.8    
Constraints:           
Maintains scaffold structure  No   No      
Scaffold Imaging  No   No      
Budget ($524)  No   No      
Time (28 weeks)  No   No      
Material Availability  No   No      
Lab Equipment Availability  No   No      
 
Allows for Cellular Marking          
            
MAX WEIGHTED SCORE = 152 
 
GFP 
mark
ed 
EC's 
Weight
ed 
Normaliz
ed 
Hoec
hst 
Staini
ng 
Weight
ed 
Normaliz
ed 
Alexa-
Fluoro4
88 
Stainin
g 
Weight
ed 
Normaliz
ed 
Objectives: Weight          
I. Effective           
a. Allow culture of EC's 4 4 16 
0.10526
316 4 16 
0.10526
316 4 16 
0.10526
316 
b. Allow for fluorescence 
imaging 4 4 16 
0.10526
316 4 16 
0.10526
316 4 16 
0.10526
316 
c. Allow for staining of cells 4 4 16 
0.10526
316 4 16 
0.10526
316 4 16 
0.10526
316 
d. Allow for histological 
analysis 4 4 16 
0.10526
316 4 16 
0.10526
316 4 16 
0.10526
316 
           
II. Quantifiable           
a. Accurate quantification 3 4 12 
0.07894
737 3 9 
0.05921
053 4 12 
0.07894
737 
b. Quantifies EC ingrowth 3 3 9 
0.05921
053 3 9 
0.05921
053 3 9 
0.05921
053 
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c. Precise/Reproducible 
Quantification 3 4 12 
0.07894
737 3 9 
0.05921
053 3 9 
0.05921
053 
           
III. Efficient           
a. Produce accurate results 2 4 8 
0.05263
158 3 6 
0.03947
368 4 8 
0.05263
158 
b. Produce reporducible 
results 2 4 8 
0.05263
158 4 8 
0.05263
158 4 8 
0.05263
158 
c. minimize data collection 
time 2 4 8 
0.05263
158 3 6 
0.03947
368 3 6 
0.03947
368 
d. High throughput 2 3 6 
0.03947
368 3 6 
0.03947
368 3 6 
0.03947
368 
e. Cost effective 2 1 2 
0.01315
789 4 8 
0.05263
158 2 4 
0.02631
579 
           
IV. Ease of Use           
a. Easily assembled/prepared 1 4 4 
0.02631
579 3 3 
0.01973
684 3 3 
0.01973
684 
b. Minimal time for assembly 1 4 4 
0.02631
579 3 3 
0.01973
684 3 3 
0.01973
684 
c. Use 1 variation of media 1 4 4 
0.02631
579 4 4 
0.02631
579 4 4 
0.02631
579 
Totals  55 141 
0.92763
2 52 135 
0.88815
8 52 136 
0.89473
7 
Constraints:           
Maintains scaffold structure  No   No   No   
Scaffold Imaging  No   No   No   
Budget ($524)  No   No   No   
Time (28 weeks)  No   No   No   
Material Availability  No   No   No   
Lab Equipment Availability  No   No   No   
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Appendix F: Experimental Procedures for Feasibility Testing 
Alginate Gel Procedure: 
Materials 
5g CaCl (Sigma-Aldrich) 
.5 liters and 100mL deionized H20 
2g Alginic Acid sodium salt from brown algae (Sigma-Aldrich) 
2 500mL beakers 
Magnetic Plate and magnetic stirrer 
Plastic stirrer 
 
 Procedure 
a. Place CaCl in .5 liters of deionized water (use a 500mL beaker) 
b. Stir with plastic stirrer till forms a solution 
c. Place alginic acid sodium salt in 100mL deionized water (use a 500mL beaker) 
d. Place beaker with alginic acid on a magnetic plate. Place magnetic stirrer in 
beaker and allow to stir at medium speed for a ½ hour or until all the alginate 
clumps have dissolved, forming a viscous liquid. 
e. Pour viscous alginate liquid into the CaCl solution for long strings of gel or 
pipette droplets into the solution to get round drops of gel.  
f. Good for use immediately 
Collagen Gel: 
Materials 
0.8ml collagen at 10mg/mL in HCL (Pins Lab) 
200microliters 5xDMEM (Pins Lab) 
40microliters .1M NaOH  
3 Syringes 
PDMS circle (~16mm radius) 
 
 Procedure 
a. Place ingredients and p35 plate on ice 
I. Use separate syringes to measure out each ingredient 
b. Mix using the tip of the collagen syringe 
I. Do not pipette mixture up and down 
c. Once well mixed, scrap mixture to corner of p35 plate and use pipette to remove 
mixture 
d. Pipette mixture on circle of PDMS 
e. Spread mixture to achieve the appropriate thickness 
f. Incubate overnight in 37 degree Celsius at 5%CO2, then use. 
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Agarose Gel Procedure: 
Materials 
1g Agarose (SeaKem LE Agarose from LONZA) 
100mL deionized H20 
Microwave 
500mL beaker 
Metal stirrer 
 
 Procedure 
a. Place agarose in 100ml deionized H2O (use 500ml beaker) 
b. Stir with metal stirrer till forms a solution 
c. Place in microwave for 1 minute, then take out and stir 
d. Repeat step C two more times 
e. Let beaker sit for 5min 
f. Pour gel into mold or coat molds by dipping into alginate 
g. Let sit for 15min, then use. 
NIH/3T3 Fibroblast Meidum Recipe: 
 500ml DMEM 1X w/glucose + sodium pyruvate w/out glutamine (CellGro) 
 10% FBS (Ambady Lab) 
 5ml PenStrep 10000 U Pen./ml + 10000 ug Strep./ml (LONZA) 
Protocol for Making Polydimethylsiloxane (PDMS): 
 
 Materials 
Sylgard Silicone Elastomer base (Ellsworth Adhesive #184 SYL ELAST) 
Sylgard Silicone Elastomer curing agent (Ellsworth Adhesive #184 SYL ELAST) 
Gloves (The elastomer reagents are sticky and may be difficult to wash off) 
  
Procedure 
a. Weigh 10 parts Sylgard silicone elastomer base and 1 part Sylgard silicone 
elastomer curing agent.  Note: DO NOT MIX THE STOCK SOLUTIONS!!!  Use 
separate weighing materials for each reagent. 
b. Pour reagents together and thoroughly mix the elastomer base and curing agent. 
c. Pour the well mixed solution into your mold. 
d. De-gas the PDMS by putting it into a vacuum chamber for at least 1 hour 
(larger/thicker volumes of PDMS may require more time). 
e. After degassing, visually inspect the PDMS to ensure that there are no more 
bubbles.  If there are, repeat steps 4 and 5. 
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f. Cure the PDMS by placing the mold into an oven set for 60 °C for at least 1 hour 
(larger samples may require more time). 
One important thing to keep in mind is that the uncured reagents are very tacky and can make a 
big mess of anything they contact (the degassing chamber, the scale used to weigh reagents).  
Students should wear gloves when handling PDMS, be careful not to spill, and make sure they 
clean up the space and equipment they use when preparing PDMS.   We keep “Goo Gone” in the 
lab for this reason…Students using PDMS will need access to the desiccating/vacuum chambers, 
a vacuum source, a scale (~ grams), weigh boats and an oven for curing.   
 
Protocol for Fabrication of Gelatin Microspheres: 
 
1. Make an aqueous gelatin solution  
a. Measure out 1g of gelatin on weigh paper using a scale and 9 ml of water in a 
centrifuge tube using a scale  
b. Combine in centrifuge tube  
2. Make a 40°C hot water bath  
3. Heat gelatin solution in water bath at 40°C for 15 minutes inverting intermittently  
4. Heat 150 mL olive oil in bottle to 40°C in container  
5. Add gelatin solution to olive oil drop-wise using a 1000 μl micropipette in a circular motion to 
avoid placing droplets on top of one another.  
6. Stir using a magnetic stirrer that completely covers the bottom of the container at 500 rpm for 
10 minutes  
7. Place in a refrigerator to decrease the temperature to 4°C (about 24 hours) which will allow 
the microspheres to form  
8. Centrifuge top portion of olive oil (this should barely have any microspheres) at 5000 rpm for 
5 minutes in centrifuge tubes  
9. Pour off olive oil into a container to save for another use in making microspheres  
10. Add 5-10mL of acetone to the oil and gelatin solution (Note: Work with acetone in fume 
hood)  
11. Stir the solution at 60rpm for 30 seconds  
12. Separate solution into centrifuge tubes  
13. Centrifuge each tube at 5000rpm for 5 minutes  
14. Discard supernatant from each tube  
15. Add 40-50mL of acetone to each centrifuge tube  
16. Invert each centrifuge tube vigorously, until the pellet is re-suspended  
17. Centrifuge each tube at 5000rpm for 5 minutes  
18. Remove supernatant from each tube  
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19. Repeat steps 14 to 17 until the oil is removed (microspheres will be able to move freely and 
should be the same color as the gelatin powder used to make microspheres)  
20. Combine all microspheres into a beaker  
21. Allow to dry in fume hood (about 2-3 hours)  
22. Once dry move microspheres to centrifuge tube  
23. Store in 4°C fridge  
 
Washing and Sterilizing:  
 
1. Measure out necessary amount of microspheres  
2. Place in a 50mL centrifuge tube  
3. Fill the tube to 45mL mark with room temperature IPA  
4. Shake tube vigorously or vortex at highest speed  
5. Place in centrifuge at 200 rcf for 5 minutes  
6. Aspirate off IPA in culture hood  
7. In same hood add cold DMEM to 45mL mark  
8. Shake vigorously or vortex at highest speed  
9. Place in centrifuge at 200 rcf for 5 minutes  
10. Aspirate off DMEM in culture hood  
11. In same hood add cold DMEM to 45 ml mark  
12. Vortex microspheres at highest speed setting until microspheres appear dispersed.  
13. Centrifuge at 200 rcf for 5 minutes  
14. Aspirate off DMEM in culture hood  
15. Add the necessary amount of warm full medium to microspheres for desired concentration  
16. Shake tube vigorously.  
 
Note: Solution can be stored after step 12. Complete steps 13 through 16 immediately before use 
with cells.  
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Appendix G: Image Analysis of NIH/3T3 Fibroblasts on Gels for 
Feasibility Testing 
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Appendix H: Preliminary Assay Design Concept  
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Appendix I: Preliminary Assay Design: SolidWorks Model I 
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Appendix J: Preliminary Assay Design: SolidWorks Model II 
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Appendix K: Image Analysis for Containment of Scaffold 
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Appendix L: Protocol for Heparin Immobilization on Collagen-GAG 
Sponge and FGF-2 Binding: 
 
Heparin Immobilization on Collagen-GAG Sponge 
1. Collagen-GAG sponges are cut into circular scaffolds using a 9mm biopsy punch. 
2. Sponges are incubated at room temperature in MES Buffer (0.5M & 8.0 pH) for at least 30 
minutes. 
 
3. A solution of MES Buffer containing Heparin Sodium Salt (Intestinal Mucosa) (CalBioTech), 
N-(3-Dimethylamideopropyl) ethylcarbodiimide hydrochloride (EDC) (Sigma-Aldrich), and N-
Hydroxysuccinimide (NHS) (Sigma-Aldrich) was prepared. 
 -Heparin Sodium Salt was added at 2% w/v MES Buffer Solution 
 -EDC added at molar ratio of EDC:Heparin = 1:2 
 -NHS added at molar ratio EDC: NHS = 0.6:1 
 
4. Sponges are then incubated in the Heparin solution for 2 hours at room temperature to allow 
heparin binding to occur.  
 
5. Heparinized sponges are transferred to a culture dish containing DPBS(-) and stored overnight 
in the incubator.  
 
FGF-2 Binding Procedure  
1. FGF-2 solutions in the lab were available at a concentration of 100 µg/mL at a volume of 25 
µL.  
 
2. Solutions of FGF-2 are diluted by increasing the volume using calculated volumes of PBS 
(with 1% BSA w/v) too concentrations of 100 ng/mL, 200 ng/mL, and 300 ng/mL. 
 
3. Sponges are incubated individually in a 100 µL solution of the desired concentration within a 
24-well plate. The sponges are incubated for a total of 90 minutes at room temperature.   
 
4. The sponges are then washed in DPBS(-) to rid unbound FGF-2 and placed overnight in 
individual wells of 100 µL of antibiotics to be sterilized.  
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Appendix M: Fibroblast Outgrowth Analysis for Six Conditions 
Heparin Negative FGF-2 Negative (Control): 
Trial 1:    Trial 2: 
T0:     
T8:    
T12:  
T16:  
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T20:  
Heparin Positive FGF-2 Negative: 
Trial 1:  Trial 2: 
T0:    
T8:    
T12:  
T16:  
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T20:  
Heparin Positive FGF-2 (100 ng/mL): 
Trial 1:  Trial 2: 
T0:    
T8:    
T12:  
T16:  
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T20:  
Heparin Positive FGF-2 (200 ng/mL): 
Trial 1:  Trial 2: 
T0:    
T8:    
T12:  
T16:  
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T20:  
Heparin Positive FGF-2 (300 ng/mL): 
Trial 1:   Trial 2: 
T0:    
T8:    
T12:  
T16:  
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T20:  
Heparin Negative FGF-2 (300 ng/mL): 
Trial 1:  Trial 2: 
T0:    
T8:    
T12:  
T16:  
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T20:  
 
